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ABSTRACT 
Temperance Rebecca Rowell: Flavor-Dependent Effects of E-cigarette Liquids and their Chemical 
Constituents on Lung Epithelial Toxicity and Cell Ca2+ Signaling 
(Under the direction of Robert Tarran) 
 
 E-cigarettes (e-cigs) are a cigarette alternative that do not contain tobacco or tar, and whose e-
liquids are available in over 7,000 flavors.  While marketed as a safer smoking alternative, the basic 
health effects of vaping commercially available e-liquids and their constituent components (i.e., 
propylene glycol (PG), vegetable glycerin (VG), nicotine, flavors) are not well understood.  However, 
inhalation of diacetyl (butter flavor) has been shown to cause bronchiolitis obliterans (‘Popcorn Lung’).  
In this dissertation, we sought to better understand the biological effects of flavored e-liquids and their 
chemical constituents on airway cells. 
 We first screened 13 flavored e-liquids, PG/VG, and nicotine for toxicity in a pulmonary 
epithelial cell line.  We demonstrated that the responses were both dose- and flavor-dependent by 
exposing cells to either the unheated or heated (aerosolized) e-liquids.  4 of 13 flavored e-liquids had 
more pronounced toxicity effects than the PG/VG base or other flavors, and did not share a flavoring 
chemical between them that might be universally toxic.  We then demonstrated that the toxic effects that 
we were measuring were either due to (1) direct cytotoxicity or (2) inhibiting cell proliferation.  We 
further explored the ability of flavored e-liquids to inhibit cell proliferation by characterizing their effects 
on intracellular Ca2+ signaling, which can affect cell proliferation and apoptosis.  Specifically, we 
demonstrated that a Banana Pudding-flavored e-liquid could stimulate phospholipase C-dependent 
inositol 1,4,5-triphosphate generation leading to ER Ca2+ depletion and elevations in cytosolic Ca2+.  
Moreover, we screened 100 additional e-liquids and found 42 of 100 elicited cytosolic Ca2+ responses, 
suggesting many flavors can alter Ca2+ homeostasis.  Analysis of their chemical constituents correlated 
  
iv 
the presence of common flavorings (e.g., ethyl vanillin, vanillin, and ethyl maltol) with the cytosolic Ca2+ 
responses.  Additional testing confirmed that those flavors caused dose-dependent Ca2+ signaling.  Altered 
Ca2+ homeostasis can have profound effects on airway physiology and has been implicated in disease 
(i.e., cancer, autoimmune diseases, inflammation).  Therefore, these products should be further assessed 
for their flavor-dependent effects on airway physiology (e.g., Ca2+ homeostasis) and potential 
consequences of long-term inhalation toxicity from chronic vaping.  
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Chapter 1: Introduction - Will Chronic E-cigarette Use Cause Lung Disease? 
1.1. Overview 
Chronic tobacco smoking is a major cause of preventable morbidity and mortality worldwide.  In 
the lung, tobacco smoking increases the risk of lung cancer, and also causes chronic obstructive 
pulmonary disease (COPD), which encompasses both emphysema and chronic bronchitis.  E-cigarettes 
(e-cigs), or electronic nicotine delivery systems (ENDS), were developed over a decade ago and are 
designed to deliver nicotine without combusting tobacco.  Although tobacco smoking has declined since 
the 1950s, e-cig usage has increased, attracting both former tobacco smokers and never smokers.  E-cig 
liquids (e-liquids) contain nicotine in a glycerol/propylene glycol vehicle with flavorings, which are 
vaporized and inhaled.  To date, neither e-cig devices, nor e-liquids, are regulated by the Food and Drug 
Administration (FDA).  The FDA has proposed a deeming rule, which aims to initiate legislation to 
regulate e-cigs, but the timeline to take effect is uncertain.  Proponents of e-cigs say that they are safe and 
should not be regulated.  Opposition is varied, with some opponents proposing that e-cig usage will 
introduce a new generation to nicotine addiction, reversing the decline seen with tobacco smoking, or that 
e-cigs generally may not be safe and will trigger diseases like tobacco.  In this review, we shall discuss 
what is known about the effects of e-cigs on the mammalian lung and isolated lung cells in vitro.  We 
hope that collating this data will help illustrate gaps in the knowledge of this burgeoning field, directing 
researchers toward answering whether or not e-cigs are capable of causing disease. 
 
 
1This chapter previously appear as an article published in American Journal of Physiology Lung Cell 
Molecular Physiology and is reprinted with permission with some modifications. The original citation is 
as follows: Rowell TR, Tarran R. Will chronic e-cigarette use cause lung disease?. Am J Physiol Lung 
Cell Mol Physiol 309: L1398-L1409, 2015. 
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1.1. Lung Anatomy & Physiology 
The lung is a complex organ that is partitioned into two zones: the conducting zone and the 
respiratory zone.  As air is inhaled, it passes down the trachea into a system of branching bronchi and 
bronchioles which comprise the conducting zone.  It is also in the conducting zone that air is warmed, 
moistened, and passed through defenses to prevent infection.  Air then flows into the respiratory zone at 
the end of the small airways where alveolar sacs (~480 million alveoli/lung) are enriched with their own 
blood supply (177).  The lung’s primary function is to exchange oxygen for carbon dioxide into the blood 
supply via alveolar capillary beds (262).  It is also at the alveolar sacs that blood pH can be regulated with 
gas exchange.  Specifically, carbon dioxide concentration can increase or decrease the blood pH and is 
regulated through ventilation rate. 
The lung is one of the first lines of defense against inhaled allergens, environmental pollutants, 
and pathogens.  Many different cell types comprise the lung and are important to providing defenses (i.e., 
physical barrier, local inflammatory responses, mucociliary clearance) (264).  These cell types are 
summarized in Figure 1.3 and include the pulmonary epithelia that line the conducting zones and contain 
both ciliated and secretory (goblet) cells.  Beneath the epithelia are layers of fibroblasts and connective 
tissue, as well as airway smooth muscle cells that are responsible for constricting and dilating the airways.  
Immune cells are present in the airways (e.g., resident macrophages) or are recruited by inflammatory 
signaling (e.g., neutrophils, dendritic cells).  Lastly, the respiratory zone is rich in alveolar type 1 and 2 
cells in the terminal sacs that exchange gas with the endothelial cells of the capillary beds nearby (193, 
264).  Prominent airway diseases such as COPD (emphysema and chronic bronchitis) or asthma involve 
the destruction and/or dysregulation of different lung cell types (i.e., bronchiolar alveoli and epithelia, 
airway smooth muscle cells), suggesting that they are all susceptible to chronic e-cig exposure. 
1.2. E-cigarettes (E-cigs) 
 Electronic cigarettes or e-cigarettes (e-cigs), also known as ENDS, were designed to deliver 
aerosolized nicotine in a minimal liquid vehicle that was thought to be relatively safe compared with 
tobacco (Fig. 1.1).  It has been proposed by e-cig manufacturers that, since these products do not burn 
  
3 
tobacco, they will not expose the lung to the same toxic chemicals as regular smoked tobacco and so will 
not cause the lung disease that is frequently associated with chronic tobacco inhalation, including lung 
cancer and COPD.  E-cig users are a fast-growing subset of nicotine users who are described as vapers 
rather than smokers, since e-cigs heat and generate aerosols but do not burn e-liquids.  There is 
considerable controversy regarding the disease risk and toxicity of e-cigs (178, 186, 209).  However, 
because e-cigs do not currently fall under the auspices of the Food and Drug Administration (FDA), they 
have not undergone the typical toxicological evaluation, followed by human clinical trials that are 
required of other inhaled products (e.g., inhaled therapeutic agents), and, as such, no safety data exist 
from either humans or animals.  Because of this, it is hard to predict whether these products will be 
benign when chronically inhaled, possibly over a lifetime, or whether they will induce tobacco-like 
disease or other types of lung disease such as bronchiolitis obliterans, a disease that has been caused by 
the inhalation of the buttery-tasting flavor diacetyl (124).  The clinical evaluation of biomarkers of harm 
(e.g., inflammatory and cytotoxic markers) is required to inform the FDA and for ensuring safety and 
proper regulation.  However, these studies are only just beginning in what can at best be described as 
“investigator-initiated trials” rather than formal clinical trials.  A further confounder is that many e-cig 
users have switched after chronically smoking tobacco products, making it difficult to differentiate 
between the previous effects of tobacco vs. the effects of the e-cigs (58).  To date, there are currently 
1,273 e-cig articles on Pubmed, of which 135 are reviews and only 85 include the terms “e-cigarette” and 
“lung.”  In contrast, “tobacco” and “lung” yields 9,769 hits, indicating the lack of maturity of this field.  
In this review, we shall list and evaluate what is known about the effects of e-cig exposure on 
lungs/airways in vivo and in vitro (Fig. 1.3). 
1.3. Health Effects of Nicotine and Tobacco Use 
Nicotine is a highly addictive compound that, through nicotinic acetylcholine receptors (nAChR), 
exerts potent effects on the brain, including the saturation and desensitization of nAChRs (α4β2-subtype) 
leading to significant changes in the brain’s physiology such as activation of the reward/pleasure regions 
of the cortex and reduced anxiety (24, 71, 210).  Inhaling tobacco is a relatively simple and efficient way 
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of delivering nicotine into the bloodstream.  Nicotine is a weak base that can be absorbed across the lung 
in its unionized form into the bloodstream (25).  The effects of nicotine on the brain are complex and only 
just beginning to be understood.  Importantly, its effects on the adolescent brain are markedly different 
compared with the adult brain and can affect neural development.  For example, exposure to nicotine in 
adolescent rats led to an increased sensitivity to nicotine in these rats as adults, even if a smoking 
cessation period was introduced, suggesting that e-cig inhalation (i.e., vaping) by adolescents may have 
serious consequences later in life (59).  
Nicotine craving causes a huge drive to continue smoking, and smokers maintain fairly constant 
plasma nicotine levels during waking hours, despite the significant risks: lung cancer (including both 
small cell and nonsmall cell) accounts for 27% of all diagnosed cancers and is the deadliest form of 
cancer, killing ~150,000 people in the United States of America (USA) per year (38, 221).  It is thought 
that ~85% of all lung cancer is caused by smoking, and secondhand smoke exposure increases the chance 
of lung cancer by ~25% (38).  COPD is also caused primarily by tobacco exposure in Western countries 
and kills a similar amount of people as lung cancer (~140,000/yr) (18, 87).  COPD is also the third 
leading cause of death in the USA and worldwide (179), although tobacco exposure is a primary risk 
factor of COPD in first-world countries; smoke from biomass fuels is also a risk factor for COPD in 
second- and third-world countries (70).  COPD often occurs with other comorbidities, and presentation 
with COPD is a major risk factor for the development of lung cancer (107, 165).  The fact that tobacco 
exposure is a key factor in the development of both of these diseases was first denied by the tobacco 
industry and later accepted, following the Tobacco Master Settlement Agreement in 1998 (76, 116).  
In the 1950s, ~50% of the adult population were regular tobacco smokers in the USA (224).  
Following the Surgeon General’s 1954 report linking tobacco smoke with disease, a series of public 
health campaigns led to 1) increased public awareness about the dangers of smoking, 2) bans on tobacco 
advertising, 3) age limits for purchasing tobacco, 4) bans on tobacco products that allegedly target minors 
(e.g., flavored cigarettes), 5) increased taxation on tobacco, and 6) restrictions on where tobacco products 
can be smoked (e.g., bans on smoking in public places) (110, 191).  Due to these pressures, tobacco 
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companies began developing “safe cigarettes.”  In the 1980s, “low-tar” cigarettes were developed, which 
were purportedly safer than regular cigarettes because they exposed users to less of the tar phase from 
cigarettes.  This premise was based on flawed science.  In part, the reduced tar output was generated by 
putting holes at the base of the cigarette, which served to reduce airflow through the cigarette.  However, 
these cigarettes were not safer than regular cigarettes.  In fact, users learned to compensate by either 
covering up the holes with their fingers or taking larger puffs, thus negating the “low-tar effects” (96, 
187).  Furthermore, the gas phase of cigarette smoke is also highly toxic and was not addressed in “low-
tar cigarettes” (176, 205).  Additional types of safe cigarettes have been developed, including “heat not 
burn” types (e.g., the “Eclipse”), which heats a rod in the middle of the cigarette to give off tobacco 
smoke without burning it.  This style of cigarette was not successful commercially (8), and there is no 
evidence that they are actually safer (101).  
Despite these failed attempts at safe cigarettes, the Institute of Medicine issued a report in 2001 
that outlined the feasibility of focusing efforts on harm reduction tobacco products, which were referred 
to as “Potential to Reduced Exposure Products” or “PREPs,” since they wanted to avoid implying “that 
any product currently known is safe” (238).  At that time, there were no conclusive data that the current 
products on the market were reducing the individual users’ exposure to harmful tobacco substances.  
However, the committee did conclude that there was potential merit in “harm reduction” as a part of the 
national tobacco program that “emphasizes abstinence oriented prevention and treatment” (238).  Thus, 
when e-cigs were brought to market, they appeared to be likely candidate PREPs, since they neither 
contain tobacco nor is the e-cig vapor produced by combustion.  E-cigs were introduced into European 
markets in 2006 and in the USA in 2007 (206).  The first generation of e-cigs were dubbed “cigalikes” 
due to their resemblance to conventional cigarettes, and they came in both rechargeable/refillable and 
disposable formats (206, 276).  Subsequently, as their popularity grew, second- and third-generation e-
cigs have been developed which, although they have ceased to resemble cigarettes, have significantly 
improved their ability to deliver nicotine through the lung and into the bloodstream (Fig. 1.1) (276).  
However, the health effects of long-term inhalation of e-cig aerosols are currently unknown. 
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1.4. Components of Neat and Heated Flavored E-liquids 
Cigarette smoke is a complex and highly reactive mixture that includes metals (e.g., Cr, Cd, Hg), 
aldehydes (e.g., 4-aminobiphenyl, acrolein, formaldehyde), carbon monoxide, free radicals, and, of 
course, nicotine (82, 245).  Adverse effects can be caused by adduct formation, especially of aldehydes, 
with DNA or proteins (183), or due to excessive oxidative stress (119).  Aldehydes and heavy metals have 
been shown to have a number of cytotoxic effects on epithelia, including adduct formation to DNA (43, 
237, 258).  Additionally, tobacco smoke, as well as aldehydes, cadmium, and oxidative stress, also affect 
plasma membrane proteins such as the cystic fibrosis transmembrane conductance regulator (CFTR) (36, 
49, 100, 230), which is required for fluid secretion in the lung (51, 87).  In contrast, e-liquids (the flavored 
liquids that are heated to form the e-cig vapor) are thought to be much simpler and ostensibly contain 
nicotine (~6–18 mg/ml) in a liquid vehicle (typically propylene glycol and/or vegetable glycerin), along 
with sweeteners and flavorings (94).  
To date, over 400 different brands of e-cigs have been produced (276).  Unlike disposable e-cigs, 
second- and third-generation e-cigs contain a refillable tank to which the e-liquid is added, a battery-
powered atomizer that generates the aerosol vapor from the e-liquid, and a mouthpiece that collects and 
delivers the aerosol (Fig. 1.1).  This function is usually controlled by a microchip, which may activate a 
light-emitting diode at the tip of the e-cig during inhalation for aesthetics.  The amount of aerosol that is 
generated is directly proportional to the power of the battery, which has led some users to modify their e-
cig to increase battery power to get a greater nicotine “hit.”  This is not without risks, however, since 
there is a chance of battery explosion, which can lead to injury (34).  Although the number of fires and 
explosions from e-cig devices has increased since inception, interestingly, many of these instances 
occurred while the device was being charged and are still considered rare 
(https://www.usfa.fema.gov/downloads/pdf/publications/electronic_cigarettes.pdf).  An additional, 
behavioral modification that has developed among e-cig users is “dripping,” which entails dripping e-
liquid directly on the atomizer (i.e., the heating element) and inhaling the resultant vapor, which is 
supposed to give the largest amount of nicotine delivery possible with current e-cig devices (246).  
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Parameters of e-cig emission, such as aerosol size, mass output, and chemical composition, vary by 
device and e-liquid types and are predicted to impact the user’s exposure to the e-cig aerosol.  For 
example, aerosol size strongly affects how much of an aerosol is delivered to different regions of the lung 
and how much is retained in the oral cavity (23, 123).  
There are currently over 7,000 different flavored e-liquids that are commercially available (276).  
Because these e-liquids are not FDA regulated, the vendors do not have to list their e-liquid ingredients, 
perform any safety testing before they reach the market, nor generate these products under Good 
Manufacturing Practice-type conditions.  For example, the reported amount of nicotine has been found to 
vary by up to 20% from what is reported on the e-liquid label and has even been found in purportedly 
nicotine-free e-liquids (55, 56, 91).  It is likely that many of the compounds used in e-liquids fall within 
the FDA’s Generally Regarded as Safe (GRAS) list 
[http://www.accessdata.fda.gov/scripts/fdcc/?set_SCOGS].  The typical vehicle for e-liquids contains a 
mix of propylene glycol and glycerol, which are both GRAS products (34).  To date, most GRAS 
testing/toxicology has been performed following oral ingestion rather than following aerosolization to the 
lung.  For example, diacetyl is sometimes added to foods as a buttery flavor and is on the GRAS list, 
based on its oral toxicology (227).  Due to the potential for adverse health effects from inhaling other 
chemicals, the Flavor and Extract Manufacturers’ Association of the USA issued a statement warning that 
additives on the GRAS list apply to food only and should not be characterized as safe for use in e-cig 
products without further testing (https://www.femaflavor.org/safety-assessment-and-regulatory-authority-
use-flavors-focus-e-cigarettes).  Propylene glycol is used as a common e-liquid vehicle component in part 
because of its perceived low toxicity.  However, both ocular and upper respiratory irritation were reported 
in nonasthmatic adults following a short controlled occupational exposure (265).  Furthermore, diacetyl 
inhalation is known to cause bronchiolitis obliterans or “popcorn workers lung” (124).  Bronchiolitis 
obliterans caused by the inhalation of diacetyl can cause a range of symptoms from mild reversible 
respiratory impairment to a more severe nonreversible lung obstruction from extensive scarring in the 
small airways (17).  With no current consensus on e-cig user topography, it is possible that even 
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nonasthmatic users who vape frequently could experience, at the very least, respiratory irritation although 
to date no long-term data are available regarding chronic propylene glycol or flavorant exposure in 
humans. 
1.5. E-liquid Thermal Decomposition (Pyrolysis) 
E-cig aerosols are typically generated at temperatures of 100–250°C, which is predicted to cause 
pyrolysis of the e-liquid vehicle (274) and may also induce breakdown of other e-liquid constituents.  
Recently, formaldehyde has been detected in e-cig emissions (114).  However, these data have been 
disputed (80).  Part of the problem lies in deciding which temperature the e-liquid is heated to during the 
experiment vs. what occurs during actual vaping.  For example, Jensen et al. found significant amounts of 
formaldehyde (~380 µg/10 puffs) in the emission from a tank-style e-cig device when the battery voltage 
was set at 5.0 V, with no formaldehyde being detected when a lower voltage (3.3 V) was used (114).  
Because the power consumption/electrical resistance of the coil was not quoted by Jensen et al., it will be 
hard to see how this observation transfers to other e-cig devices.  That is, the power generated by the 
heating coil cannot be determined purely by the quoted voltage since it also depends on the current, and 
the temperature reached by the e-liquid is dependent on the power output of the heating element.  Thus, 
for reproducibility, it may be useful for researchers to quote the power output of their e-cig device in 
addition to the puff profile used.  Farsalinos et al. have reported that e-cig users do not use this higher 
voltage setting, and they also proposed that e-cigs only produce formaldehyde in “dry puff” conditions 
(80), where a dry puff refers to the scenario where there is little liquid on the atomizer coil and 
temperatures get higher than would be seen with sufficient liquid, leading to the potential for increased 
pyrolysis.  However, acrolein and other carbonyls have also been found by other investigators both in neat 
e-liquids and in e-cig aerosols that were generated by unmodified e-cig devices (222), suggesting that the 
occurrence/production of these compounds may be more common than originally suspected.  
Interestingly, neat glycerin does not pyrolyze at 900°C.  However, when diluted, significant amounts of 
acrolein were produced following pyrolysis of glycerol (39).  Similarly, these aldehydes are known to be 
released from vegetable oil (of which glycerol is a major component) when it is heated during cooking, 
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even to 180°C, which is close to temperatures reported for e-cigs (130–350°C) (246).  For example, the 
acrid smell that occurs when oil is burned on a stove is from acrolein (20, 40).  Similarly, the chemical 
decomposition of sugars also causes the release of aldehydes, including acrolein (244).  
It has been proposed that e-cig users tend to avoid the bitter taste that is associated with release of 
aldehydes during overheating/dry puffing and that, in actual e-cig users, aldehyde exposure never actually 
happens (80).  However, during the aforementioned practice of dripping, where the e-liquids are placed 
directly on the coil, it is possible that significant pyrolysis occurs.  Certainly, cigarettes can produce a 
harsh taste that is concomitant with the production of significant amounts of acrolein, formaldehyde, and 
other aldehydes, along with many other toxicants (244).  However, this relatively unpleasant taste is soon 
overcome in new smokers due to the power of the nicotine drive (229) and due to cross-desensitization of 
transient receptor potential ankyrin subtype 1 (TRPA1) channels in sensory neurons (29).  Therefore, it is 
also possible that e-cig users will “learn” to overcome any unpleasant taste due to increased aldehyde 
production if the nicotine drive is great enough.  It is also worth pointing out at this point that many 
flavors are themselves aldehydes, including anisaldehyde (sweet), cinnamaldehyde (cinnamon), and 
isovaleraldehyde (nutty).  The effects of these flavors on pulmonary surfaces are not known.  However, 
their potential inclusion in e-liquids may increase overall aldehyde exposure to the lung.  Indeed, 
cinnamaldehyde is present in some e-liquids (21) and activates TRPA1 (167), suggesting that they may 
exert effects on the lung.  Similarly, activation of this ion channel in sensory neurons in the airways of 
rodents by unsaturated aldehydes has previously been shown to trigger neurogenic inflammation (9) and 
to inhibit the CFTR ion channel (4), suggesting that a higher aldehyde burden may indeed be toxic to the 
lung.  However, the degree of adverse effects will likely depend on dose ranging and whether aldehydes 
are actually generated in sufficient quantities during real vaping conditions to trigger these responses. 
In addition to aldehydes, Lerner et al. also found that e-cig aerosols generated from two separate 
devices produced oxidants and reactive oxygen species (OX/ROS) (137).  Because the amount of 
OX/ROS changes with time as smoke matures, these data suggest that freshly produced e-cig aerosols 
may be more potent than “aged” e-cig aerosols, which has important implications for their study.  Indeed, 
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with regular cigarette smoke, different biological effects are seen with freshly produced vs. aged smoke, 
with aged smoke often being less biologically potent, which has previously been attributed to the decline 
in OX/ROS over time (108).  Furthermore, because OX/ROS are highly reactive, they may also react with 
other components in the e-cig aerosol, further changing its chemical composition.  Indeed, Sussan et al. 
demonstrated that e-cigs contain 1011 free radicals/puff, which is about 100 times less than is seen in 
regular cigarettes (240), but still likely to exert significant biological effects (66). 
1.6. E-cig Topography 
When generating cigarette smoke through a smoke machine, there are several international 
standards.  These standards are important since the rate and duration that air passes through a cigarette 
affects the burn temperature and the relative amount of chemicals that are subsequently produced (96, 
150), and this is likely true for e-cigs.  Also, smoking tobacco in a reproducible fashion facilitates cross-
laboratory data comparisons.  Smoking profiles are designed to mimic the inhalation topography seen in 
actual smokers.  For example, the Federal Trade Commission/International Standard Organization 
protocol calls for 2 s/35 ml puff every 60 s, and this is likely the most common puff profile used in the 
laboratory.  However, it has been suggested that this profile underestimates how much people actually 
inhale, and a second profile, called “Canadian Intense,” which uses 2 s/55 ml puff every 30 s, has also 
been adopted, and it has recently been recommended that experiments be repeated with both profiles to 
study smoke generation over the range of exposures (96, 150).  Similarly, for e-cigs, knowing user’s puff 
topography characteristics will be important for setting smoke machine parameters in the laboratory and 
for studying appropriate e-cig emissions.  To date, no consensus exists on how to set e-cig parameters, 
and nothing comparable to the Canadian Intense profile has been developed.  However, Farsalinos et al. 
found that e-cig users took puffs of 4.2 s every 23 s, although they did not record the puff volume (78), 
whereas Lee et al. found the average puff duration to be 3.1 s (136).  In contrast, Behar et al. found that 
the average puff duration was 2.75 s every 17 s, with an inhalation volume of 56 ml (22).  These authors 
studied several different types of e-cig and found that parameters varied only slightly with the type of e-
cig used.  It may be that the users puff harder/more frequently on e-cig devices that are less efficient at 
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delivering nicotine to maintain sufficient plasma nicotine levels.  Indeed, data suggested that users were 
able to maintain constant nicotine uptake, despite switching brands (22).  Importantly, until a greater 
consensus is reached, these data suggest that a modified Canadian Intense profile may be a suitable 
parameter for studying e-cig aerosol generation. 
1.7. Will Nicotine and Chemical Constituents in E-liquids/E-cigs Alter Airway Physiology? 
Nicotine is a highly addictive substance that is a major component of both cigarette smoke and e-
cig aerosols that can cause physiological changes to users through nAChRs expressed throughout the 
body (52).  Traditionally, nAChRs were primarily studied as part of the acetylcholine neurotransmitter 
signaling system in the central and peripheral nervous system.  However, nAChR expression has been 
characterized in the airways as well (52, 145, 155, 277).  These ligand-gated ion channels are permeable 
to both Na+ and divalent cations and are physiologically stimulated by acetylcholine.  nAChRs contain 
five subunits of which different subtypes exist (e.g., α, β, γ and δ) (3, 166).  For example, the (α4)3, (β2)2 
nAChR subunit configuration is the most common type in the brain while the (α7)5 or α3, α5, and β4 
subunits are more common in the lung (247).  Lee et al. found that inhaled nicotine from cigarette smoke 
caused airway irritation and a cough reflex via nAChRs expressed in pulmonary afferent neurons (132). 
Interestingly, nAChRs regulate cell proliferation and inhibit apoptosis (69).  For instance, 
Maouche et al. found that α7 nAChRs were enriched in basal lung epithelia and that, during development, 
α7 regulated basal cell proliferation (149), which is important for the maintenance of epithelial cell 
turnover and differentiation.  It is well established that smoking is linked to lung cancer, and a hallmark of 
lung cancer is uncontrolled cell proliferation.  West et al. reported that both nicotine and its metabolite 
(nicotine-derived nitrosamine ketone) stimulated Akt signal transduction downstream of nAChR 
activation, which altered cell proliferation and apoptosis in bronchial epithelia (263).  Specifically, α3, α5, 
and β4 were identified as candidate genes for a potential role in lung cancer from genome-wide 
association studies (37, 109, 214, 235).  Additionally, Lam et al. found different nAChR subunit gene 
expression profiles between nonsmokers and smokers with nonsmall cell lung cancer (128).  In the same 
study, human bronchial epithelial cultures (HBECs) were exposed to nicotine, and expression was 
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compared before and after removal of nicotine.  Interestingly, exposing HBECs briefly upregulated 
nAChR α1, α5, and α7 expression at 72 h that returned to baseline levels after removal of nicotine.  While 
all classes of nAChRs are capable of desensitization through chronic agonist exposure, there are definite 
immediate effects of nicotine on nAChRs in a subunit-dependent manner.  Although it is currently 
unknown whether chronic exposure of nAChR to nicotine via e-cigs can cause lung cancer, the role of 
nAChR α7 in contributing to nonsmall cell lung cancer by altering cell proliferation and apoptotic 
resistance has been reported (128, 180).  
Many inflammatory cells contribute to COPD pathogenesis, including, but not limited to, 
dendritic cells, T and B lymphocytes, monocytes, macrophages, and neutrophils (18, 106).  Of note, 
monocytes, macrophages, and neutrophils, which are impacted by inhaling cigarette smoke in the lungs, 
also express nAChRs.  The effects of noncholinergic signaling in airway inflammatory cells have been 
described (93).  Nicotine suppressed inflammation in human monocytes and in mouse macrophages (154, 
272).  Neutrophil influx occurs in COPD, and indeed neutrophils present in smokers have upregulated 
nAChR expression and display a reduced ability to undergo apoptosis (11, 54).  Likely, these neutrophils 
are more sensitive to inhaled nicotine and have extended life spans, which may serve to prolong 
inflammation in the lungs.  Taken together, these data indicate that nicotine has a proinflammatory effect 
on neutrophils.  However, nicotine also has an anti-inflammatory effect on monocytes/macrophages, 
which may be negated in the case of cigarette smoke due to the inhalation of other proinflammatory 
products such as the tar phase.  This dualism has curious implications for the chronic inhalation of 
nicotine from e-cig aerosols, since many of the cigarette tobacco and tar byproducts that contribute to 
inflammation are not present in e-cig aerosols.  It is possible that the anti-inflammatory effects of 
nicotine, in the absence of proinflammatory constituents, could suppress the user’s immune system.  
Certainly, it is reasonable to assume that high nicotine exposure from e-cigs will be a major 
pharmacological player following e-cig exposure in any organ where nAChR are expressed.  Thus, e-cig 
use may affect inflammation in the airways that could alter a user’s susceptibility to infection and/or 
increase the risk of developing COPD or lung cancer.  
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Despite nicotine’s known addictive and airway irritant properties, it is also known to be bitter 
tasting.  Because of this, e-cigs and their e-liquids present a novel mix of chemical constituents that not 
only contain nicotine but also flavors, sweeteners, and other chemicals, many of which have not been 
studied in the lung.  Many of these chemicals are present to mask the bitter nicotine taste.  Thus, while 
nicotine has been shown to alter many aspects of airway physiology, the potential exists for salty, sweet-, 
and bitter-flavored constituents from e-liquids to stimulate taste receptor signaling pathways that could 
alter airway physiology with chronic use.  To date, however, there is no current literature on the effects of 
e-cigs and chronic vaping in pulmonary physiology of nAChRs or taste receptors.  nAChRs are ligand-
gated ion channels, similar to ion channels that regulate salty taste transduction (e.g., epithelial sodium 
channel) (103).  However, sweet and bitter taste receptors are G protein-coupled receptors (GPCRs).  
GPCRs typically act through Gα proteins to activate phospholipase Cβ (PLCβ) that cleaves membrane-
bound PIP2 to generate inositol 1,4,5-triphosphate (IP3) (64, 75, 233).  IP3 molecules act on ER IP3 
receptors (IP3Rs), eliciting ER Ca2+ release.  The ER transmembrane protein stromal interaction molecule 
1 (STIM1) senses ER Ca2+ depletion and causes puncta formation to interact with the membrane Ca2+ 
channel Orai1 to initiate store-operated Ca2+ entry (SOCE) (Fig. 1.2A-C) (141, 189).  Ca2+ continues to 
initiate signaling downstream by the phosphorylating proteins such as protein kinase Cα (PKCα) (65, 73).  
Of note, membrane receptor tyrosine kinases (RTKs) also have the ability to trigger a similar signaling 
mechanism, though RTKs are not known to detect tastants/odorants (161, 173). 
Interestingly, the ability to taste bitter substances may contribute to smoking behavior and 
nicotine addiction (35, 72, 147).  Bitter taste receptors (T2Rs) are ligand-activated GPCRs that use 
intracellular Ca2+ as a downstream signaling molecule.  There are ~30 T2Rs expressed in humans.  T2Rs 
are most abundant in the tongue, and T2R polymorphisms (e.g., T2R38) that impair the ability to taste 
bitter compounds have been correlated with populations that are more nicotine dependent and/or heavy 
smokers (118, 147).  Furthermore, when tongue tissue was compared for T2R mRNA expression in 
smokers vs. nonsmokers, overall T2R gene expression was reduced in the smoking compared with the 
nonsmoking group (10).  It is unknown whether the reduction of T2R gene expression was genetic or was 
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suppressed by a component of cigarette smoke.  Yet, a correlation between T2R expression and age was 
present in the nonsmoker group and absent in the smoker group, suggesting that starting smoking earlier 
in life could suppress T2R gene expression and contribute to nicotine addiction.  
Many T2Rs have been identified in the upper and lower airway epithelia as well as airway 
smooth muscle cells (50, 63, 223, 253).  Interestingly, T2R38 polymorphisms have also been linked to 
increased susceptibility of upper respiratory infections (135).  Although an endogenous ligand is still 
unknown, known bitter agonists activate these T2Rs and increase intracellular Ca2+, stimulating ciliary 
beat frequency.  Thus, they play a role in detecting noxious inhalants and expelling them from the airways 
due to increased rates of mucociliary clearance.  Nasal mucosa have been reported to express both sweet 
receptors (T1Rs) as well as T2Rs in special nonciliated epithelial cells called solitary chemosensory cells 
(SCCs) (133).  SCCs in the nasal epithelium harbor these receptors along with known components of the 
taste receptor signaling pathway and trigeminal nerve innervation.  Tizzano et al. characterized the 
presence of SCCs with T2Rs and the T2Rs’ ability to detect known bitter agonists and acyl-homoserine 
lactones (253), which are intercellular chemical signaling compounds secreted by Gram-negative bacteria, 
providing more evidence for T2R roles in innate immunity.  Furthermore, Lee et al. found that T1Rs and 
T2Rs in nasal epithelium converge to arbitrate innate immunity (134), that is, when T1Rs are activated 
(e.g., hyperglycemia, chronic rhinosinusitis), they can block the antimicrobial effects of T2Rs, causing 
persistent airway infections.  Together, these data suggest that taste reception in the airways is important 
to innate immunity.  
Nonciliated SCCs are found throughout the lower airways, although T1Rs are not detected there 
(162, 163).  Interestingly, Dehkordi et al. reported that intrapulmonary epithelial SCCs coexpress T2R38, 
its T2R signaling components, and many nAChR subunits in the same cells (60).  Although it is unknown 
whether these two signaling pathways directly interact, it is possible that the coexpression of multiple 
chemosensation receptor types may increase the repertoire and sensitivity of airway cells to inhaled 
irritants, specifically nicotine.  In this case, nicotine might be sensed by either receptor type, and an 
interaction might exist between downstream components of the T2R and nAChR signal transduction 
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pathways (e.g., Ca2+ as a common second messenger) that regulate cellular responses to nicotine.  For 
example, triggering Ca2+ influx from the activation of one nAChR subunit can attenuate the response of a 
second subunit through desensitization of the stimuli or prolong increases in intracellular Ca2+ (86). 
 As mentioned previously, Ca2+ is a common second messenger that acts downstream of not only 
nAChRs but also transient receptor potential (TRP) membrane ion channels.  TRP channels are non-
selective cation channels that have the ability to increase cytosolic Ca2+ concentrations upon activation.  
Several subtypes have been discovered and some natural odorant molecules have been reported as targets 
(190).  These TRP channel subtypes include TRP vanilloid (TRPV), TRP ankyrin (TRPA), and TRP 
melastatin (TRPM).  For example, menthol is able to activate TRPM8 (160) and has been used in menthol 
cigarettes where the TRPM8 activation triggers a cooling sensation that suppresses the bitter nicotine 
flavor for smokers (182).  Cinnamaldehyde is the common cinnamon flavoring used in food and now e-
cig products and is capable of activating TRPA1 (16, 117).  Lastly, vanillin is a common vanilla flavoring 
capable of activating TRPV1 and TRPV3 (143, 269). 
1.8. Effects of E-liquids and E-cig Aerosols on Cultured Cells from the Lungs 
Tobacco smoke is highly proinflammatory and has been shown to trigger the release of 
inflammatory cytokines from endothelia, epithelia, and leukocytes (30, 95, 131).  These cytokines can 
then trigger additional changes, including goblet cell metaplasia and neutrophil influx (127).  
Inflammation may be beneficial in the short term, especially when resolving infection.  However, chronic 
inflammation can act as a precursor to cancer, and continued influx of neutrophils, with the subsequent 
increase in free elastase levels, can lead to cell damage and denudation of the epithelia (32, 243).  
Tobacco exposure is also associated with cellular cytotoxicity, including increased apoptosis, 
autophagosome formation, membrane permeability, and mitochondrial damage (67, 115, 130, 213).  
Furthermore, micronuclei form when chromosomes or parts of chromosomes are excluded from daughter 
nuclei following cell division (81).  As such, micronuclei formation is associated with a high risk of 
cancer and is a common assay that is used to screen for genotoxic substances, and increased micronuclei 
formation has been observed in cigarette smokers (61, 251).  Tobacco smoke has also been shown to alter 
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gene expression and DNA methylation in both the whole lung and in airway epithelia (99, 184, 257), 
macrophages (68), and endothelia (273).  Many of these assays have been established as outcome 
measures for tobacco smoke exposure, and they should be useful for probing the effects of e-cig exposure.  
To date, many cell types have been exposed to e-liquids and/or e-cig aerosols.  These cell types 
include lung epithelial cell lines (H292, A549), lung fibroblasts, human primary trachea-bronchial cells, 
and HaCaT keratinocytes (42, 137, 267).  Whereas e-liquids are aerosolized, a common early approach 
has been to add e-liquids directly to cells at various dilutions.  Although this protocol would not pick up 
any additional effects of pyrolysis due to heating the e-liquid, it is a useful first step to determine whether 
e-liquids themselves have inherent toxicity.  Wu et al. exposed nondifferentiated tracheobronchial 
cultures to a tobacco-flavored e-liquid that contained either 18 mg/ml of nicotine (which equates to 111 
mM) or was nicotine free for 24–48 h over the range (vol/vol) 0.01–0.3% (InnoVapor, Boise, ID) and 
found that exposures in this range did not increase lactate dehydrogenase (LDH) levels, suggesting that 
they were not cytotoxic (267).  However, the upper levels of dosing caused significant increases in IL-6 
and IL-8 levels, also increasing rhinovirus infection and rhinovirus-induced IL-6 secretion and decreasing 
mRNA levels of SPLUNC1, an innate defense molecule (248, 267).  Whereas increases in IL-6 secretions 
have been detected after rhinovirus infections (195), the implication of this observation in the context of 
e-cig and/or tobacco exposure is not fully understood and needs additional testing.  However, increased 
IL-6 responses to viral infection have been detected in COPD patients, suggesting that this may be a 
relevant assay for e-cig exposure (219).  Lerner et al. found that e-liquids altered HFL-1 cell morphology 
(137).  Bahl et al. tested the effects of e-liquids, directly added to murine pulmonary fibroblasts, human 
embryonic stem cells, and murine neural stem cells (15).  Although effects of e-liquids were typically 
seen with ≥0.1% (vol/vol) addition, in general, the stem cells were more sensitive than the fibroblasts, 
suggesting that some cell types in the lung may be more vulnerable to e-cigs than others.  Furthermore, of 
the 36 e-liquids tested, ~15 showed cytotoxicity, with cinnamon flavors being especially toxic.  Of 
interest, the authors found significant variability in cytotoxicity from batch to batch, even for one flavor 
from one vendor, which suggests that poor quality control may exist in some cases. 
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In addition to directly studying the effects of e-liquids, they can be heated/aerosolized and then 
studied.  Cervellati et al. exposed A549 (lung epithelial) and HaCaT (keratinocytes) cells to whole 
cigarette smoke or e-cig vapor from three combinations of e-cigs (nicotine; nicotine + flavor; no flavor, 
no nicotine) (42).  After 50 min of smoke or aerosol exposure, cultures were then left for 24 h, and LDH 
release and cell viability were studied.  No information was given regarding whether these cells were 
polarized or not.  However, they found that, under these conditions, e-cigs with nicotine and/or flavor 
induced similar cytotoxicity (increased LDH release and decreased cell viability) as standard cigarettes 
while nicotine and flavor-free e-cigs did not have any effect.  E-cig aerosols (generated using a 4 s/35 ml 
pulse) also caused an increase in IL-6 and IL-8 secretion, which in the case of one flavor (cinnamon roll) 
was greater than the IL-8 secretion seen with cigarette smoke extract addition (137).  
The effects of e-cig exposure have also been studied on the lung’s microvasculature.  For 
example, Schweitzer et al. found that e-cigs decreased the electrical resistance of endothelial cells derived 
from mice, rats, and humans, and exerted significant effects on cell viability and 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide production that were associated with changes in cell signaling 
(activation of p38 mitogen-activated protein kinase) (222).  Interestingly, these changes were similar to 
those observed after exposure to cigarette smoke extract (222).  They also detected increased 
phosphorylation of myosin light chain and Rho kinase following e-cig exposure, which may have been 
due to activation of sphingolipids (222).  Changes in the permeability in the lung’s microvasculature may 
induce edema and/or increase the number of leukocytes that can enter the lung, thus increasing 
inflammation, as described elsewhere (126).  
1.9. Effects of E-cigs on the Murine Lung 
Although little is known about the effects of e-cigs on humans, some studies have been performed 
in mice.  E-cig exposure has been shown to elicit neuropharmacological effects, including upregulation of 
nAChR, in different areas of the brain and also caused signs of addiction and increased serum and 
cotinine levels, suggesting that comparable systemic nicotine levels can be obtained with e-cig exposure 
as are seen with tobacco exposure (2, 188).  Lerner et al. exposed mice to e-cig aerosols for 5 h/day for 3 
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days and examined the mice 1 day later.  They found that several cytokines were increased in the 
bronchoalveolar lavage of these mice, including IL-1α, IL-6, IL-13, and monocyte chemoattractant 
protein-1 (MCP-1) (2015).  Of note, MCP-1 recruits macrophages to the lung, IL-6 is a proinflammatory 
cytokine, and IL-13 induces cellular remodeling and goblet cell hyperplasia.  Schweitzer et al. found that 
an e-cig exposure regimen, which was equivalent in dose to exposure to smoke from two cigarettes, 
caused a significant increase in 8-oxo-2’-deoxyguanosine (8-oxo-dG) in both plasma and bronchoalveolar 
lavage (222).  8-oxo-dG is a marker of systemic oxidative stress and is indicative of DNA damage (169).  
They also detected increased nitrotyrosine levels in plasma.  Nitrotyrosine can be formed following 
exposure to reactive nitrogen species such as peroxynitrite anion and nitrogen dioxide and is also a 
marker of cell stress/damage (204).  A 2-wk exposure to e-cigs smoked under relatively standard 
conditions (2-s 35-ml puff) caused a significant increase in the number of macrophages in murine lungs 
and actually decreased IL-6 (222).  The differences in IL-6 levels observed between the two experiments 
are most likely due to differences in smoking (vaping) regimens since one was acute and the other was 
chronic (137, 222).  Mouse strain differences and/or differences in e-cig device/e-liquid may also have 
been factors.  
After infection with Streptococcus pneumonia, e-cig-exposed mice were less able to clear this 
infection, suggesting that innate defense was impaired (240).  They also found that H1N1 influenza virus 
infection also was poorly cleared.  Although these data will need to be repeated by other groups, it is the 
first report that e-cig exposure leads to increased susceptibility to infection, which has important 
implications for the safety of e-cig users.  Interestingly, increased susceptibility to pathogens is a hallmark 
of tobacco exposure and is seen following both viral and bacterial infections (84, 175, 197).  In addition 
to these aerosol exposures, a 50-fold-diluted e-cig liquid has been shown to increase IL-4, IL-5, and IL-13 
in allergen-sensitized mice when tracheally instilled (140), again suggesting that e-liquids can still have 
adverse effects even before they are vaporized.  
The adverse effects of tobacco on both prenatal and postnatal development have been well 
described and include low birth weight, increased incidence of sudden infant death syndrome, and 
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development of lung disease later in life (e.g., asthma) (1, 90).  Whereas most published studies to date 
have focused on adult mice, it has been demonstrated that e-cig exposure also adversely effects neonatal 
mice and leads to impaired development, including decreased weight gain and reduced cell proliferation 
in the lungs, suggesting that secondhand vaping may also potentially be a cause for concern and could 
adversely affect lung development (158). 
1.10. Effects of E-cig Exposure in Humans 
Currently, many adult e-cig users are former smokers and have a significant history of tobacco 
usage before using e-cigs and/or continue to be mixed tobacco/e-cig users (89, 192).  This will make 
studying the chronic effects of e-cigs difficult since the airways/lung retain a significant memory of 
smoking history/exposure even after smoking cessation.  For example, Rager et al. found significant 
evidence of DNA methylation in the nasal epithelia of ex-smokers (194).  Thus, for any observed effects 
on e-cig smokers, the previous and/or current tobacco smoking history must be taken into account.  That 
said, the largest and fastest-growing population of e-cig users who have never smoked tobacco is 
adolescents.  For example, in North Carolina, 15% of high school students have vaped e-cigs, and 60% 
thought that e-cigs were safe.  In contrast, among the same group, 24% had smoked cigarettes (7).  This 
trend is reflected nationally (156).  
It has been shown that short-term (e.g., 5 min) e-cig inhalation leads to comparable plasma 
cotinine levels as regular tobacco smoking and exerts rapid physiological effects on the cardiovascular 
system, including elevated heart rate (255).  These data indicate that modern e-cigs are delivering 
significant amounts of nicotine to the bloodstream.  Although to date no studies have been performed to 
look at the adverse effects of e-cigs on pulmonary health (e.g., inflammation, etc.),  Vardavas et al. looked 
at the effects of 5 min e-cig exposure on pulmonary function using standard spirometry (256).  
Interestingly, they found that a 5-min e-cig exposure caused a significant increase in peripheral airway 
resistance, which is indicative of changes to the small airways.  The authors noted that these changes were 
relatively small and likely not great enough to be of immediate clinical significance.  However, the 
changes were observed after only 5 min of exposure, and they speculated that chronic exposure may lead 
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to greater changes in resistance.  They also found that this 5-min exposure caused a significant decrease in 
exhaled nitric oxide (NO) levels.  NO has a number of functions in the lung, and changes in NO levels 
can affect ciliary beating, transcription, inflammation, ion transport, and airway smooth muscle tone (31).  
NO is altered in many diseases, including asthma (increased), cystic fibrosis (decreased), primary ciliary 
dyskinesia (decreased), and COPD (may be suppressed or mildly increased) (275).  Thus, it is possible 
that e-cig exposure could cause different lung disease to COPD. 
1.11. Conclusions and Future Directions 
There is a long history of deceptive marketing tactics used by the tobacco industry regarding the 
‘safety’ of cigarettes (76).  Thus, it is interesting to speculate whether the same will hold true for the 
nascent e-cig industry.  Certainly, users want to believe that e-cig products are safe, but, unfortunately, no 
definitive data currently exist to prove or disprove this hypothesis.  Studying e-cig exposure is very much 
like trying to hit a moving target, but one where researchers are not completely sure what the target looks 
like, since e-cig devices, the way that they are used, and the types/flavors of e-liquids available are 
constantly changing.  However, some facts have been established: 1) current e-cig devices deliver 
nicotine at comparable levels to cigarettes, and certainly at levels high enough to evoke physiological 
responses in humans and rodents (79, 158, 234), 2) nicotine is highly addictive and, along with its  
metabolites, can cause cancer and affect neuronal development in adolescents irrespective of its source 
(71, 260), 3) e-liquids have been shown to contain potentially toxic aldehydes and ROS (246), and 4) 
some type of a biological response (e.g., change in cytokine levels) has been observed in the vast majority 
of murine in vivo and in vitro studies following e-cig vapor/e-liquid exposure (137, 222, 256).  Although 
it seems certain that e-cig aerosols contain toxicants, it is fair to say that they likely contain less types of 
toxicants than cigarette smoke (i.e., e-cig aerosols likely have hundreds of chemicals in them while 
tobacco smoke has thousands of chemicals).  The remaining question is then one of dose ranging, that is, 
are the toxicants in e-cigs present in sufficiently high concentrations to elicit lung disease over a similar 
time frame as tobacco smoking?  
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Given the paucity of information that is available regarding the effects, not only of e-cigs, but 
also of many of the chemical constituents of e-liquids on the lungs, we propose that all commercially 
available e-cig products be regulated in a similar fashion as any inhaled therapeutic agent, that is, 
thorough inhalation toxicology and safety-based clinical trials.  Although this would be an undeniably 
expensive undertaking, the estimated value of the e-cig market is in the billion dollar range, indicating 
that tobacco and e-cig companies could likely foot this bill. 
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Figure 1.1.  1st-3rd generation e-cig device schematics.  A: Schematic of 1st generation disposable 
‘cigalike’ device.  B: 2nd generation vape pen with refillable tank and rechargeable battery.  C: Schematic 
of 3rd generation refillable atomizer tank with replaceable coil and corresponding mod device equipped 
with user controls and rechargeable battery. 
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Figure 1.2.  GPCR signaling pathway causes IP3-mediated ER Ca
2+ release and SOCE.  A: At basal 
conditions, Ca2+ concentrations are low within the cytosol and high in the extracellular space and within 
the ER.  B: GPCR activation elicits PLCβ cleavage of PIP2 to generate IP3, which acts on ER IP3Rs to 
release ER Ca2+ and increase cytosolic Ca2+ concentrations.  C: STIM1 senses ER Ca2+ depletion and 
forms aggregates and interacts with Orai1 to activate SOCE, prolonging the elevated Ca2+ concentration 
as the ER Ca2+ store is refilled by the SERCA pump. 
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Figure 1.3.  Summary of the effects of e-cig and e-liquid exposures in pulmonary cell types.  
Included in the table is a short list of the current in vitro and in vivo study outcomes for lung-related cell 
types that are depicted in the cartoon and labeled appropriately.
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Chapter 2: Flavored E-cigarette Liquids Reduce Proliferation and Viability in the CALU3 Airway 
Epithelial Cell Line 
2.1. Overview 
E-cigarettes are generally thought of as a safer smoking alternative to traditional cigarettes.  
However, little is known about the effects of e-cigarette liquids (e-liquids) on the lung.  Since over 7,000 
unique flavors have been identified for purchase in the United States, our goal was to conduct a screen 
that would test whether different flavored e-liquids exhibited different toxicant profiles.  We tested the 
effects of 13 different flavored e-liquids [with nicotine and propylene glycol/vegetable glycerin (PG/VG) 
serving as controls] on a lung epithelial cell line (CALU3).  Using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay as an indicator of cell proliferation/viability, we demonstrated 
a dose-dependent decrease of MTT metabolism by all flavors tested.  However, a group of four flavors 
consistently showed significantly greater toxicity compared with the PG/VG control, indicating the 
potential for some flavors to elicit more harmful effects than others.  We also tested the aerosolized vapor 
from select e-liquids on cells and found similar dose-dependent trends, suggesting that direct e-liquid 
exposures are a justifiable first-pass screening approach for determining relative e-liquid toxicity.  We 
then identified individual chemical constituents for all 13 flavors using gas chromatography-mass 
spectrometry.  These data revealed that beyond nicotine and PG/VG, the 13 flavored e-liquids have 
diverse chemical constituents.  Since all of the flavors exhibited some degree of toxicity and a diverse  
 
 
2This chapter previously appeared as an article published in American Journal of Physiology Lung Cell 
Molecular Physiology and is reprinted with permission. The original citation is as follows: Rowell TR, 
Reeber SL, Lee SL, Harris RA, Nethery RC, Herring AH, Glish GL, Tarran R. Flavored e-cigarette 
liquids reduce proliferation and viability in the CALU3 airway epithelial cell line. Am J Physiol Lung Cell 
Mol Physiol 313: L52-L66, 2017. 
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array of chemical constituents with little inhalation toxicity available, we conclude that flavored e-liquids 
should be extensively tested on a case-by-case basis to determine the potential for toxicity in the lung and 
elsewhere. 
2.2. Introduction 
E-cigarettes (e-cigs) have been growing in popularity since their debut in 2007 and are estimated 
to become a $50 billion global market by 2025 (202).  E-cigs differ from tobacco cigarettes in that they do 
not contain tobacco, have varied nicotine concentrations (0–36 mg/ml), and produce an inhalable aerosol 
(vapor) that is generated without combustion.  Instead, an e-cig liquid (e-liquid) is drawn and heated over 
a battery-operated coil as the user inhales.  E-liquids are usually composed of a vehicle with varying 
ratios of propylene glycol (PG) and vegetable glycerin (VG) that contain nicotine and chemical flavors. 
Recently, the Food and Drug Administration (FDA) introduced rules to regulate e-cig products 
(https://www.fda.gov/TobaccoProducts/Labeling/ProductsIngredientsComponents/ucm456610.htm) (206, 
209).  Despite this legislation, there continues to be much debate over the safety and efficacy of these 
products.  E-cigs have commonly been marketed as a safer smoking alternative because they lack the 
carcinogens from tobacco and presumably fewer of the pyrolysis products from combusting tobacco that 
are associated with smoking-related diseases.  However, some e-cig devices are capable of producing 
pyrolysis products (i.e., reactive aldehydes) and oxidant species similar to traditional cigarettes (137, 218, 
240), but the conditions under which users would actually be exposed to disease-causing levels of these 
products remain a source of controversy. 
While the direct health effects of cigarette smoke exposure have been extensively studied with 
evidence-based links found between tobacco use and both lung cancer and chronic obstructive pulmonary 
disease, e-cig research is still lagging behind consumer use.  A review of all known studies reporting 
effects of e-cig aerosols and e-liquids on the lung amounted to less than 15 in 2015 (212).  Fortunately, 
the interest concerning lung health effects of e-cigs has led to many more research publications since 
then.  However, there is still much that is unknown about the biological effects of e-cigs.  Of particular 
concern, e-cig use in middle and high school students has tripled in just three years (156) and by 2015, 
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more than a quarter of middle and high students had tried e-cigs (254).  Furthermore, the availability of 
over 7,000 unique flavors in the United States (276) alone may contribute to their popularity in 
adolescents (6). 
It is currently unknown whether or not long-term e-cig use will cause respiratory diseases similar 
to cigarette smoke, none at all, or something entirely different.  For example, bronchiolitis obliterans or 
“Popcorn Workers’ Lung” is scarring of the small airways that can range from mild and reversible to 
severe and irreversible.  Prolonged inhalation of diacetyl, a buttery-flavored chemical used in microwave 
popcorn manufacturing and elsewhere, can and has caused this disease in some workers at microwave 
popcorn manufacturing plants (17, 124).  Although diacetyl is safe to eat and thus found on the “generally 
recognized as safe” list, it is clearly not safe to inhale.  Diacetyl and many other flavorings have only been 
tested and approved for ingestion and have not been tested for inhalation toxicology.  Despite the known 
link between diacetyl and bronchiolitis obliterans, Allen et al. reported that either diacetyl or 2 other 
prominent butter-flavored chemicals (2,3-pentanedione and acetoin) were detected in 47 of 51 flavored e-
liquid aerosols tested (5).  Thus there is the potential for e-liquid flavors to have as yet unknown and 
possibly negative effects on the lung, as has recently been discussed (19). 
Given the variety of available flavors and devices, information is needed regarding the biological 
effects of different e-liquids and their individual constituent(s) on the different cell types in the respiratory 
system.  Therefore, we used a high-throughput screening approach to assess the potential effects of 13 
different flavored e-liquids and their respective controls on cell proliferation and an array of viability and 
toxicity markers over a range of doses following direct- and vaped- e-liquid exposure.  Although several 
researchers have investigated the effects of e-liquids or e-cig aerosols on the lung, few studies have 
focused on 1) identifying component chemicals and 2) assessing their biological effects (15, 21, 79, 111, 
112, 217, 226, 252).  Therefore, we also conducted mass spectrometry analysis on all 13 flavors to pair 
biological outcomes with chemical constituent(s) identified in each flavor to understand which flavors 
and individual constituents may alter lung epithelial cell proliferation and/or viability. 
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2.3. Methods 
Flavored e-cig liquids.  All flavored e-cig liquids (e-liquids) were purchased from The Vapor Girl 
(https://www.thevaporgirl.com/).  The tested flavors were Captain Black Cigar, Peanut Butter Cookie, T-
bone, Popcorn, Black Licorice, Energon (orange energy drink), Vanilla Tobacco, Banana Pudding 
(Southern Style), Kola, Hot Cinnamon Candies, Menthol Tobacco, and Solid Menthol.  All e-liquids were 
ordered to contain 12 mg/ml nicotine.  An additional 0 mg/ml nicotine Captain Black Cigar was 
purchased as a nicotine-free control.  At the time of purchase, the vehicle liquid was advertised as a 70/30 
ratio of PG to VG.  Thus a vehicle control was made in our laboratory using 70 PG/30 VG.  For all 
aerosol experiments, additional Peanut Butter Cookies, Banana Pudding, and Hot Cinnamon Candies e-
liquids were purchased from The Vapor Girl.  All three additional e-liquids were ordered to contain 12 
mg/ml nicotine and a 55/45 ratio of PG/VG.  Therefore, we made an additional 55 PG/45 VG control for 
the aerosol experiments. 
Chemicals and reagents.  PG, VG, DMSO, probenecid, and methanol were purchased from 
Sigma-Aldrich. DAPI, calcein (AM), MitoTracker Red (CMXRos), fluo-4 (AM), and the Vybrant MTT 
Cell Proliferation Assay Kit were purchased from Life Technologies.  Nicotine was purchased from Alfa 
Aesar.  The Cytotoxicity Detection KitPLUS (LDH) was purchased from Roche. DAPI, calcein (AM), 
MitoTracker Red (CMXRos), and fluo-4 (AM) were reconstituted using DMSO and applied to cells in 
experiments where the final DMSO concentration was ≤0.1%. 
Cell culture.  CALU3 cells were cultured in MEM alpha with 10% FBS and 
penicillin/streptomycin (GIBCO) as described (49).  For the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay, MEM alpha without phenol was used per the manufacturer’s 
guidelines.  Cells were seeded into 96-well black-walled clear bottom plastic plates (Corning).  For e-
liquid 24-h studies, cells were seeded at 12,500 or 45,000 per well for 12 h overnight and the 24-h 
treatment began the next morning.  E-liquids were diluted (%vol/vol) in CALU3 media.  After 24 h, e-
liquid-treated media was removed from cells and assays were performed.  For aerosol 24-h studies, cells 
were seeded at 25,000 per well for 4–8 h and media were changed just before aerosol treatments were 
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performed.  After aerosol exposures, cells were incubated for 24 h before aerosol-exposed media were 
removed and assays were performed. 
Cell proliferation.  The MTT assay was performed as instructed by the manufacturer after cells 
were treated for 24 h with either PBS, 70 PG/30 VG, nicotine, or flavored e-liquids.  Cells were allowed 
to proliferate for 4 h after removal of the treatments.  Data were calculated as percent absorbance of each 
treatment compared with the average of the 0% e-liquid (media control) treatments in each plate.  
Nonlinear regression curves were fit to each flavor or nicotine ± PG/VG dose responses in the MTT 
assays using GraphPad Prism to calculate IC50 values where appropriate. 
Cell number and viability.  Total cell number was measured at the end of the 24-h e-liquid and 
aerosol exposures.  Cultures were rinsed with PBS and fixed with 100% methanol.  After fixation, cells 
were rinsed again with PBS and stained with DAPI for 10 min.  Cultures were rinsed following staining, 
and DAPI fluorescence intensity was measured using the Tecan Infinite Pro plate reader [excitation (ex): 
360 ± 5 nm; emission (em): 460 ± 5 nm].  Total cell number was calculated as percent fluorescence of the 
e-liquid- or aerosol-treated cells compared with the average of the 0% e-liquid or 0 puff (media control) 
wells in each plate.  Cell/mitochondrial viability was assessed using calcein and MitoTracker Red 
fluorescent indicators.  After 24-h e-liquid or aerosol exposures, treated media were exchanged for fresh 
media containing either 3 µM calcein or 125 nM MitoTracker Red.  Cultures were incubated for 30 min at 
37°C.  Cultures were then rinsed, media were replaced with a standard Ringer’s solution, and 
fluorescence intensities were read using the Tecan Infinite Pro plate reader for calcein (ex: 495 ± 5 nm; 
em: 516 ± 5 nm) or MitoTracker Red (ex: 579 ± 5 nm; em: 599 ± 5 nm), respectively.  Cell/mitochondrial 
viability was calculated as a percent fluorescence of e-liquid or aerosol-treated cells compared with the 
average of the 0% e-liquid or 0 puff (media control) wells in each plate. 
Cytotoxicity (membrane permeability – LDH release).  Membrane permeability due to e-liquid 
exposure was measured using the Cytotoxicity Detection KitPLUS.  Media were collected from e-liquid-
treated wells after 24-h exposure and the LDH assay was performed per manufacturer’s instructions.  
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Data were calculated as percent LDH release compared with a lysed control and reported as %LDH 
release, where 
%𝐿𝐷𝐻 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 =
𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑣𝑎𝑙𝑢𝑒 − 𝑙𝑜𝑤 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
ℎ𝑖𝑔ℎ 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑙𝑜𝑤 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
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Ca2+ signaling.  Changes in cytosolic Ca2+ concentration were measured using 8 µM fluo-4 dye 
loaded into cells in the presence of 1 mM probenecid for 40 min at 37°C.  Cultures were then rinsed, and 
media were replaced with a standard Ringer’s solution and fluorescence intensities were read every 15 or 
30 s using a Tecan Infinite Pro plate reader for fluo-4 (ex: 494 ± 5 nm; em: 516 ± 5 nm).  A fluorescent 
baseline was established before the nicotine doses were added to the wells, and changes in fluorescence 
were normalized to the baseline (F/F0).  The peak change in F/F0 was measured for each dose, and a 
nonlinear regression curve was fit using GraphPad Prism to calculate the EC50. 
RNA extraction, cDNA synthesis, and quantitative RT-PCR.  RNA was extracted from untreated 
CALU3 cells using the Qiagen RNeasy kit following the manufacturer’s protocol.  cDNA was 
synthesized using the Bio-Rad iScript cDNA synthesis kit following the manufacturer’s protocol.  Gene 
expression was measured using Taqman gene expression assays from Applied Biosystems for Orai1, 
Scnn1A, P2Y2R, GAPDH, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNB1, CHRNB2, and CHRNB3 
using human primers.  Genes of interest were normalized to GAPDH and fold change was calculated 
using ∆∆CT method relative to Orai1. 
Aerosol exposures.  E-liquids were heated to generate aerosols using Uwell Crown tanks with 
0.25-Ω dual-coils and a Sigelei Fuchai 200W device.  The power output was set to either 40 or 100 W, as 
indicated. Filter pads (GE Healthcare Life Sciences) with a 2-µm pore size were used to collect 
particulates from the aerosol.  The filter pads were weighed before and after 15 or 35 puffs of either 40 W 
or 100 W, 55 PG/45 VG were passed through them.  CALU3 cells seeded in 96-well plates were exposed 
to a range of puffs (0 –35) from either air, 55 PG/45 VG vehicle, 70 PG/30 VG vehicle, Peanut Butter 
Cookies, Banana Pudding, or Hot Cinnamon Candies.  A syringe was used to collect, measure, and apply 
the aerosol to the wells.  A 70-ml puff was applied once every 30 s and was distributed among six wells at 
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once using a three-dimensional printed acrylic six-channel manifold.  After aerosol exposures, the cells 
were incubated for an additional 24 h before measuring total cell number or viability.  These were 
calculated as percent fluorescence of the aerosol-treated cells compared with the average of the 0 puff 
(media control) wells per plate, which were covered with silicone strips to avoid aerosol exposures.  
Mass spectrometry.  Samples of e-liquids were diluted 10- or 50-fold in methanol and analyzed 
by gas chromatography-mass spectrometry (GC-MS) using an Agilent 6890 GC with an Agilent MSD 
mass spectrometer.  One-microliter volumes were introduced by manual injection and were separated on 
an Agilent DB-5 column with helium carrier gas.  The temperature was ramped from 60 to 300°C at a rate 
of 20°C/min.  GC-MS spectra were analyzed using NIST AMDIS software coupled to the NIST 2008 
mass spectral database for automated database searching.  Constituent profiles of flavors were compared 
between all 13 e-liquid flavors using peak areas under the curve from GC-MS data that were discretized 
into a value of 0 (absent) or 1 (present) and compared using R software.  
Statistical analyses.  Data (see Figs. 2.1A, C; 2.3A–D; 2.4A, B; and 2.5A, B) were fit using a 
linear mixed model with main effects for flavor and dose, a flavor by dose interaction, and a random 
intercept to control for possible plate effect.  A similar analysis was performed (see Fig. 2.5C, D), where 
puff number and wattage were analogous to flavor and dose.  Based on these models, subanalyses were 
performed to investigate if there was an association between dose and response within a flavor.  To 
reduce inflation of type 1 errors, a step-down approach was used in testing.  Overall tests for a statistically 
significant dose and flavor interaction were performed first, and tests for the presence of a dose and 
response association within each individual flavor were performed only if the overall test was significant.  
Further tests to determine which doses were significantly different within a flavor were performed only if 
the previous test confirmed the existence of a dose and response association within that specific flavor.  In 
the nicotine-dosing experiments, responses within each nicotine ± PG/VG treatment were compared with 
the respective 0 mg/ml. Graphpad Prism software was used to compare the log(IC50) values between 
dose-response curves for select flavored e-liquids (%vol/vol) and nicotine (mg/ml) ± PG/VG (see Figs. 
2.1B, D; Table 2.1). 
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For Fig. 2.2A, we fit a linear model to each log-transformed outcome with a fixed effect for gene 
type.  Log transformations were used to ensure adherence to the modeling assumptions.  If an overall test 
for the effect of gene type was found to be significant, we tested for pair-wise differences between each 
gene and Orai1.  In Fig. 2.5E we fit a linear model with main effects for puff number and wattage and a 
puff number by wattage interaction term.  Significant differences in puff numbers within each wattage 
level and significant differences in wattage levels within each puff number were identified using 
contrasts.  Statistical modeling was performed using R statistical software (250) with the nlme package 
(185).  Statistically significant relationships in all figures were reported (#,*P ≤ 0.05; ##,**P ≤0.01; 
###,***P ≤ 0.001). 
2.4. Results 
E-liquid exposures inhibit cell proliferation/viability in a dose-dependent manner.  To compare 
the effects of different flavored e-liquids on airway epithelia, we selected a range of flavors that covered 
not only traditional menthol and tobacco cigarette flavors but a variety of foods and beverages.  We also 
purchased the Captain Black Cigar flavor with and without nicotine to control for the effects of nicotine.  
Cells were exposed to a range of e-liquid dilutions directly into the culture media over 24 h to assess cell 
viability and proliferation after treatment, with 70 PG/30 VG serving as the vehicle control.  To control 
for the possible effects of diluting the media, we also provided a PBS control group where we serially 
diluted media with PBS.  We used the MTT assay to indirectly assess the number of viable cells and their 
ability to proliferate in each treatment.  We found dose-dependent decreases in each e-liquid flavor tested, 
irrespective of nicotine, as well as our 70 PG/30 VG vehicle.  These effects were not due to dilution of the 
growth media since the PBS dilutions had no effect on MTT absorbance (Fig. 2.1A).  The T-bone flavored 
e-liquid was not tested at a 6 or 10% dose because our purchased stock had run out and the vendor 
discontinued this flavor before these experiments were completed.  There were dose-dependent decreases 
in MTT metabolism for all flavors and the 70 PG/30 VG vehicle at ≥3% dose.  Moreover, four flavors 
[Banana Pudding (Southern Style), Kola, Hot Cinnamon Candies, and Menthol Tobacco] showed 
significantly greater decreases in MTT metabolism compared with 70 PG/30 VG at 3% (P ≤  0.001).  
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When these four flavors were fitted with dose-response curves to calculate their IC50s, these flavors had 
lower IC50s than 70 PG/30 VG (Fig. 2.1B; Table 2.1), suggesting that they were more toxic.  We also 
directly compared the responses of cells exposed to the Captain Black Cigar flavor ± nicotine and found 
that there were more severe effects in the nicotine-containing e-liquid compared with the nicotine-free e-
liquid at ≥3% (Fig. 2.1C), suggesting that nicotine exerted additional effects beyond what was seen with 
the base e-liquid. 
Nicotine decreases cell proliferation/viability dose dependently and is cytotoxic.  Since we found 
additional dose-dependent effects of nicotine beyond what was seen with the Captain Black e-liquid 
alone, we sought to determine whether these negative effects were mediated by nicotinic acetylcholine 
receptors (nAChRs).  We used quantitative RT-PCR to survey nAChR subtype gene expression in 
CALU3 cells relative to a common membrane Ca2+ channel (Orai1; Fig. 2.2A).  As additional controls, 
we also looked at Scnn1a (epithelial sodium channel alpha subtype) and P2Y2R (purinergic receptor) 
expression.  Five of 7 nAChR subtypes were detected in CALU3 cells, but only CHRNA5 was expressed 
above the levels of Orai1, Scnn1a, or P2Y2R levels, while CHRNA6, CHRNA7, CHRNB1, and CHRNB2 
had much lower expression levels.  nAChRs are ligand-gated ion channels that are permeable to Ca2+ 
ions, and since there was detectable nAChR subtype expression in CALU3 cells, we tested for functional 
activity using a fluorescent cytosolic Ca2+ indicator (fluo-4).  The peak change in fluorescence per 
nicotine dose was plotted (Fig. 2.2B), and the EC50 was calculated (Table 2.1).  The EC50 for nicotine was 
2.89 mg/ml (17.8 mM) in CALU3 cells.  However, the EC50 of nicotine for various nAChRs has been 
reported in the micromolar range (48, 92).  Since increases in cytosolic Ca2+ can also be caused by 
cytotoxicity from permeabilized membranes, we measured cell viability and found a decrease in calcein 
fluorescence in cultures treated with ≥4.9 mg/ml nicotine (Fig. 2.2C; Table 2.1), suggesting that the 
effects of Ca2+ were due to cytotoxicity rather than being mediated by nAChRs.  
Finally, we measured percent MTT absorbance in cells exposed to increasing doses of nicotine ± 
1 or 3% 70 PG/30 VG to understand the potential negative role that nicotine ± vehicle might be having on 
CALU3 proliferation/viability.  We chose a range of doses that encompassed the nicotine concentrations 
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in our e-liquid exposures (%vol/vol) from Fig. 2.1A.  Irrespective of the presence of PG/VG, we found 
that there were dose-dependent decreases in percent absorbance with increasing doses of nicotine (Fig. 
2.2D).  Treating cells with 1% 70 PG/30 VG in combination with nicotine did not have additional effects.  
However, 3% 70 PG/30 VG decreased the threshold of MTT absorbance alone compared with either 0 
mg/ml nicotine (media control) or 1% 70 PG/30 VG (P ≤ 0.001).  There was no difference between 
log10(IC50) values of each nicotine treatment ± 70 PG/30 VG (Table 2.1), suggesting that adding nicotine 
to 70 PG/30 VG did not have a synergistic effect on cell proliferation.  However, since most flavors 
caused a significant decrease in MTT absorbance at 3% (Fig. 2.1A), it is likely that 3% 70 PG/30 VG, 
rather than nicotine, caused the decrease, since 3% e-liquid contains 0.36 mg/ml nicotine, which is 
insufficient to affect MTT metabolism when combined with 70 PG/30 VG (Fig. 2.2D). 
The four flavors of interest decreased cell number/viability in subconfluent CALU3 cultures.  The 
initial screening of the 13 purchased e-liquid flavors on CALU3 cells directed our attention to four flavors 
of interest because of their lower IC50s in the MTT assays compared with 70 PG/30 VG.  Therefore, we 
continued screening the effects of all of the flavors on other measures of cell viability and toxicity but 
focused on the effects of these four flavors in this paper [i.e., Banana Pudding (Southern Style), Kola, Hot 
Cinnamon Candies, and Menthol Tobacco].  We also tested Peanut Butter Cookies, a less toxic flavor, as 
well as Captain Black Cigar ± nicotine to control for the potential effects of nicotine.  We performed 
additional analyses by measuring total cell number using DAPI staining (Fig. 2.3A).  We found dose-
dependent decreases in cell number 24 h after exposure to 70 PG/30 VG, Captain Black Cigar ± nicotine, 
Peanut Butter Cookies, as well as our four flavors of interest.  We then used the fluorescent dyes calcein 
(Fig. 2.3B) and MitoTracker Red (Fig. 2.3C) as indicators of viable cells and active mitochondria, 
respectively (62, 102).  Overall, 70 PG/30 VG only exerted effects on total cell number at 3% (Fig. 2.3A).  
However, the Captain Black Cigar e-liquids, irrespective of nicotine, as well as the four more toxic 
flavors of interest, showed dose-dependent decreases in all three measures (Fig. 2.3A–C).  Moreover, the 
four flavors of interest were significantly more toxic than either 70 PG/30 VG or Captain Black Cigar ± 
nicotine at the 3% dose (P ≤ 0.0001).  Since cell density and viability were reduced, we further 
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investigated the potential for cytotoxicity using LDH release as a marker (Legrand et al., 1992).  A 24-h 
exposure to 70 PG/30 VG, Captain Black Cigar ± nicotine, Peanut Butter Cookies, or Banana Pudding 
(Southern Style) did not induce LDH release.  However, there were significant dose-dependent increases 
in LDH release following exposure to Kola, Hot Cinnamon Candies, and Menthol Tobacco flavors (Fig. 
2.3D). 
Hot Cinnamon Candies and Menthol Tobacco 24-h e-liquid exposures show cytotoxicity in 
confluent CALU3 cultures.  Since the previous experiments were performed on subconfluent, proliferating 
cultures to accommodate the MTT assay (Figs. 2.1–3), we next assessed the effects of the flavors on 
confluent, non-proliferating cultures to ascertain whether decreases in cell number/viability were due to 
cytotoxicity or decreased cell growth.  We seeded CALU3 cells into 96-well plates at a higher density 
where they formed confluent monolayers before conducting the 24-h e-liquid exposures.  We found that 
there were dose-dependent decreases in DAPI fluorescence following exposure to the 70 PG/30 VG 
vehicle, Peanut Butter Cookies, and the 4 flavors of interest (Fig. 2.4A).  However, the decreases in 
Peanut Butter Cookies, Banana Pudding (Southern Style), and Kola were not significantly greater than 
that seen with 70 PG/30 VG, while those seen with Hot Cinnamon Candies and Menthol Tobacco were 
significantly different.  Additionally, there were dose-dependent decreases in calcein fluorescence with 
the 70 PG/30 VG vehicle, Hot Cinnamon Candies, and Menthol Tobacco at 3% (Fig. 2.4B).  However, 
the decreases in 3% Hot Cinnamon Candies and Menthol Tobacco were greater than those seen for 70 
PG/30 VG (P ≤ 0.001).  
Aerosolized e-liquids have similar toxicity profiles as neat e-liquids.  We next exposed CALU3 
cells to aerosolized e-liquid vapor from the PG/VG controls (70 PG/30 VG and 55 PG/45 VG), Peanut 
Butter Cookies (less harmful flavor), and two of our more toxic flavors (Banana Pudding and Hot 
Cinnamon Candies).  E-liquids were loaded into a tank attached to an e-cig device, and a syringe was 
used to collect and measure out 4 s/70 ml puffs that were then manually administered to cells at 30-s 
intervals.  Cells were given 100 µl new media before exposure and then left in the aerosol-exposed media 
for 24 h before total cell number (%DAPI fluorescence) and cell viability (%calcein fluorescence) were 
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measured.  A media control group (0 puffs) was run in every plate, and wells were covered with fitted 
silicone strips during the exposure to ensure no unwanted exposures.  Control groups with equal numbers 
of air puffs were also run.  A 55 PG/45 VG vehicle group was added because the vendor had shifted from 
a 70 PG/30 VG to 55 PG/45 VG ratio and additional Peanut Butter Cookies, Banana Pudding, and Hot 
Cinnamon Candies e-liquids were required to conduct our experiments. 
We found that all of the flavors and the PG/VG vehicle controls caused dose-dependent decreases 
in cell number (Fig. 2.5A).  However, there was no effect of our air control group.  We also found that 
both Banana Pudding and Hot Cinnamon Candies were more toxic than either Peanut Butter Cookies or 
the PG/VG groups after aerosol exposure at greater or equal to five puffs (Fig. 2.5A; P ≤ 0.001).  We also 
found again that all flavors and PG/VG vehicle controls caused dose-dependent decreases in cell viability 
(Fig. 2.5B), and again, there was no effect of air exposure.  Both Banana Pudding and Hot Cinnamon 
Candies were more toxic than either Peanut Butter Cookies or the PG/VG groups after aerosol exposure at 
greater or equal to five puffs (Fig. 2.5B; P ≤ 0.001).  Importantly, the same order of toxicity demonstrated 
after aerosol (vape) exposure was also seen after e-liquid exposures, suggesting that direct e-liquid 
exposure is valid for determining relative toxicity.  
Since many e-cig devices have adjustable power settings, we decided to investigate the impact of 
this parameter of aerosol output on cell number and viability as well.  The aerosol data in Fig. 2.5A-B, 
were generated at 40 W.  We next compared the effects of the 55 PG/45 VG vehicle produced at 40 vs. 
100 W.  We found that aerosol generated at 100 W exerted significant biological effects after 5 puffs, 
while the threshold for the 40 W setting was 15 puffs (Fig. 2.5C-D).  We also observed significant 
differences in the DAPI and calcein outcomes for 40 vs. 100 W settings at 15 and 25 puffs.  However, 
wattage no longer had any effect at 35 puffs.  We then passed either 15 or 35 puffs of the 55 PG/45 VG 
vehicle at either 40 or 100 W through preweighed Cambridge filter pads (2-µm pores) to collect aerosol 
particles.  We observed a significant increase in weight for both wattage settings, indicating that the filter 
pads were collecting aerosolized e-liquid.  We also detected a significantly greater weight when aerosol 
was generated at 100 W than at 40 W per puff number.  Taken together, these data suggest that either 
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increasing the number of puffs or the wattage increases the amount of aerosol that cells are exposed to.  
There was no significant difference in the weight of filter pads exposed to fifteen, 100-W puffs or 35, 40-
W puffs 55 PG/45 VG (Fig. 2.5E), suggesting that cells were exposed to a similar toxic burden with either 
setting (Fig. 2.5C-D). 
GC spectra identify a range of chemical constituents per flavor, displaying the variety of unique 
flavor profiles in commercially available e-liquids.  GC-MS was conducted on all 13 e-liquids flavors.  
Annotated gas chromatograms for representative flavors are shown in Fig. 2.6A–E.  Between 9 and 25 
individual chemical constituents were identified in each e-liquid flavor that we investigated.  Flavors in 
this screen were grouped using hierarchical clustering based on the presence or absence of all constituents 
detected (Fig. 2.7).  For example, our analysis demonstrated that Banana Pudding (Southern Style) is least 
similar to Captain Black Cigar (12 mg/ml nicotine) and most similar to Peanut Butter Cookies and 
Vanilla Tobacco based on their constituent profiles. 
Comparing flavor profiles in our four flavors of interest to identify potential shared or unique 
constituents that could contribute to cytotoxicity or inhibition of cell proliferation.  Since we reported that 
Banana Pudding (Southern Style), Kola, Hot Cinnamon Candies, and Menthol Tobacco had the most 
negative effects on cell proliferation and viability, we chose to focus on comparing their constituent 
profiles to potentially target unique or shared constituents that could be causing cytotoxicity or inhibiting 
cell proliferation in CALU3 cells for future studies.  Hot Cinnamon Candies and Menthol Tobacco 
showed cytotoxicity in confluent CALU3 cultures and when compared, their flavor profiles shared 8 
constituents and have 9 and 11 unique constituents, respectively (Fig. 2.8A).  Since Banana Pudding 
(Southern Style) and Kola inhibited cell proliferation, we compared these 2 flavors and found 3 shared 
constituents and 14 and 15 unique constituents, respectively (Fig. 2.8B).  A detailed list of the 
constituents identified in these comparisons can be found in Table 2.2.  When all four of these flavors 
were compared, they only shared three constituents (Fig. 2.8C).  However, there were 9, 6, 7, and 11 
unique constituents in Banana Pudding (Southern Style), Menthol Tobacco, Hot Cinnamon Candies, and 
Kola, respectively (Table 2.3). 
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2.5. Discussion 
In this study, we found that all 13 flavors of e-liquids, as well as the PG/VG vehicle, caused dose-
dependent decreases in MTT absorbance in CALU3 cells, indicating that all e-liquids negatively affected 
cell proliferation.  These effects were not due to the dilution of growth media since comparable dilutions 
with PBS were without effect (Fig. 2.1A-B).  Using this process, we also identified flavors of interest 
[Banana Pudding (Southern Style), Kola, Hot Cinnamon Candies, and Menthol Tobacco] that were 
significantly more toxic than the 70 PG/30 VG vehicle, indicating that some flavors are more harmful 
than others (Table 2.1).  Similar dose-dependent effects have previously been reported.  For instance, 
Bahl et al. tested the effects of 40 flavored e-liquids and categorized them as “noncytotoxic,” “moderately 
cytotoxic,” and “highly cytotoxic” based on their effects on human embryonic stem cells, mouse neural 
stem cells, and human pulmonary fibroblasts (15).  They also found that cytotoxicity was caused by 
certain chemical constituents found in these e-liquids rather than by nicotine.  Behar et al. also tested the 
effects of 10 cinnamon flavored e-liquids on human embryonic stem cells and pulmonary fibroblasts, 
using the MTT assay, and found that all flavors exhibited cytotoxicity with stem cells being more 
sensitive than fibroblasts (21).  Sherwood and Boitano screened specific flavored constituents on 
immortalized human bronchial epithelial cells (16HBE14o-) for toxicity thresholds and found cytotoxic 
threshold for five of the seven chemicals tested (226).  Taken together, both the data reported here and the 
published data all suggest a broad heterogeneity of responses that is e-liquid dependent. 
We also characterized the effects of flavored e-liquids using other well-established markers of 
exposure including cell number (DAPI), cell viability (calcein, MitoTracker Red), and cytotoxicity (LDH 
release).  We also chose to measure total cell number and cell viability in both subconfluent (Fig. 2.3A–D) 
and confluent (Fig. 2.4A-B) cultures to assess whether these flavored e-liquids inhibited proliferation or 
elicited a cytotoxic response, respectively.  Using these complementary techniques, we again found that 
Banana Pudding (Southern Style), Kola, Hot Cinnamon Candies, and Menthol Tobacco caused dose-
dependent decreases in DAPI, calcein, and MitoTracker Red fluorescence that were greater than what was 
induced by the 70 PG/30 VG vehicle (Figs. 2.3A–C).  However, only Hot Cinnamon Candies and 
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Menthol Tobacco exerted effects on confluent cultures (Fig. 2.4A-B).  These data suggest that some 
flavors (i.e., Banana Pudding Southern Style and Kola) tend to inhibit cell proliferation, while other 
flavors (i.e., Hot Cinnamon Candies and Menthol Tobacco) are more cytotoxic.  Importantly, our data 
indicate that the growth phase must be taken into consideration when measuring the effects of e-liquids 
and when comparing different studies. 
E-liquids are typically heated to temperatures (100–250°C) at which glycerin can decompose 
(274) and form reactive aldehydes.  However, whether or not e-liquids undergo significant chemical 
transformation, including pyrolysis and degradation, following the heating required for aerosol formation 
is controversial.  Thus, to test the effects of heating/aerosolization, we vaped e-liquids using a common 
third generation tank-style e-cig device using 4 s/70 ml puffs, based on existing topography (74, 78, 208).  
Using DAPI and calcein staining in subconfluent cultures as our markers of exposure, we found that all 
except the air treatment were sensitive to aerosolized e-liquid exposure.  Moreover, the Peanut Butter 
Cookies flavor had similar dose responses to the PG/VG vehicle treatments, while Banana Pudding and 
Hot Cinnamon Candies exposures were more toxic (Fig. 2.5A-B).  Importantly, we observed the same 
trends in decreasing cell number and viability with aerosol exposure (Fig. 2.5A-B) as seen with direct e-
liquid exposure (Figs. 2.1–4).  That is, Banana Pudding and Hot Cinnamon Candies flavors were more 
toxic than Peanut Butter Cookies and the PG/VG vehicle both after neat e-liquid exposure and after 
vaping. 
We also investigated the effect of wattage on aerosol output and subsequent cellular toxicity.  
When we compared the effects of multiple 70 ml puffs of 55 PG/45 VG on cells generated at either 40 or 
100 W, we found that the 100-W setting left-shifted the dose-dependent effects, compared with the 40-W 
setting (Fig. 2.5C-D).  Indeed, when we passed 55 PG/45 VG through a filter pad to collect aerosol-phase 
particles, an increase in weight, as a proxy for aerosol output, could be achieved by both increasing the 
puff number and by increasing the wattage (Fig. 2.5E).  Thus the effects that we saw are likely due to an 
increase in aerosol produced by increasing the wattage (power).  These observations also follow online e-
cig forums on subohm vaping that describe 40 W as being on the cooler side with less aerosol produced, 
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while 100 W is on the hotter side with more aerosol produced using the UWell Crown tanks 
[http://vaping360.com/crown-sub-ohm-tank-review-topfilling-sub-ohm-tank-uwell/, 
http://ecigarettereviewed.com/uwell-crown-review/].  Our data are similar to other studies that have 
exposed cells to either e-cig aerosols or aerosol that has been condensed back to a liquid, where both e-cig 
aerosol or condensate exposures result in measurable toxicity and/or oxidative stress (111, 137, 172, 217, 
218, 222).  However, ours is one of the only studies to investigate and compare the effects of both neat e-
liquids and their respective aerosols in a variety of flavors. 
Nicotine is the addictive substance in tobacco smoke and e-liquids that drives addiction and 
maintenance of use (24).  Nicotine exerts its physiological effects through nAChRs, which are ligand-
gated ion channels that are expressed both in the nervous systems and the lung (3, 52, 155, 166, 277).  We 
found that CALU3 cells expressed a number of nAChR subunits, with α5 being the most abundant (Fig. 
2.2A).  Stimulation of nAChR with nicotine elicits an increase in cytoplasmic Ca2+ levels, with an EC50 in 
the low micromolar range (48, 92).  We tested the effects of nicotine on cytoplasmic Ca2+ homeostasis by 
measuring the change in fluo-4 fluorescence and found the EC50 to be 2.89 mg/ml nicotine (17.8 mM) 
with nicotine levels greater than ~2 mg/ml causing acute cytotoxicity (Fig. 2.2C-D; Table 2.1).  Since we 
found a difference in the Captain Black Cigar flavor ± nicotine on MTT metabolism (Fig. 2.1C), we then 
investigated the effects of nicotine on our cells.  We tested the effects of nicotine alone and in 
combination with 1 or 3% PG/VG using the MTT assay (Fig. 2.2D).  We found a dose-dependent 
decrease in percent absorbance with an IC50 of ~1.7 mg/ml (10 mM; Table 2.1).  Although adding 3% 
PG/VG with nicotine decreased the magnitude of the response, the IC50s were not different (Fig. 2.2D; 
Table 2.1).  Thus, although nicotine and 3% PG/VG individually reduced MTT metabolism, together, 
they were not synergistic.  Furthermore, since 3% e-liquid contains ~0.36 mg/ml nicotine (2.2 mM), at 
this dose, it is likely that PG/VG rather than nicotine caused the decrease in cell proliferation since this 
value was below the thresholds at which nicotine increased cytoplasmic Ca2+ and induced cytotoxicity 
(Fig. 2.2B-C).  We included concentrations of nicotine used in our dilutions (i.e., 0–1.2 mg/ml nicotine) 
as well as those reported in the literature.  For example, e-liquids with up to 36 mg/ml are commercially 
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available and nicotine delivery can vary depending on the device itself (77-79, 220).  Similarly, 
Schweitzer et al. found dose-dependent decreases in cell proliferation in lung endothelial cells exposed to 
1–20 mM nicotine, which falls within our dose-response range (222).  Garcia-Acros et al. administered 
aerosol containing PG/VG ± 36 mg/ml nicotine to bronchial epithelia and found that nicotine alone 
reduced ciliary beat frequency and reduced CFTR activity, suggesting a failure of mucus clearance and 
impaired host defense against pathogens (83).  However, Lam et al. found that ~100 nM nicotine 
increased gene expression of nAChRs (128), while West et al. found an increase in cell number after 1 
nM–10 mM of nicotine exposure in human bronchial epithelia (263).  It is possible that increased 
proliferation could occur via nAChRs with lower more physiological levels of nicotine (1 nM–1 mM), 
while our results, and those of Garcia-Acros et al., may have been nonspecific cytotoxic effects from the 
extremely high (i.e., mM) nicotine levels seen in e-liquids (83).  Further studies will be required to 
differentiate between receptor-mediated and nonspecific effects of nicotine, and to understand the 
contribution of nicotine to the potential toxicity of e-liquids. 
In our study, we conducted GC-MS analysis on all 13 flavors (Fig. 2.6) and performed 
hierarchical clustering (Fig. 2.7) before focusing on the individual constituents found in our 4 more toxic 
flavors of interest (Fig. 2.8).  In this approach, we found that Banana Pudding (Southern Style) was more 
similar to Peanut Butter Cookies than to Captain Black Cigar.  Further comparisons of just the four more 
toxic flavors of interest identified flavoring constituents such as cinnamaldehyde and vanillin, which were 
shown to have potentially cytotoxic properties elsewhere (21, 112, 137, 226, 252).  We also found that 
benzene derivatives were identified in several e-liquids (Fig. 2.7).  Of note, benzene has been directly 
linked with the induction of cancer (159).  We also identified 9, 11, 7, and 6 unique constituents, 
respectively (Table 2.3), most of which have no available toxicity data.  Importantly, our data indicate the 
list of constituents for each e-liquid should be made available to the consumers to better make informed 
choices. 
In conclusion, our study provides biological data from direct and aerosol based exposures to a 
diverse range of e-liquid flavors, PG/VG, and nicotine.  While we do not yet know the concentrations of 
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e-liquid in the lungs after inhalation, recent studies have found that particle size from e-cig aerosols is 
similar (164) or slightly smaller (151), than cigarette smoke, suggesting that it may deposit in the same 
fashion (148).  Moreover, based on aerosol particle size, the predicted deposition of e-cig aerosol in the 
lungs is 15–45% (232), which is similar to the reported range of some jet nebulizers (~13–25%) (53).  
Thus, if 10 ml of e-liquid is vaped, and given that the airway surface liquid volume in the lung is ~3 ml, 
this could lead to a dilution of 5–15%, suggesting that our dosing range of ≤10% e-liquid (vol/vol) is 
appropriate.  However, additional experiments will be needed to directly measure e-liquid deposition 
patterns in the lung.  Since our biological results were paired to analytical data, this has enabled the 
identification of a wide range of e-liquid constituents.  We also provided evidence that direct e-liquid 
exposures are comparable to the more realistic, but more time-consuming, aerosol exposures.  Thus we 
are providing a data set that informs as to the basic toxicological parameters of flavored e-liquids on a 
lung epithelial cell line that could potentially harm the lung of flavored e-cigs users. 
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Table 2.1.  List of Log10(IC50)/Log10(EC50) and IC50/EC50 values for dose response curves in Figures 
2.1 and 2.2.  Nonlinear regression curves were fit to the mean % absorbance values of all doses within 
each flavored e-liquid (Figure 2.1B) and nicotine ± 70 PG/30 VG (Figure 2.2D).  A nonlinear regression 
curve was fit to mean peak changes in cytosolic Ca2+ fluorescence with nicotine dosing (Figure 2.2B).  A 
nonlinear regression curve was fit to mean %calcein fluorescence with nicotine dosing (Figure 2.2C).  
The Log10(IC50) ± SEM was reported where appropriate for all treatments.  The Log10(EC50) ± SEM was 
reported for where appropriate.  ND represents ‘not determined’, where curves could not be fit in the 
range of doses tested.  The IC50 and EC50 were reported, where appropriate, in either % v/v for flavored e-
liquids or mg/ml for nicotine ± 70 PG/30 VG treatments.  Statistics were calculated using Prism software 
to compare Log10IC50 values where applicable.  ***p<0.001 in the above flavors compared to the 70 
PG/30 VG vehicle. 
 
Treatment Log10(IC50) ± SEM IC50 (% v/v) 
PBS ND ND 
Vehicle (70 PG/30 VG) 0.5755 ± 0.02 3.763 
Captain Black Cigar  
(0 mg/ml nicotine) 
ND ND 
Captain Black Cigar ND ND 
Peanut Butter Cookies ND ND 
T-bone ND ND 
Popcorn ND ND 
Black Licorice ND ND 
Energon ND ND 
Vanilla Tobacco 0.4730 ± 14.79 2.792 
Banana Pudding, Southern Style 0.0094 ± 0.02 1.022 
Kola -0.0005 ± 0.02*** 0.999 
Hot Cinnamon Candies -0.4908 ± 0.02*** 0.323 
Menthol Tobacco 0.0714 ± 14.18 1.179 
Solid Menthol ND ND 
   
Treatment Log10(IC50) ± SEM IC50 (mg/ml) 
Nicotine Only 0.2513 ± 0.07 1.784 
Nicotine + 1% PG/VG 0.2157 ± 0.04 1.643 
Nicotine + 3% PG/VG 0.2048 ± 0.08 1.603 
   
Treatment Log10(EC50) ± SEM EC50 (mg/ml) 
Nicotine Only 0.4605 ± 0.05 2.887 
   
Treatment Log10(EC50) ± SEM EC50 (mg/ml) 
Nicotine Only ~0.4431 ± ND ND 
 
 
  
 
4
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Table 2.2.  List of chemical constituents identified and compared using Venn diagrams in Figure 2.8A-B.  Chemical constituents identified 
from GC-MS of e-liquids in 4 flavors of interest.  Data were compared using R software and lists were generated of unique and shared constituents 
between grouping 1 (Menthol Tobacco and Hot Cinnamon Candies) or grouping 2 [Kola and Banana Pudding (Southern Style)] (A-F). 
 
(A) Menthol 
Tobacco Only 
(B) Hot Cinnamon 
Candies Only 
(C) Both Menthol 
Tobacco & Hot 
Cinnamon Candies 
(D) Kola Only (E) Banana Pudding 
(Southern Style) Only 
(F) Kola & 
Banana Pudding 
(Southern Style) 
1,2-
Cyclopentanedione, 
3-methyl- 
1H-Inden-2-ol, 2,3-
dihydro-1-methoxy-, 
cis- 
1,2,3-Propanetriol, 
monoacetate 
1,4-Cyclohexadiene, 
1-methyl-4-(1-
methylethyl)- 
1,2-Cyclopentanedione, 3-
methyl- 
2-Propanol, 
1,1’oxybis- 
Cyclopentane, 1,1,3-
trimethyl- 
2,2-
Dimethoxybutane 
2,4-Dimethyl-1-
heptene 
1,6-Octadien-3-ol, 
3,7-dimethyl- 
1-Butanol, 3-methyl-, 
acetate 
Glycerin 
D-menthone 2-Propen-1-ol, 3-
phenyl-, acetate 
2-Propanol, 1,1’-
oxybis- 
1-Propanol, 2-(2-
hydroxypropoxy)- 
2(3H)-Furanone, 5-
ethyldihydro- 
Nicotine 
Decane, 3,7-
dimethyl- 
4-Nonene, 3-methyl-
, (Z)- 
Acetic acid, methyl 
ester 
2,4-Dimethyl-1-
heptene 
2,6-Octadien-1-ol, 3,7-
dimethyl-, acetate, (Z)- 
 
Benzoic acid, 3,4-
methylenedioxy-, 3-
formylphenyl ester 
Benzaldehyde, 3,4-
dimethoxy-, 
methylmonoacetal 
Benzoic acid, 4-
ethoxy-, ethyl ester 
3-Cyclohexen-1-ol, 
4-methyl-1-(1-
methylethyl)- 
3-Acetyl-2,5-dimethyl furan  
Ethyl Vanillin Cinnamaldehyde Glycerin Benzene, 1-methyl-3-
(1-methethyl)- 
3-Hexen-1-ol  
Menthol Eugenol Hexane, 3-ethyl- Benzoic acid, 4-
ethoxy-, ethyl ester 
4-Methoxycarbonyl-4-
butanolide 
 
Phenol, 2-methoxy- Maltol Nicotine Bicyclo[2.2.1]heptan-
2-ol, 1,3,3-trimethyl-, 
(1R-endo)- 
4H-Pyran-4-one, 2-ethyl-3-
hydroxy- 
 
Pyrazine, trimethyl- Pentanoic acid, 1,1-
dimethylpropyl ester 
 Cyclotrisiloxane, 
hexamethyl- 
5-Thiazoleethanol, 4-
methyl- 
 
 Propylene Glycol  Cinnamaldehyde Benzaldehyde, 4-methoxy-  
 Vanillin  D-limonene Ethyl Vanillin  
   Eucalyptol Eugenol  
   Triacetin Pentanoic acid, 1,1-
dimethylpropyl ester 
 
   Beta pinene Phenol, 2-methoxy-  
    Vanillin  
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Table 2.3.  List of unique chemical constituents identified from Venn diagram comparisons in 
Figure 2.8C.  Chemical constituents identified from GC-MS of e-liquids in 4 flavors of interest.  Data 
was compared using R software and lists were generated of unique and shared constituents between all 4 
flavors of interest Banana Pudding (Southern Style), Kola, Hot Cinnamon Candies, and Menthol 
Tobacco. 
 
Banana Pudding 
(Southern Style) 
Kola Hot Cinnamon 
Candies 
Menthol Tobacco 
4H-Pyran-4-one 2-
ethyl-3-hydroxy- 
1,4-Cyclohexadiene, 1-
methyl-4-(1-
methylethyl)- 
1H-Inden-2-ol, 2,3-
dihydro-1-methoxy-, 
cis- 
Pyrazine, trimethyl- 
1-Butanol, 3-
methyl-, acetate 
beta pinene 2,2-Dimethoxybutane Cyclopentane, 1,1,3-
trimethyl- 
3-Hexen-1-ol Eucalyptol Maltol D-menthone  
4-
Methoxycarbonyl-
4-butanolide 
1,6-Octadien-3-ol, 3,7-
dimethyl- 
Benzaldehyde, 3,4-
dimethoxy-, 
methylmonoacetal 
Decane, 3,7-
dimethyl- 
2(3H)-Furanone, 5-
ethyldihydro- 
3-Cyclohexen-1-ol, 4-
methyl-1-(1-
methylethyl)- 
Propylene Glycol Menthol 
Benzaldehyde, 4-
methoxy- 
Bicyclo[2.2.1]heptan-2-
ol, 1,3,3-trimethyl-, 
(1R-endo)- 
4-Nonene, 3-methyl-, 
(Z)- 
Benzoic acid, 3,4-
methylenedioxy-, 3-
formylphenyl ester 
3-Acetyl-2,5-
dimethyl furan 
Benzene, 1-methyl-3-
(1-methylethyl)- 
2-Propen-1-ol, 3-
phenyl-, acetate 
 
2,6-Octadien-1-ol, 
3,7-dimethyl-, 
acetate, (Z)- 
Cyclotrisiloxane, 
hexamethyl- 
  
5-Thiazoleethanol, 
4-methyl- 
D-Limonene   
 1-Propanol, 2-(2-
hydroxypropoxy)- 
  
 Triacetin   
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Figure 2.1.  Flavored e-liquids cause dose-dependent decreases in cell proliferation and viability.  
CALU3 cells were seeded at 12,500 per well in 96-well plates and were challenged with increasing doses 
of e-liquid flavors diluted in media (% vol/vol) for 24 h.  Cell proliferation/viability was measured at the 
end of the 24 h treatment using the MTT assay.  A: mean %absorbance was plotted for all flavors and 
controls in all doses.  B: nonlinear regression curves were fit to calculate the IC50 of each flavor.  C: MTT 
responses were compared in Captain Black Cigar containing either 0 or 12 mg/ml nicotine to determine 
the effects of nicotine.  Bars and triangles represent average %absorbance measured normalized to 0% e-
liquid (media control) treatment per plate ± SEM.  n = 12-24 wells run in 4-8 independent experiments 
per treatment.  Statistics were calculated using a linear mixed model with pairwise comparisons for doses 
within flavor (A) or between flavors in each dose (C).  A: P values for overall tests of dose within flavor 
denoted (***P < 0.001), and, where applicable, further pairwise significant differences (P < 0.05) are 
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indicated using cluster lines above the graph.  C: P values for pairwise differences denoted (**P < 0.01, 
***P < 0.001). 
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Figure 2.2.  Nicotine alone decreases cell proliferation and cytotoxicity that is independent of 
nAChR stimulation.  A: RNA was isolated from untreated CALU3 cells and mRNA expression of 
nAChR subunits relative to Orai1, a Ca2+ channel, were measured (n = 4-10 wells per gene).  B and C: 
CALU3 cells were seeded at 45,000 per well in 96-well plates overnight and were challenged with 
nicotine doses acutely to measure Ca2+ activity (fluo-4) or measure viability (calcein).  Peak changes in 
fluo-4 fluorescence (F/F0) per nicotine dose was plotted and fit with a nonlinear regression curve to 
calculate the EC50 (n = 14-30 wells per treatment).  Cell viability was measured 1 h post-nicotine 
exposure by measuring calcein fluorescence and fitting dose response with a nonlinear regression curve (n 
= 11-18 wells per treatment).  D: Cells were seeded at 12,500 per well in 96-well plates overnight and 
were challenged with varying doses of nicotine ± 70 PG/30 VG diluted in media for an additional 24 h.  
Cell proliferation/viability was measured at the end of the 24 h treatment using the MTT assay.  Mean 
%absorbance were plotted for all treatments and doses and fit with nonlinear regression curves to 
calculate the IC50 of each treatment (Table 2.1) (n = 12-15 wells per treatment).  Bars represent average 
gene expression relative to Orai1 ± SEM (A).  Triangles represent average %fluorescence or 
%fluorescence measured normalized to 0 mg/ml dose (media control) per plate ± SEM (B-D).  Statistics 
were calculated using a linear model of log-transformed outcomes with a fixed effect for gene type and 
pair-wise comparisons between genes (A) (***P < 0.001; ND, not determined). 
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Figure 2.3.  E-liquids decrease cell number/viability in sub-confluent CALU3 cultures.  CALU3 cells 
were seeded at 12,500 per well in 96-well plates for 12 h before e-liquids were diluted in media in a dose-
dependent manner (% vol/vol) and cells challenged for 24 h.  A: Cell number was measured by fixing 
cells and measuring DAPI fluorescence.  Cell/mitochondrial viability was measured using calcein (B) and 
MitoTracker Red (C).  D: Cytotoxicity was measured from the cell supernatants collected at 24 h and 
compared to lysed cell positive controls.  Bars represent average fluorescence or absorbance measured 
normalized to 0% e-liquid (media control) treatment per plate + SEM.  n = 9-15 wells run in 3-5 
independent experiments per treatment.  Statistics were calculated using a linear mixed model with 
pairwise comparisons for doses within flavor (A-D).  P values for overall tests of dose within flavor 
denoted (**P < 0.01, ***P < 0.001), and, where applicable, further pairwise significant differences (P < 
0.05) are indicated using cluster lines above the graph. 
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Figure 2.4.  Confluent CALU3 cultures show cytotoxicity after Hot Cinnamon Candies and 
Menthol Tobacco flavor exposure.  CALU3 cells were seeded at 45,000 per well in 96-well plates for 
12 h until confluent monolayers were formed.  E-liquids were diluted in media in a dose-dependent 
manner (% vol/vol) and cells were challenged for 24 h.  Cell number was measured by fixing cells and 
measuring DAPI fluorescence (A) and cell viability was measured using calcein (B).  Bars represent 
average fluorescence measured normalized to 0% e-liquid (media control) treatment per plate + SEM.  n 
= 12 wells run in 4 independent experiments per treatment.  Statistics were calculated using a linear 
mixed model with pairwise comparisons for doses within flavor (A-B).  P values for overall tests of dose 
within flavor denoted (*P < 0.05, **P < 0.01, ***P < 0.001), and, where applicable, further pairwise 
significant differences (P < 0.05) are indicated using cluster lines above the graph. 
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Figure 2.5.  E-cigarette aerosols dose-dependently decrease cell number/viability in sub-confluent 
CALU3 cultures.  CALU3 cells were seeded at 25,000 per well in 96-well plates for 4-8 h before aerosol 
exposure.  Aerosols were generated at 40 or 100 W and each 70 ml puff was distributed among 6 wells 
using a multi-channel manifold at a rate of 1 puff/30 s.  Media was not changed for 24 h following aerosol 
exposure.  A-D: Dose-dependent outcomes of cell number (DAPI) or cell viability (calcein) between 
flavors or PG/VG controls were measured (n = 18-54 wells per treatment).  C and D: Effects of wattage 
(40 and 100 W) were compared in the 55 PG/45 VG treatment where %DAPI and calcein fluorescence 
were measured (n = 18-48 wells per treatment).  Aerosol phase particles were captured from 55 PG/45 
VG at either the 40 or 100 W settings for 15 and 35 puffs using Cambridge filter pads.  E: Aerosol was 
collected on pre-weighed filter pads and the net weight (g) of aerosol-phase particles were plotted (n = 7 
per treatment).  Bars represent average %fluorescence measured normalized to 0 puff (media control) 
treatment per plate + SEM (A-D) or average net weight of filter pads per treatment + SEM (E).  Statistics 
were calculated using a linear mixed model with pairwise comparisons for doses within exposure 
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treatment (A-D).  A linear model was used to obtain the statistical results in (E).  A-E: P values for overall 
test of dose within flavor denoted (***P < 0.001) with further pairwise significant differences (P < 0.05) 
indicated using cluster lines above the graph.  Differences shown without brackets were compared to 
either the 0 puff control for respective treatments (C and D) or between puff numbers within a wattage 
setting (E) (#P < 0.05, ##P < 0.01, ###P < 0.001). 
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Figure 2.6.  Gas chromatography-mass spectrometry (GC-MS) identified individual chemical 
constituents in the 13 different e-liquids.  GC-MS was used to detect between 9 and 25 individual 
chemical constituents for individual e-liquid flavors across all 13 flavors tested.  Annotated gas 
chromatograms of Banana Pudding (Southern Style) (A), Kola (B), Hot Cinnamon Candies (C), Menthol 
Tobacco (D), and Captain Black Cigar (0 mg/ml nicotine) (E) depict examples of peaks derived for 
individual constituent identification in e-liquids diluted 50x. 
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Figure 2.7.  Heat map compares individual chemical constituent profiles from 13 different e-liquid 
flavors tested.  All e-liquid flavors were compared for constituent flavor profile using a heat map 
showing presence (blue) or absence (red) of a single constituent detected respectively.  The black box 
indicates the presence or absence of nicotine in each flavor as an example.  All identified constituents are 
listed on the right and brackets group flavors by ‘likeness’ using hierarchical clustering. 
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Figure 2.8.  Flavor profiles for the 4 flavors of interest compared to identify potential constituents 
responsible for either cytotoxicity or cell proliferation inhibition.  Comparing between Menthol 
Tobacco and Hot Cinnamon Candies e-liquid flavor profiles, only 8 constituents are shared (A) while 
Kola and Banana Pudding (Southern Style) only share 3 constituents (B).  When all 4 are compared 
against each other, Banana Pudding (Southern Style), Menthol Tobacco, Hot Cinnamon Candies, and 
Kola have 9, 6, 7, and 11 unique constituents respectively (C). 
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Chapter 3: Banana Pudding-Flavored E-liquid Activates Phospholipase C and Store-Operated Ca2+ 
Entry in Lung Epithelia 
3.1. Overview 
E-cigarettes (e-cigs) are available in over 7,000 flavors and there is still much to understand 
regarding their potential biological effects.  Calcium (Ca2+) is a ubiquitous second messenger, which 
regulates cell homeostasis.  Chronic changes to Ca2+ homeostasis can have dramatic cellular effects, 
including the facilitation of chronic inflammation (e.g., increased cytokine/mucin secretion) and altered 
cell growth/proliferation.  Therefore, we characterized the novel effects of a Banana Pudding (BP)-
flavored e-liquid on Ca2+ metabolism.  We found that acute BP exposure caused inositol 1,4,5-
triphosphate (IP3) formation, ER Ca2+ release, and store-operated Ca2+ entry (SOCE), followed by protein 
kinase C (PKCα) phosphorylation.  However, longer BP exposures blunted thapsigargin-induced ER Ca2+ 
release and SOCE, suggesting that BP may alter Ca2+ homeostasis with time.  We have not identified the 
upstream target of phospholipase C stimulated IP3 generation, though we determined that the response is 
independent of receptor tyrosine kinase activation.  Further studies are needed to understand both the 
upstream target of Ca2+ activation, as well as the widespread nature of altered Ca2+ homeostasis signaling 
with flavored e-liquid exposure and the potential effects of individual chemical flavorings common to 
these products.  However, dysregulation of Ca2+ signaling can cause chronic inflammation and/or cancer, 
flavored e-cig products should be further evaluated for potential toxicity. 
 
 
3Contributing authors: Temperance R Rowell, Andrew Kennedy, Stephen B Shears, and Robert Tarran. 
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3.2. Introduction 
E-cigs are electronic nicotine delivery systems (ENDS) that utilize a battery-powered coil to heat 
flavored e-liquids into an inhalable aerosol.  E-liquids are usually composed of a propylene 
glycol/vegetable glycerin (PG/VG) base to which nicotine and a number of individual flavoring chemicals 
are added to create flavored e-liquids for purchase.  E-cig use in adolescent populations has particularly 
increased over time (13).  Interestingly, the availability of flavors, especially sweet flavors, may 
contribute to e-cig use in adolescents and young adults (6, 98).  With over 7,000 flavored e-liquids 
commercially available in the United States (276) and little information available about the inhalation 
toxicity for many flavored e-liquids or their constituent chemicals (19, 212), e-cig health effects and 
safety are widely debated.  Concern regarding inhalation safety for individual flavoring chemicals stems 
from cases of chronic diacetyl inhalation in manufacturing plant workers (124).  Though diacetyl, a butter 
flavor, is ‘generally recognized as safe’ (GRAS) for ingestion, chronic inhalation exposure can lead to the 
development of bronchiolitis obliterans or ‘Popcorn Lung’, which causes scarring and fibrosis of the 
airways (17).  Interestingly, several recent studies have implicated flavored e-liquids and individual 
flavoring chemicals in causing toxicity or altering other biological functions of respiratory cells in 
addition to PG/VG (21, 47, 85, 211, 226, 252).  
Pulmonary epithelia are one of the first lines of defense against inhaled toxicants.  They serve as a 
physical barrier  and are integral in coordinating innate defenses, often through second messenger 
signaling molecules such as intracellular Ca2+ (97, 139, 153).  Typically, cells rely upon a number of 
pumps, receptors, and channels to control fluctuations in cytosolic Ca2+ and sequester it in specific 
organelles (26).  Following activation, canonical G protein-coupled receptors (GPCRs) can activate 
phospholipase Cβ (PLCβ) to generate inositol 1,4,5-triphosphate (IP3).  The subsequent stimulation of IP3 
receptors (IP3Rs) triggers ER Ca2+ release, often followed by store-operated Ca2+ entry (SOCE) to 
replenish ER Ca2+ stores.  SOCE requires the translocation of stromal interaction molecule 1 (STIM1) to 
ER plasma membrane junctions where it activates Orai1, a plasma membrane Ca2+ release-activated Ca2+ 
channel to permit Ca2+ entry (141, 189).  The signaling cascade continues downstream of SOCE and 
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increases the phosphorylation of kinases such as protein kinase C (PKC).  The PKCα isoform is 
canonically activated downstream of both PLC activation (i.e., diacylglycerol formation) and Ca2+ release 
(122, 241), and its activation in turn can cause cellular responses (e.g., cell proliferation or apoptosis) 
(146, 261).  Some membrane receptor tyrosine kinases (RTK) have also been shown to activate a similar 
response (i.e., IP3 formation, ER/SOCE-dependent Ca2+ release, and PKCα phosphorylation) through 
PLCγ (161, 173).  Activating Ca2+ pathways can have profound effects on cell function.  For example, the 
ability to maintain Ca2+ homeostasis is paramount to cell survival and regulation of many important 
processes (i.e., exocytosis, enzyme activity, transcription, cell cycle, apoptosis).  Dysregulation of any of 
these key components of Ca2+ signaling can result in pathophysiology (i.e., overexpression or 
hyperactivity of some PLC isoforms has been linked to cancer) (27, 231).  
Given the number of flavored e-cig products that are available for purchase, and the lack of safety 
information regarding their effects on the lung, we tested the effects of commercially available e-liquids 
for their ability to alter an important universal cell signaling pathway (i.e., PLC-activated Ca2+ signaling).  
We initially characterized one flavored e-liquid (BP) that had previously been shown to inhibit cell 
proliferation (211).  We then tested the hypothesis that e-liquids with similar flavoring constituents could 
also affect cytoplasmic Ca2+ levels. 
3.3. Methods 
Flavored e-cig liquids (e-liquids).  Experiments were performed using the Banana Pudding (BP)-
flavored e-liquid purchased from The Vapor Girl (www.thevaporgirl.com).  Two different lots (or 
batches) of BP (designated #09 or #165) were used after they were verified for chemical composition (not 
shown), toxicity, and cytosolic Ca2+ responses (Fig. 3.2).  BP-flavored e-liquid was purchased ± 12 mg/ml 
nicotine.  The e-liquid vehicle was advertised as 55/45 propylene glycol (PG) to vegetable glycerin (VG) 
mixture.  Thus, a vehicle control was made in our laboratory using 55 PG/45 VG.   
Chemicals and reagents.  PG, VG, DMSO, human placental type VI collagen, probenecid, 
thapsigargin, methanol, uridine triphosphate (UTP), and carbonyl cyanide m-chlorophenyl hydrazine 
(CCCP) were purchased from Sigma-Aldrich.  DAPI, calcein (AM), fura-2 (AM), fluo-4 (AM), rhod-2 
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(AM), and lipofectamine 2000 were purchased from ThermoFisher.  Paraformaldehyde (PFA) was 
purchased from Affymetrix.  2-aminoethoxydiphenyl borate (2-APB) was purchased from Tocris.  DAPI, 
calcein (AM), thapsigargin, fura-2 (AM), fluo-4 (AM), and rhod-2 (AM) were reconstituted using DMSO 
and applied to cells in experiments where the final DMSO concentration was ≤ 0.1%.  STIM1 tagged with 
mCherry on the C-terminus was kindly provided by Dr. Ricardo Dolmetsch (181).  Orai1 labelled with 
YFP on the C-terminus was purchased from Addgene (19756) (189). 
Cell culture and transfections.  Primary human bronchial epithelial cells (HBECs) were procured 
from non-smoker human excess donor lungs under a protocol approved by the University of North 
Carolina Institutional Review Board as described previously (196).  HBECs were grown on glass 
coverslips coated with human placental type VI collagen, cultured in bronchial epithelial growth medium 
(BEGM) with 5% CO2 at 37°C, and assayed within a week of plating.  CALU3 cells were cultured in 
Minimum Essential Media (MEM) alpha with 10% FBS and penicillin/streptomycin (Gibco) with 5% 
CO2 at 37°C.  CALU3 cells were seeded onto glass coverslips for fura-2 experiments or 12 and 96 well 
and 60 mm plastic dishes (Corning) for all other experiments.  HEK293T cells were cultured in D-MEM 
(high glucose) with 10% FBS and penicillin/streptomycin (Gibco) with 5% CO2 at 37°C.  HEK293T cells 
were plated onto glass coverslips for fura-2 and STIM1/Orai1 puncta imaging experiments.  HEK293T 
cells were seeded into 12 and 24 well plastic dishes (Corning) for fluo-4 and total inositol phosphate 
activation experiments. 
Ca2+ signaling.  Changes in cytosolic [Ca2+] were measured using either fura-2 or fluo-4 dyes.  
HBECs and CALU3 cells were loaded with 8 μM fura-2 in the presence of 1-2.5 mM probenecid for 40 
min at 37°C prior to experiments.  HEK293T cells were loaded with 5 μM fura-2 for 20 min at 37°C prior 
to experiments.  All cultures were then rinsed with PBS and replaced with a standard Ringer’s solution as 
described (198).  Fura-2 fluorescence intensities were measured every 15 or 30 sec using a 40 x 1.3 NA 
oil objective on a Nikon Ti-S inverted microscope using alternating excitation at 340 and 380 nm 
(emission > 450 nm) using LUDL filter wheels at room temperature.  Images were captured with an Orca 
CCD camera (Hammamatsu) and analyzed using HCImage software.  Fura-2 signals were calculated 
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using the ratio (340/380).  Thapsigargin was added to cultures in to a final concentration of 2 μM.  In 
some cases, nominally Ca2+-free Ringer’s solution was added extracellularly as described (198). 
In some cases, CALU3 and HEK293T cells were loaded with fluo-4 in the same fashion as fura-
2.  Fluorescence intensities were measured every 15 or 30 sec using a Tecan Infinite Pro plate reader (ex: 
490 ± 10 nm, em: 516 ± 5 nm) at room temperature.  Changes in fluo-4 fluorescence were normalized to 
the baseline (F/F0) after subtracting background light levels.  Traces were plotted to show F/F0 over time 
and the peak F/F0 was measured for each dose and compared between treatments.  Thapsigargin was 
added to cultures at a final concentration of 2 μM.  Neat e-liquids were diluted in Ringer’s solution and 
exposed to cells at final concentration (%vol/vol).  CALU3 cells were pretreated with 10 μM CCCP for 1 
h at 37°C as designated (Fig 3.5C-D).  HEK293T cells were pretreated with 100 μM 2-APB for 1 min 
prior to UTP or e-liquid treatment (Fig 3.7B-C). 
Changes in mitochondrial Ca2+ signals were measured in CALU3 cells ± CCCP pretreatment.  
Cells were loaded with 3 µM rhod-2 for 1 h at 37°C, rinsed with PBS, and incubated in media for 12-24 h 
as described (198).  Cultures were rinsed and media was replaced with a standard Ringer’s solution.  
Fluorescence intensities were measured every 15 or 30 sec using a Tecan Infinite Pro plate reader (ex: 
550 ± 5 nm, em: 580 ± 5 nm) at room temperature.  Changes in rhod-2 fluorescence were plotted as peak 
changes in arbitrary fluorescence units (AFU) after subtracting background light levels. 
Aerosol exposures.  Aerosol exposures were conducted in 96 well plates using a Sigelei Fuchai 
200W device and Uwell Crown tanks as before (57, 211, 216).  BP (12 mg/ml nicotine) or PG/VG were 
heated to generate aerosols with the power output set to 100 W.  CALU3 cells were seeded into 96 well 
plates and loaded with fluo-4 prior to the aerosol exposures.  Cells were submerged in 100 µl Ringer’s 
solution per well and baseline fluorescence was measured for 1 min before cells were moved to a dark 
chemical hood and exposed to 0-25 puffs of air or heated aerosols.  A 70 ml aerosol or air puff was 
applied manually (1 puff every 30 sec) using a 100 ml syringe and a three-dimensional printed acrylic six-
channel manifold (57).  Naïve wells were run on each plate and covered with silicone strips to avoid 
aerosol exposures.  Plates were returned to the plate reader and fluorescence was read over time.  
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Total cell number (DAPI) and viability (calcein).  As an indicator of total cell number, cultures 
were fixed with 100% methanol for 10 min at room temperature, rinsed with PBS, and stained with 
1:1000 DAPI for 5-10 min.  DAPI fluorescence was measured using a Tecan Infinite Pro plate reader (ex: 
360 ± 5 nm, em: 460 ± 5 nm) at room temperature.  Fluorescence intensities were plotted as DAPI 
fluorescence (AFU) after background subtraction (Fig 3.11E-F) or calculated as percent fluorescence of 
the e-liquid-treated cells compared to the average of the 0% e-liquid control (Fig. 3.2C) (211).  Cell 
viability was measured using the fluorescent indicator calcein.  After 24 h BP e-liquid exposure, media 
was replaced and cells were incubated with 3 μM calcein for 30 min at 37°C.  Then cultures were rinsed 
and replaced with Ringer’s solution and fluorescence intensities were read using the Tecan Infinite Pro 
plate reader (ex: 495 ± 5 nm; em: 516 ± 5 nm).  Cell viability was calculated as percent fluorescence of e-
liquid-treated cells compared with the average of the 0% e-liquid control group (Fig. 3.2D). 
Measurement of total intracellular inositol phosphates.  HEK293T cells were plated in 24 well 
plates for 6 h before an 18 h incubation with [3H]inositol (4 μCi/ml; American Radiolabeled Chemicals; 
Saint Louis, MO) in culture media.  Cells were then rinsed and given fresh incubation media (115 mM 
NaCl, 25 mM HEPES, 10 mM glucose, 5 mM KCl, 1.35 mM CaCl2, 1 mM NaH2PO4, and 0.5 mM 
MgSO4) for 2 h at 37°C.  10 mM LiCl was added to each culture before initiating the experiment where 
cells were exposed to buffer only, 200 μM UTP, 3% PG/VG, 3% BP (12 mg/ml nicotine), or 3% BP (0 
mg/ml nicotine) for 2 min.  Assays were quenched by aspiration of the media and addition of 0.4 ml of 
ice-cold 2 M perchloric acid / 0.2 mg/ml inositol phosphate 6 (InsP6).  Culture plates were left on ice for 
10 min before media was transferred to microcentrifuge tubes and neutralized with 1M KCO3 and 40 mM 
EDTA.  Samples were left overnight at 4°C and perchlorate precipitate was removed via centrifugation.  
Gravity-fed ion-exchange chromatography was used to separate [3H]inositol (Ins) from the [3H]inositol-
labeled inositol phosphates ("InsP", i.e, InsP1 + InsP2 + InsP3 + InsP4) (225).  Data were calculated as 
1000 x (InsP / Ins) and then transformed to percent activation at 2 min for each experiment. 
% 𝐴𝑐𝑡𝑖𝑣𝑎𝑡𝑖𝑜𝑛 =
𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑣𝑎𝑙𝑢𝑒 − 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑃𝐺/𝑉𝐺 𝑣𝑎𝑙𝑢𝑒
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑃𝐺/𝑉𝐺 𝑣𝑎𝑙𝑢𝑒
∗ 100 
  
62 
STIM1 and Orai1 puncta quantification.  HEK293T cells were plated onto glass coverslips and 
transfected with Orai1-YFP and STIM1-mCherry using lipofectamine 2000 per manufacturer’s protocol 
as described (198).  Cells expressing STIM1-mCherry or Orai1-YFP were treated with 0% BP (media), 
3% PG/VG, 2 µM thapsigargin, 3% BP (0 mg/ml nicotine), or 3% (12 mg/ml nicotine) for 5-10 min.  
Cells were fixed with 4% PFA for 10 min following treatment and rinsed with PBS before imaging.  All 
puncta imaging was conducted on a Leica SP8 confocal microscope with a 63 x 1.4 NA oil immersion 
objective.  Multiple images were taken per coverslip from different parts of the coverslip and ≥ 12 
transfected cells were visually analyzed for the percentage of puncta positive cells per coverslip.   
Immunoblots.  Rabbit anti-phospho-PKCα (1:1000) and anti-PKCα (1:1000) (Abcam); mouse 
anti-phospho-tyrosine (1:2000) (Cell Signaling); mouse anti-GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) (1:1000) (Santa Cruz); peroxidase-conjugated-rabbit or mouse (all 1:3000, Jackson 
ImmunoResearch) were purchased from commercial sources.  CALU3 cells were plated in 60 mm dishes 
and exposed to 3% BP (12 mg/ml nicotine) for 0-60 min.  Cells were lysed  in modified Pierce IP lysis 
buffer with 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA and supplemented with 1X 
proteinase inhibitor cocktail and 1X phosphatase inhibitor cocktail (Roche) to detect protein expression 
from total cell lysates.  Lysates were processed by sodium dodecyl sulfate (SDS)-polyacrylamide 
electrophoresis and immunoblot.   
RNA extraction, cDNA synthesis, and quantitative RT-PCR.  RNA was extracted from untreated 
primary whole lung tissue and HBECs, as well as immortalized CALU3 and HEK293T cells using the 
Qiagen RNeasy kit following the manufacturer’s protocol.  cDNA was synthesized using the Bio-Rad 
iScript cDNA synthesis kit following the manufacturer’s protocol.  Gene expression was measured using 
Taqman gene expression assays from Applied Biosystems for CFTR, ADRB2, ORAI1,GNAT3, TAS1R1, 
TAS1R2, TAS1R3, TAS2R1, TAS2R3, TAS2R4, TAS2R5, TAS2R7, TAS2R8, TAS2R9, TAS2R10, TAS2R13, 
TAS2R14, TAS2R16, TAS2R19, TAS2R20, TAS2R30, TAS2R31, TAS2R38, TAS2R42, TAS2R43, TAS2R45, 
TAS2R46, TAS2R50, and TAS2R60 using human primers.  Genes of interest were normalized to GAPDH 
and fold change was calculated using ∆∆CT method relative to CFTR or ORAI1. 
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E-liquid internalization imaging.  CALU3 cells were plated onto glass coverslips and media was 
rinsed and replaced with Ringer’s solution prior to imaging.  All imaging was conducted on a Leica SP8 
confocal microscope with a 63 x 1.4 NA oil immersion objective similar to (88).  Bright field and 
fluorescent (ex: 405 nm, em: 460 nm) images were taken before and after cells were exposed to BP e-
liquid.  Images were compiled into Z-stacks.  
Statistical analyses.  All statistics were run using Prism Graphpad (San Diego) software.  Data 
were analyzed using the Kruskal-Wallis test with Dunn’s multiple comparisons test or Mann-Whitney test 
as appropriate.  P-values ≤ 0.05 were found to be significant and reported (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 
0.001; #P ≤ 0.05, ##P ≤ 0.01, ###P ≤ 0.001).  All experiments were performed on at least three separate 
occasions.  Whole lung and HBECs were obtained from three or more normal donors (Fig. 3.1A,D; 3.9A; 
Table 3.1). 
3.4. Results 
BP-flavored neat e-liquid elicits acute dose-dependent cytosolic Ca2+ responses in both primary 
and immortalized epithelial cells.  We loaded cells with cytosolic Ca2+ indicators (fura-2 or fluo-4) as 
specified and exposed them to the BP e-liquid diluted (%vol/vol) in Ringer’s solution.  We found that 
primary HBECs, CALU3 cells, and HEK293T cells increased cytosolic Ca2+ after BP addition (Fig. 3.1A-
C).  An additional 3% PG/VG vehicle control was run in both CALU3 and HEK293T cells and did not 
elicit a response.  Peak responses to each treatment were grouped by cell type and compared (Fig. 3.1D).  
Addition of 3% BP diminished the response to thapsigargin, suggesting that BP was causing ER Ca2+ 
release (Fig. 3.1A-D).  
BP e-liquid lot (batch) testing reveals similar acute cytosolic Ca2+ and 24 h cell 
viability/proliferation responses.  Since the e-liquids used in this study were purchased from commercial 
vendors, our BP-flavored e-liquid results were performed using two different lots (batches) prepared at 
different times, and thus were tested for chemical composition and functional similarities before 
continuing the study.  GC-MS analysis verified that both BP e-liquids has similar chemical constituent 
profiles (not shown).  Figure 3.1 data included lots of BP (designated #09 or #165), so we compared 
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responses by lot and found that both lots displayed similar dose-dependent responses in CALU3 cells 
(Fig. 3.2A-B).  Our previous study also showed BP e-liquid affected cell viability/proliferation at similar 
doses (%vol/vol) following 24 h exposure, so we compared total cell number and viability data between 
the lots and found those responses to be similar as well (Fig. 3.2C-D).  
Cytosolic Ca2+ responses following BP exposure independent of nicotine.  The BP e-liquid used 
in Fig. 3.1 contained 12 mg/ml nicotine.  To control for the potential effects of nicotine on cytosolic Ca2+ 
responses, a separate BP e-liquid was purchased that contained 0 mg/ml nicotine.  CALU3 cultures were 
loaded with fluo-4, exposed to 3% BP ± 12 mg/ml nicotine ± wash out, and the cytosolic Ca2+ responses 
were measured (Fig. 3.3A-B).  BP with nicotine caused a peak response, followed by a sustained plateau 
that was removed following wash out (Fig. 3.3C-D).  In contrast, BP without nicotine had a similar peak 
response.  However, the plateau phase was diminished in the absence of nicotine ± wash out, suggesting 
that nicotine contributed to the plateau but not the peak phase. 
BP aerosol exposure to submerged CALU3 cultures acutely elicits cytosolic Ca2+ responses, 
similar to unheated e-liquids.  Since we found dose-dependent increases in cytosolic Ca2+ following direct 
BP exposure, we sought to determine whether aerosolized BP would also increase cytosolic Ca2+.  We 
loaded CALU3 cells with fluo-4 and measured cytosolic Ca2+ responses following 0-25 puffs of aerosol 
as indicated.  Neither puffs of air nor PG/VG (vehicle) elicited a change in cytosolic Ca2+ (Fig. 3.4A-B).  
In contrast, addition of thapsigargin elevated Ca2+, suggesting that the cells were responsive to stimuli.  
However, exposure to 5-25 puffs of BP aerosol elicited robust increases in cytosolic Ca2+ and diminished 
the thapsigargin response, indicating that the ability of BP to affect thapsigargin-sensitive stores was 
maintained when BP was exposed to cells as an aerosol (Fig. 3.4C-D). 
BP e-liquid cytosolic responses are ER/SOCE-dependent and do not involve mitochondrial Ca2+.  
Ca2+ is sequestered into multiple intracellular stores, including the ER (242).  Thapsigargin is a 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump inhibitor that depletes ER stores to activate 
SOCE (144).  Since cultures did not respond to thapsigargin after BP exposure, we decided to test 
whether this signal was dependent on the ER/SOCE pathway.  We performed Ca2+ replacement studies to 
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measure cytosolic Ca2+, where cells were placed in Ca2+-free Ringer’s solution then, after ER Ca2+ was 
depleted, 2 mM Ca2+ was added extracellularly.  Following this protocol, thapsigargin caused a small 
peak due to ER Ca2+ release that was followed by a second, larger SOCE response when Ca2+ was 
returned extracellularly (Fig. 3.5A).  3% BP (12 mg/ml nicotine) elicited a similar peak in nominal Ca2+-
free solution and a second larger peak in the presence of extracellular Ca2+ solution that was thapsigargin-
insensitive (Fig. 3.5A).  Taken together, these data suggested that BP activated a classic ER-dependent 
SOCE response.  Moreover, pretreating cells with thapsigargin abolished the 3% BP Ca2+ response (Fig. 
3.5B). 
The mitochondria are also a significant store of intracellular Ca2+ (203).  To test for mitochondrial 
Ca2+ contributions to the BP response, we pretreated cells with CCCP, which caused mitochondrial Ca2+ 
depletion.  We found that there was a similar cytosolic Ca2+ response with CCCP pretreatment in CALU3 
cells (Fig. 3.5C).  Additionally, we loaded CALU3 cells with the mitochondrial Ca2+ indicator rhod-2 to 
directly measure mitochondrial Ca2+ stores.  There was no significant difference in rhod-2 fluorescence 
following 3% BP or PG/VG compared to 0% BP ± CCCP pretreatment (Fig. 3.5D).  In contrast, CCCP 
diminished rhod-2 mitochondrial Ca2+ levels (Fig. 3.5D).  
  Ca2+-eliciting BP e-liquid initiates STIM1 and Orai1 puncta formation (SOCE) and downstream 
protein kinase Cα (PKCα) phosphorylation.  IP3-dependent ER Ca2+ release causes aggregation of the ER 
membrane protein STIM1 into discrete puncta at the ER-plasma membrane junction, which then activates 
Orai1 and is required for subsequent plasma membrane Ca2+ influx (SOCE) (141, 189).  We transfected 
HEK293T cells with STIM1-mCherry or Orai1-YFP and looked for the puncta formation of these 
proteins following BP exposure.  Transfected cells were treated with 0% BP, 3% PG/VG, thapsigargin, or 
3% BP (± 12 mg/ml nicotine) and both STIM1-mCherry and Orai1-YFP were imaged by confocal 
microscopy (Fig. 3.6A).  3% BP treatment increased both STIM1 and Orai1 puncta formation to a similar 
degree as thapsigargin, independent of the presence of nicotine (Fig. 3.6B-C).  Thus, BP e-liquid caused 
downstream activation of STIM1 and Orai1.  Downstream of ER/SOCE activation, Ca2+ alters the 
phosphorylation of key protein kinases, which further impacts cell function, including gene expression 
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and protein translation (65, 73).  For example, protein kinase Cα (PKCα) is canonically activated 
downstream of IP3 formation and Ca2+ signaling and plays a role in many biological functions (e.g., cell 
proliferation) (122, 146, 241, 261).  We tested whether BP could induce phosphorylation of PKCα.  
Western blots for phosphorylated-PKCα (p-PKCα), total PKCα, and GAPDH were generated from 
CALU3 cells treated with 3% BP (12 mg/ml nicotine) over time (Fig. 3.6D).  There was a significant 
increase in PKCα phosphorylation at 15-30 min, indicating that BP e-liquid has the ability not only to 
induce SOCE, but to phosphorylate important downstream protein kinases (Fig. 3.6E). 
BP e-liquid produces inositol phosphate (InsP) accumulation upstream of ER/SOCE Ca2+ 
response.  Since we determined that the Ca2+ response was ER/SOCE-dependent, we next sought to 
identify upstream signaling components.  IP3 is a common cellular messenger that is produced by PLC-
dependent cleavage of phosphatidylinositol 4,5-biphosphate (PIP2) and causes ER Ca2+ release after 
activating the IP3Rs on ER membranes.  To determine whether BP generated IP3 formation, total InsP 
accumulation was measured following a 2 min exposure to either 3% PG/VG, buffer control, UTP, or 3% 
BP ± 12 mg/ml nicotine.  3% BP significantly increased total InsP production (percent activation) 
compared to 3% PG/VG independently of nicotine (Fig. 3.7A).  The response was similar to UTP, which 
is known to induce IP3 formation following activation of the P2Y2 receptor (Gq-linked GPCR) (64).  
Additionally, we exposed HEK293T cells to the IP3R antagonist 2-APB (152, 228) to test the 
involvement of IP3 formation in eliciting the BP Ca2+ response.  Traces of cytosolic Ca2+ in response to 
UTP or 1% BP ± 2-APB pretreatment were shown (Fig. 3.7B).  UTP and 1% BP treatments elicited a 
cytosolic Ca2+ signal compared to 0% BP (Fig. 3.7C).  2-APB pretreatment blunted the Ca2+ response of 
UTP and 1% BP. 
BP-initiated IP3 formation, ER Ca2+/SOCE response, and PKCα phosphorylation are 
independent of upstream receptor tyrosine kinase (RTK) activation.  RTKs are a large family of kinases 
that phosphorylate proteins on tyrosine residues to regulate important cellular functions and can involve 
pathways such as the one activated by 3% BP exposure (161, 173).  We used a phospho-tyrosine (p-Tyr) 
antibody to measure phosphorylation in protein lysates collected from 3% BP-treated CALU3 cells over 
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time (Fig. 3.8A).  We found that BP treatment did not increase p-Tyr among detected proteins in our gel 
(normalized to GAPDH), suggesting that BP does not activate RTKs and PLCγ upstream of IP3 formation 
(Fig. 3.8B). 
Low endogenous mRNA expression in primary lung epithelia suggests that BP signaling is 
independent of taste receptor activation.  Since our previous data showed that BP treatment did not 
increase p-Tyr expression, GPCRs are another family of receptors where ligand binding causes a similar 
signaling cascade to BP exposure.  Both sweet taste receptors (T1Rs) and bitter taste receptors (T2Rs) are 
GPCRs that respond to sweet and bitter tastants/odorants.  Taste receptors are typically found in the 
tongue, but have also been reported in other tissue types including the upper and lower airways (50, 63, 
223, 253).  To try to identify candidate taste receptors that could be targets of flavored e-liquids, we tested 
the mRNA expression of three T1Rs, 22 T2Rs, and the Gα protein associated with taste reception 
gustducin (GNAT3), in primary whole lung, primary HBECs, CALU3 cells, and HEK293T cells.  Since 
GPCRs are not highly abundant proteins, expression was calculated relative to CFTR, an important 
airway ion channel that is also not highly expressed.  HBEC expression data were shown as a bar graph 
(Fig. 3.9) but data for all tissue/cell types expression were summarized elsewhere (Table 3.2).  Generally, 
almost all taste receptors and gustducin were detected at extremely low levels of expression, if at all.  
HEK293T cells were the only samples that were normalized to ORAI1 instead because HEK293T cells do 
not express CFTR (Table 3.2).  In HEK293T cells, five T2Rs (TAS2R3, TAS2R4, TAS2R14, TAS2R31, 
TAS2R45) were at similar or greater levels to ORAI1 expression. 
BP autofluorescence imaging reveals e-liquid internalization in CALU3 cells.  Previous work 
from our group has shown that some e-liquids have autofluorescent properties, especially in the UV 
excitation range (57).  BP is one of the least autofluorescent e-liquids tested.  However, some 
fluorescence can be visualized using confocal imaging with a high gain setting.  We used this property to 
test whether BP components could enter cells and potentially stimulate PLC activity independent of 
extracellular receptor activation.  After 3% BP exposure, intracellular autofluorescence was detected (Fig. 
3.10A-B), suggesting that BP components may directly stimulate PLC activity.  Though we know that BP 
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causes PLC activation to generated IP3, it is not clear whether this response is triggered by GPCR 
activation or direct activation of PLC (Fig. 3.10C). 
Thapsigargin-induced Ca2+ response is blunted over time with BP e-liquid exposure.  Since we 
have greatly detailed the acute, dose-dependent effects of BP on cell Ca2+ signaling, we next tested 
whether these effects persisted over time or altered Ca2+ homeostasis.  Accordingly, we incubated 
CALU3 cells with 3% BP or PG/VG for 24 h and then measured the thapsigargin-stimulated Ca2+ 
response (Fig. 3.11A-B).  Following exposure to 3% BP, the response to thapsigargin was attenuated.  
This blunted thapsigargin response was present by 3 h post-BP exposure and persisted over 24 h.  Some 
e-liquids are cytotoxic and decrease the number of cells in culture (211).  To check whether prolonged BP 
exposure was cytotoxic, we stained cell nuclei using DAPI and measured the resultant fluorescence.  
DAPI fluorescence was not different across groups, indicating that chronic BP exposure had not 
decreased total cell number (Fig 3.11E).  We then tested whether the thapsigargin response could be 
restored following 3 h BP exposure by then performing a 24 h wash out with media.  Indeed, the 
thapsigargin response was rescued with wash out in the BP-exposed cultures (Fig. 3.11C-D).  Again, 
there was no decrease in DAPI fluorescence with BP or PG/VG treatments compared to 0% BP (Fig. 
3.11F), suggesting that this inhibited Ca2+ response was not due to BP-related cytotoxicity.  
The attenuated thapsigargin response following 3 h BP exposure affects both ER Ca2+ release 
and SOCE.  To better understand how chronic BP exposure might be inhibiting the thapsigargin-induced 
Ca2+ response, we completed Ca2+ replacement studies as before (Fig. 3.5A).  After 3% BP exposure for 3 
h, both ER Ca2+ release and SOCE was diminished (Fig. 3.12A-D).  Moreover, cells treated with 3% BP 
for 1 h only showed a decreased SOCE response (P = 0.051), suggesting that the attenuation to 
thapsigargin starts as early as 1 h and impairs the SOCE response before the ER response.  PG/VG 
treatment did not alter ER/SOCE-dependent thapsigargin responses, as previously shown. 
3.5. Discussion 
 We have previously characterized the effects of over 100 e-liquids on cell viability (211, 216).  In 
these studies, BP was consistently more toxic than the e-liquid base constituents (i.e., PG, VG, nicotine).  
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We attempted to correlate toxicity versus chemical composition.  However, due to the chemical diversity, 
these studies did not detail how more toxic e-liquids (e.g., BP) exerted their effects.  Many cellular 
pathways regulate proliferation, and Ca2+ signaling is a well-known regulator of both cell division and 
apoptosis (26).  Since BP altered cell proliferation, we first focused on its effects on Ca2+ homeostasis.  
Indeed, we found that BP acutely stimulated ER Ca2+ release in primary HBECS as well as immortalized 
CALU3 and HEK293T cells (Fig. 3.1).  This response was independent of nicotine, but there was a 
prolonged plateau compared to baseline with the presence of nicotine (Fig. 3.3).  We also saw a similar 
Ca2+ response after both direct e-liquid addition and vaping e-liquid, suggesting that this is a robust, dose-
dependent response (Fig. 3.4). 
 Multiple lines of evidence suggested that BP elicited a classic ER/SOCE-type response.  Firstly, 
pretreatment with BP abolished the effects of the SERCA pump inhibitor thapsigargin (Fig. 3.1) and vice 
versa (Fig. 3.5B).  Second, BP still elevated cytoplasmic Ca2+ in the absence of extracellular Ca2+, and a 
second increase in cytosolic Ca2+ occurred when extracellular Ca2+ was reintroduced (Fig. 3.5A).  Third, 
the BP effect was insensitive to the mitochondrial uncoupler CCCP and no change in Ca2+ was detected 
when cells were labeled with the mitochondrial dye rhod-2 (Fig. 3.5C-D).  Finally, BP exposure caused 
STIM1 and Orai1 to reorganize into puncta (Fig. 3.6A-C), which is indicative of their activation.  Here, 
these effects reprised those seen with thapsigargin and were independent of nicotine and PG/VG.
 Thapsigargin elicits ER Ca2+ release by directly inhibiting SERCA pumps (144).  However, 
formation of IP3 activates IP3Rs on the ER membrane to physiologically elicit ER Ca2+ release (64).  
Thus, we looked to see whether BP induced IP3 formation.  Indeed, BP induced InsP formation that was 
(i) PG, VG, and nicotine-independent and (ii) equal in magnitude to the InsP formation induced by UTP 
addition (Fig. 3.7A).  Consistent with this observation, the IP3R antagonist 2-APB abolished both UTP 
and BP-induced increases in cytosolic Ca2+ (Fig. 3.7B-C).  2-APB can also affect transient receptor 
potential (TRP) channels (46).  However, given that we had established that this was an ER-dependent 
signal, it is likely that we are not observing inhibition of TRP channels here.   
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 Canonically, GPCR or RTK activation can trigger PLC-mediated IP3 formation, ER Ca2+ release, 
and SOCE (64, 161, 173, 233).  We excluded upstream RTK activation after measuring global tyrosine 
phosphorylation in BP-treated CALU3 cells (Fig. 3.8).  We could not completely exclude the possibility 
that BP acted upstream of PLC and stimulated a GPCR or its associated G-protein though.  We initially 
hypothesized that taste receptors (GPCRs) might be targets since e-liquids often contain bitter nicotine or 
sweet flavors.  Though taste receptors have been reported in the airways (63, 134, 223), we found little to 
no expression of several taste receptor isoforms and gustducin (GNAT3) in primary and immortalized 
airway samples as well as HEK293T cells, suggesting that this effect is not taste-mediated.  The 
exceptions were five T2Rs in HEK293T cells that showed similar expression to our ORAI1 control since 
HEK293T cells had no CFTR expression.  Though more experiments are necessary to rule GPCR 
activation in or out of this mechanism, it seems unlikely that the conserved response to BP would act 
through a T2R in one cell type and not the others, especially in the absence of gustducin.   
 PLC is an enzyme that is associated with the inner face of the plasma membrane that cleaves 
phospholipids (e.g., PIP2) to form IP3 (64).  Our observation that BP caused InsP formation is good 
evidence that PLC was being activated by BP however, the mechanism of activation is still unclear.  
Though we have not completely ruled out a possible GPCR target for BP, we have previously shown that 
the autofluorescent e-liquid, Pixie Dust, can internalize in HEK293T cells (88).  BP is actually one of the 
least autofluorescent e-liquids and does not interfere with the fluorescent indicators used in this study 
(57).  However, we demonstrated that BP can rapidly enter CALU3 cells (Fig. 3.10A-B) by imaging 
autofluorescence at 405 nm with high laser gain settings.  The small molecule m-3M3FBS has been 
reported to acutely activate PLC followed by increases in cytosolic Ca2+ signaling in several cell lines, 
independent of G protein stimulation (14).  Of note, Krjukova et al. found that m-3M3FBS may not be a 
reliable PLC activator in all cell types as they reported that SH-SY5Y cell line had delayed PLC activity, 
which suggested the Ca2+ signal was independent of its activation (125).  Yet, it is possible that 
components in BP e-liquid could similarly move intracellularly and directly access and activate PLC. 
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 IP3 formation is mediated by PLC activation, usually downstream of cell surface receptor 
activation.  PLC is required for normal physiological function such as Gq-linked GPCR signaling 
activation (64, 75).  However, PLC has also been denoted as a malignancy-linked signal transducing 
enzyme (270).  For instance, PLCγ overexpression increased transformation and tumorigenicity of 
NIH3T3 cells (231) and altered expression of PLC-β2 promoted mitosis and migration of breast cancer-
derived cells (27).  Indeed, chronic activation of PLC by inhaling BP or similarly flavored aerosols may 
have the potential to trigger increased cell proliferation and metastasis, similar to cancer.  Moreover, 
downstream activation of SOCE has also been shown to affect cell proliferation.  Chen et al. reported that 
SOCE responses change with cell cycle, where SOCE is upregulated to transition to the G1/S phase check 
point and then downregulated to transition from the S to the G2/M phase (44).  However, further research 
is needed to elucidate the long-term effects of vaping PLC-activating e-liquid flavors on cancer risk in the 
lung.   
Indeed, our data shows an acute and robust activation of PLC, resulting in SOCE following BP 
exposure.  Yet, Figures 3.11 and 3.12 suggest that BP e-liquid impairs ER Ca2+ release and SOCE with 
chronic exposure.  Knocking down Orai1 and/or STIM1 has been shown to reduce cell proliferation (44), 
suggesting that impairing SOCE with long-term BP exposure may offset the potential cell proliferation 
induction caused by increased PLC activity upstream.  However, the mechanism by which BP inhibits 
thapsigargin-dependent ER/SOCE responses is unclear.  Furthermore, washing out BP in cultures restores 
the thapsigargin-dependent Ca2+ signal.  This suggests that impairment of SOCE from BP or other Ca2+-
eliciting flavors would be highly dependent on the amount of e-liquid vaped and time between vaping 
sessions.  Interestingly, STIM1 protein expression was found to be upregulated in HBECs isolated from 
vapers compared to smokers and non-smokers (88).  Moreover, HBEC isolated from mice exposed to 
PG/VG aerosol showed a similar upregulation of STIM1 compared to air puff controls (88), suggesting 
that chronic PG/VG exposure alone can alter a key player in Ca2+ metabolism.  Further studies are needed 
to understand the long-term effects of vaping PG/VG, as well as Ca2+-eliciting e-liquids on Ca2+ 
metabolism in lung epithelia and other airway cells. 
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 To date, no other study has shown the ability of e-liquids to cause ER Ca2+ release.  These data 
could be used to inform FDA regulations regarding e-cig flavorings and potential health effects for users.  
Specifically, our study provides a detailed look at a BP-flavored e-liquid and its effects on cell Ca2+ 
homeostasis, which could be coupled with in vivo human data to find new biomarkers of e-cig exposure 
and understand alterations of airway cell Ca2+ homeostasis in the airways of vapers.
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Table 3.1.  List of taste receptor mRNA expression in primary and immortalized airway cells.  List 
of the mRNA expression levels of 25 sweet and bitter taste receptors (T1Rs/T2Rs) and associated Gα 
protein (GNAT3) relative to important, low expressed airway ion channels (CFTR or ORAI1) determined 
by quantitative RT-PCR in untreated primary whole lung and HBECs, as well as immortalized CALU3 
and HEK293T cell lines.  Data shown as average gene expression relative to CFTR or Orai1 ± SEM.  n = 
5 wells per gene and ND = not determined.  Primary samples included healthy, non-smoking donors (n = 
3-4). 
 
 Whole Lung HBEC CALU3 HEK293T 
Gene AVG ± SEM AVG ± SEM AVG ± SEM AVG ± SEM 
CFTR 1.003 ± 0.024 1.045 ± 0.157 1.015 ± 0.075 0.003 ± 0.003 
ADRB2 1.348 ± 0.224 - - - 
ORAI1 - - 0.050 ± 0.010 1.004 ± 0.060 
GNAT3 ND 0.001 ± 0.001 ND 0.001 ± 0.001 
TAS1R1 0.006 ± 0.003 0.001 ± 0.001 0.013 ± 0.010 0.018 ± 0.016 
TAS1R2 ND 0.018 ± 0.008 ND ND 
TAS1R3 ND 0.001 ± 0.001 0.015 ± 0.012 0.003 ± 0.003 
TAS2R1 0.006 ± 0.002 0.193 ± 0.119 ND 0.069 ± 0.029 
TAS2R3 0.027 ± 0.006 0.110 ± 0.067 0.014 ± 0.004 1.835 ± 0.549 
TAS2R4 0.031 ± 0.006 0.114 ± 0.069 0.019 ± 0.005 1.423 ± 0.350 
TAS2R5 0.035 ± 0.012 0.100 ± 0.063 0.012 ± 0.003 0.438 ± 0.088 
TAS2R7 0.001 ± 0.001 0.129 ± 0.091 < 0.001 ± 0.001 0.055 ±0.031 
TAS2R8 0.005 ± 0.001 0.052 ± 0.033 < 0.001 ± 0.001 0.196 ± 0.072 
TAS2R9 0.019 ± 0.004 0.060 ± 0.038 < 0.001 ± 0.001 0.190 ± 0.095 
TAS2R10 0.009 ± 0.002 0.142 ± 0.087 0.002 ± 0.001 0.155 ± 0.035 
TAS2R13 0.021 ± 0.005 0.072 ± 0.044 0.001 ± 0.001 0.061 ± 0.006 
TAS2R14 0.117 ± 0.019 0.221 ± 0.134 0.010 ± 0.006 1.077 ± 0.367 
TAS2R16 0.002 ± 0.001 0.072 ± 0.051 < 0.001 ± 0.001 0.198 ± 0.150 
TAS2R19 0.048 ± 0.008 0.388 ± 0.237 0.007 ± 0.003 0.584 ± 0.181 
TAS2R20 0.018 ± 0.005 0.201 ± 0.142 0.001 ± 0.001 0.296 ± 0.086 
TAS2R30 0.117 ± 0.010 0.062 ± 0.054 0.004 ± 0.003 0.196 ± 0.072 
TAS2R31 0.028 ± 0.008 0.046 ± 0.043 0.003 ± 0.002 1.578 ± 0.480 
TAS2R38 0.002 ± 0.001 0.062 ± 0.061 < 0.001 ± 0.001 0.139 ± 0.064 
TAS2R42 0.006 ± 0.002 0.099 ± 0.097 0.002 ± 0.001 0.319 ± 0.098 
TAS2R43 0.023 ± 0.009 0.012 ± 0.011 0.001 ± 0.001 0.197 ± 0.044 
TAS2R45 0.032 ± 0.008 0.027 ± 0.025 0.003 ± 0.001 1.679 ± 0.371 
TAS2R46 0.024 ± 0.005 0.073 ± 0.061 0.001 ± 0.001 0.385 ± 0.089 
TAS2R50 0.010 ± 0.003 0.048 ± 0.048 0.001 ± 0.001 0.148 ± 0.051 
TAS2R60 ND 0.037 ± 0.026 0.001 ± 0.001 0.221 ± 0.098 
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Figure 3.1.  Banana Pudding (BP)-flavored e-liquid acutely elevates cytoplasmic Ca2+ in primary 
and immortalized epithelia.  Primary human bronchial epithelial cells (HBECs), CALU3 cells, and 
HEK293T cells were plated on glass coverslips and loaded with a Ca2+ indicator (fura-2).  Cells were 
challenged acutely with flavored BP e-liquid + nicotine or PG/VG (e-liquid vehicle) diluted in Ringers 
solution followed by thapsigargin.  A-C: Ca2+ signals were measured over time and reported as the change 
in fluorescence (F/F0).  D: Peak changes for each cell type in response to the treatments are shown.  A-D: 
Symbols and bars represent mean ± SEM.  A-D: n = 4-11 coverslips per treatment.  Statistical differences 
were shown between all treatments compared to 0% BP control within cell types (D) (*P < 0.05, **P < 
0.01, ***P < 0.001). 
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Figure 3.2.  BP-flavored e-liquid retains similar cytoplasmic Ca2+ and toxicity responses between 
two purchased lots (batches).  CALU3 cells were plated onto glass coverslips glass coverslips and 
loaded with a Ca2+ indicator (fura-2).  Cells were challenged acutely with BP e-liquid from two different 
lots purchased from the same vendor (designated #09 and #165).  BP e-liquid was diluted in Ringers 
solution and followed by thapsigargin.  A: Ca2+ signals were measured over time and reported as the 
change in fluorescence (F/F0).  B: Peak changes per treatment for each BP lot are shown.  Additional cells 
were plated into 96 well plates and treated with BP (%vol/vol) from either lot (#09 and #165) for 24 h.  C: 
Cells were fixed and stained with DAPI to measure relative cell number.  D: Cells were incubated with 
calcein to measure viability.  Symbols represent mean ± SEM.  Bars represent peak F/F0 or %fluorescence 
normalized to 0% BP control.  A-B: n = 3-4 coverslips per treatment.  C-D: n = 9-19 wells per treatment.  
Statistical differences were shown between all treatments compared to 0% BP control within lot numbers 
(B-D) (*P < 0.05, **P < 0.01, ***P < 0.001). 
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Figure 3.3.  BP e-liquid elevates cytoplasmic Ca2+ independent of nicotine.  CALU3 cells were plated 
into 12 well plates and loaded with a Ca2+ indicator (fluo-4).  Cells were challenged acutely with BP e-
liquid ± nicotine diluted in Ringers solution.  A-B: Cells were exposed to the BP e-liquid ± 12 mg/ml 
nicotine and F/F0 was measured over time ± treatment wash out.  C-D: Peak and plateau changes for each 
treatment were measured at 1.5 and 25 min post-treatment respectively.  A-D: Symbols and bars represent 
mean ± SEM.  A-D: n = 8-13 wells per treatment.  Statistical differences were shown between all 
treatments compared to 0% BP control (C) or within treatment ± wash out (D) (*P < 0.05, ***P < 0.001).  
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Figure 3.4.  BP-flavored aerosol elicits acute dose-dependent increases in cytoplasmic Ca2+ in 
airway epithelia.  CALU3 cells were seeded in 96 well plates.  Cells were loaded with a Ca2+ indicator 
(fluo-4) and media was replaced with Ringers solution before baseline fluorescence was measured.  The 
cultures were then exposed to puffs of air, PG/VG aerosol, or BP aerosol.  After puffs were administered, 
fluorescence was read at timed intervals following aerosol exposure and thapsigargin addition.  Both 
PG/VG (vehicle) and air puffs were performed as controls.  A-D: The change in fluorescence (F/F0) was 
reported over time and peak changes in fluorescence to exposures were plotted.  Symbols and bars 
represent mean ± SEM.  n = 17-30 wells per treatment.  Statistical differences were shown between 
respective doses per treatment compared to their 0 puff control (**P < 0.01, ***P < 0.001).
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Figure 3.5.  BP e-liquid Ca2+ responses are ER and SOCE-dependent and do not involve 
mitochondrial Ca2+.  A-B: CALU3 cells were seeded onto glass coverslips and loaded with fura-2.  A: 
Cells were challenged with BP or PG/VG diluted in Ringers solution either containing nominal (0 mM) or 
2 mM Ca2+ as indicated.  Ca2+ signal was measured over time and reported as a trace or the peak 
fluorescence change in response to treatments.  B: Cells were challenged with thapsigargin followed by 
3% BP.  C: CALU3 cells were plated into 12 well dishes, loaded with fluo-4, and pretreated ± CCCP 
before they were exposed to BP or PG/VG diluted in Ringers followed by thapsigargin.  D: CALU3 cells 
were plated into 12 well dishes, loaded with a mitochondrial Ca2+ indicator (rhod-2), and pretreated ± 
CCCP before they were exposed to BP or PG/VG diluted in Ringers.  Peak changes in mitochondrial Ca2+ 
(AFU) in response to treatments were plotted.  Symbols and bars represent mean ± SEM.  A-B: n = 5-6 
coverslips per treatment.  C-D: n = 7-15 wells per treatment.  Statistical differences were reported 
between treatments and their 0% BP control within groups (C-D) (NS = not significant; ***P < 0.001) or 
between respective treatments between rhod-2 only and CCCP pretreatment groups (D) (*P < 0.05, **P < 
0.01, ***P < 0.001).  
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Figure 3.6.  BP exposure induces STIM1/Orai1 puncta formation and protein kinase Cα (PKCα) 
phosphorylation.  A-C: Transfected HEK293T cells were exposed to either 0% BP (media only), 3% 
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PG/VG, thapsigargin, or 3% BP ± 12 mg/ml nicotine, for 5-10 min.  Cells were fixed and imaged and the 
percentage of puncta-positive cells were measured for both STIM1-mCherry and Orai1-YFP respectively.  
Scale bar represents 25 μm.  D-E: CALU3 cells were seeded into 60 mm dishes and treated with 3% BP 
diluted in media for 0-60 min, as indicated.  Protein lysates were collected and immunoblots were 
performed for phosphorylated PKCα (p-PKCα), total PKCα, and GAPDH (loading control).  
Representative blots of all proteins with treatment were shown.  Band intensities were measured and the 
ratio of p-PKCα/GAPDH intensities were plotted.  Bars represent mean + SEM.  A-C: n = 4-9 coverslips 
per treatment.  D-E: n = 6 blots per time point.  B-E: Statistical differences were calculated between all 
groups compared to their 0% BP control or 0 min time point (*P < 0.05, **P < 0.01, ***P < 0.001).  
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Figure 3.7.  BP stimulates inositol phosphate accumulation and the BP response is sensitive to IP3R 
antagonist 2-APB.  A: HEK293T cells were seeded in 24 well plates and incubated with [3H]inositol 
phosphate.  Cells were exposed to 200 µM UTP or 0-3% BP or PG/VG for 2 min and total intracellular 
inositol phosphate was collected, measured, and plotted as percent activation normalized to 3% PG/VG.  
B-C: HEK293T cells were seeded in 12 well plates and loaded with a Ca2+ indicator (fluo-4).  Cells were 
treated with 100 µM UTP or e-liquids ± 2-APB, which was added for 1 min prior to the treatment, 
followed by thapsigargin.  Responses were measured as change in fluorescence (F/F0) and peak changes 
were also plotted.  Symbols and bars represent mean ± SEM.  A: n = 9-12 replicates per treatment with 
doses compared to 3% PG/VG control (**P < 0.01, ***P < 0.001).  C: n = 8-12 wells per treatment with 
doses compared to 0% BP only (##P < 0.01, ###P < 0.001).  Additional differences shown between 
treatments and their respective 2-APB treatments (*P < 0.05, ***P < 0.001).  
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Figure 3.8.  IP3 formation-independent of receptor tyrosine kinase (RTK) activation.  CALU3 cells 
were seeded into 60 mm culture dishes and treated with 3% BP diluted in media for 0-60 min.  Protein 
lysates were collected and immunoblots were performed for phosphorylated tyrosine residues (p-Tyr) and 
GAPDH (loading control).  A: Representative blots with indicated treatments were shown.  p-Tyr blots 
were cut to avoid overexposure of more intense bands (≥ 100 kDa).  B: Relative treatment intensities were 
measured as a ratio of p-Tyr lane intensities/GAPDH bands and were plotted.  Bars represent mean + 
SEM.  n = 3-4 blots per time point.  
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Figure 3.9.  Endogenous taste receptor mRNA expression very low or not detected in primary 
HBECs.  A: RNA was isolated from untreated primary HBECs and endogenous mRNA expression of 
gustducin (Gα) and sweet and bitter taste receptors (T1Rs/T2Rs) were measured relative to CFTR 
expression.  Results are summarized in Table 3.2 along with endogenous whole lung, CALU3 cell, and 
HEK293T cell taste receptor expression.  Bars represent mean + SEM.  n = 5 wells per gene.  ND = not 
detected. 
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Figure 3.10.  BP autofluorescence imaging shows e-liquid internalization in lung epithelia.  CALU3 
cells were plated onto glass coverslips and imaged pre- and post-3% BP, diluted in Ringer’s solution.  A: 
Representative fluorescence, bright field, and overlay images of CALU3 cells pre-BP exposure.  B: 
Representative fluorescence, bright field, and overlay images 2 min post-BP exposure.  n = 3 coverslips 
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per treatment.  C: Diagrams predict likely targets of BP e-liquid upstream of IP3 formation.  (1) BP e-
liquid components activate ligand binding with plasma membrane localized GPCR, stimulating PLCβ to 
cleave PIP2, forming IP3 which acts on ER IP3Rs to empty ER Ca2+, elicit SOCE, and increase PKCα 
phosphorylation.  (2) BP e-liquid forms direct adduct to plasma membrane-bound PLCβ and triggers 
similar IP3-dependent ER Ca2+/SOCE response and PKCα phosphorylation independent of plasma 
membrane receptor activation. 
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Figure 3.11.  Pre-treatment with BP e-liquid attenuates thapsigargin-induced Ca2+ release.  CALU3 
cells were seeded into 96 well plates and then exposed to 0-3% BP or PG/VG for 3-24 h incubations ± 
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wash out with media, as labeled.  Cells were loaded with a Ca2+ indicator (fluo-4) and media was replaced 
with Ringers solution before the cytosolic Ca2+ response to thapsigargin was measured.  A,C: Results were 
reported as a change in fluorescence (F/F0) over time.  B,D: Peak responses to thapsigargin were 
measured per treatment.  E-F: Following Ca2+ measurements, cells were fixed and stained with DAPI to 
measure relative total cell number fluorescence.  A-F: Symbols and bars represent mean ± SEM.  n = 13-
33 wells per treatment.  A-F: Statistical differences were shown between all treatments and their 
respective 0% BP control (***P < 0.001).  Overall interactions were detected at (P < 0.05) in E-F, but no 
differences were found between groups compared to 0% BP. 
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Figure 3.12.  3 h BP pre-treatment inhibits both ER and SOCE thapsigargin-induced Ca2+ release.  
CALU3 cells were seeded into 12 well plates and then exposed to 0-3% BP or PG/VG for 1 or 3 h 
incubations.  Cells were loaded with a Ca2+ indicator (fluo-4) and media was replaced with Ringers 
solution before the cytosolic Ca2+ response to thapsigargin was measured ± extracellular Ca2+.  A-B: 
Results were reported as a change in fluorescence (F/F0) over time.  C: Peak F/F0 ER (intracellular) 
thapsigargin responses were measured.  D: Peak F/F0 SOCE thapsigargin responses were measured.  A-D: 
Symbols and bars represent mean ± SEM.  n = 6-10 wells per treatment.  C-D: Statistical differences were 
shown between all treatments and respective 0% BP controls (**P < 0.01; ***P < 0.001). 
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Chapter 4: Flavoring Chemicals Identified in E-liquids Elicit Dose-Dependent Cytosolic and Store 
Operated-Ca2+ Entry in Lung Epithelia 
4.1. Overview 
Commercially available flavored e-liquids often contain a mixture of individual flavoring 
chemicals at varying concentrations.  The chemistry and biology of inhaling these complex mixtures 
through vaping is not well understood.  Calcium (Ca2+) is an important second messenger that regulates 
cell signaling, innate defenses, and proliferation in many cell types (e.g., pulmonary epithelia).  We have 
previously shown that a Banana Pudding (BP)-flavored e-liquid induced phospholipase C (PLC)-
mediated Ca2+ signaling.  To better understand how widespread this effect might be, we screened 100 e-
liquids and determined that 42 were able to acutely alter cytosolic Ca2+ levels.  When we analyzed the 
Ca2+ responses with qualitative chemical constituent data, we found several flavoring chemicals 
correlated with a cytosolic Ca2+ response.  We characterized six of the flavoring chemicals and found that 
four dose-dependently elevated cytosolic Ca2+ responses with the following potency: menthol > ethyl 
vanillin > vanillin > ethyl maltol.  We then performed additional experiments with vanillin and ethyl 
vanillin.  Ethyl vanillin acutely initiated store-operated Ca2+ entry, suggesting that it is not working 
through transient receptor potential channels.  Treating cells with a combination of vanillin and ethyl 
vanillin, also elicited a cytosolic Ca2+ response.  Lastly, long-term exposure of pulmonary epithelia to 
vanillin and ethyl vanillin inhibited cell viability/proliferation.  Thus, flavoring chemicals commonly used 
in e-liquids should be tested further for long-term health effects from inhalation exposure due to vaping. 
 
 
4Contributing authors: Temperance R Rowell, Bryan T Zorn, James E Keating, Gary L Glish, and Robert 
Tarran. 
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4.2. Introduction 
Most flavoring chemicals are commonly used in food products and ‘generally recognized as safe’ 
(GRAS) for ingestion [http://www.accessdata.fda.gov/scripts/fdcc/?set_SCOGS].  The best case for 
testing these flavorants for inhalation toxicity is the development of bronchiolitis obliterans (i.e., 
‘Popcorn Lung’) in workers exposed to diacetyl (butter flavor) inhalation in manufacturing plants (124).  
Though it is known that diacetyl inhalation can cause fibrotic lung disease, diacetyl and similar chemicals 
have still been detected in commercial e-liquids (5).  Though the scientific e-cigarette (e-cig) field is 
attempting to fill gaps in knowledge, there is still much that remains to be understood regarding the role 
of vaping flavoring chemicals in long-term airway health. 
Humans sense flavors primarily through olfactory cells located in the mouth and nose.  While 
salty flavors are detected by the activation of ion channels (e.g., epithelial sodium channel), sweet, umami 
(glutamate), and bitter flavors typically stimulate taste receptors.  Taste receptors are G protein-coupled 
receptors (GPCRs) recognized as T1Rs (sweet/umami type receptors) and T2Rs (bitter type receptors) 
(121).  Ligand binding causes activation of PLCβ2 to generate inositol 1,4,5-triphosphate (IP3) via 
gustducin, a Gα protein.  IP3 triggers a release of ER Ca2+ to continue the signal cascade, typically leading 
to store operated Ca2+ entry (SOCE) to prolong the Ca2+ signal and refill the ER Ca2+supply (Fig. 4.1).  
Taste receptors are low affinity, meaning that most ligand binding affinities occur in the high μM to mM 
range, often mirroring flavoring concentrations found in foods (121).  Beyond the tongue, taste receptor 
expression has been reported in the brain (201), pancreas (170), and the upper and lower airways (63, 
134, 223, 253).  Airway T2Rs have been shown to promote innate defenses in the respiratory tract, 
suggesting that they are a protective mechanism against inhaled noxious pollutants/toxicants which are 
generally perceived as bitter.  For example, activating T2Rs in ciliated lung epithelia increased ciliary 
beat frequency, an important mechanism in mucociliary clearance (223).  T2Rs in nasal epithelia have 
also demonstrated the ability to induce antimicrobial peptide secretion via Ca2+ signaling.  However, 
activation of T1Rs in those same nasal epithelia suppressed T2R-dependent antimicrobial peptide 
secretion and increased susceptibility of infection (134). 
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Apart from taste receptors, many flavoring chemicals (e.g., menthol, cinnamaldehyde, vanillin) 
are known ligands of transient receptor potential (TRP) channels (190).  TRP channels are generally 
permeable to Ca2+ ions, thereby increasing cytosolic [Ca2+].  However, TRP channels are not associated 
with IP3 formation or ER Ca2+ release (41), which was demonstrated with exposure to a BP-flavored e-
liquid.  It is important to understand how these e-liquids, and individual flavorings, may be triggering 
Ca2+ responses.  Interestingly, some flavoring chemicals are reactive aldehydes which have the potential 
to react with macromolecules (i.e., protein, DNA) and form adducts.  Protein and DNA adduct formation 
has been well-documented with exposure to reactive aldehydes in tobacco smoke (e.g., acrolein) and have 
biological consequences.  For instance, acrolein has formed adducts with cysteine residues in neutrophil 
nicotinamide adenine dinucleotide phosphate oxidase components, impairing neutrophil respiratory burst 
activation (174).  Similarly, cinnamaldehyde has inhibited other immune cell functions through adduct 
formation with protein kinases (120).  Thus, individual flavorings that have the ability to trigger cytosolic 
Ca2+ responses should be investigated for their ability to form adducts with upstream pathway 
components to better understand their mechanism of action.  We previously characterized the ability of a 
BP-flavored e-liquid to activate PLC-dependent ER Ca2+ release and SOCE.  Given this novel 
physiological role of an e-liquid to alter cell Ca2+ homeostasis, we aimed to conduct a screen of 100 e-
liquids to understand the scope of these commercially available products to elicit cytosolic Ca2+ responses 
in pulmonary epithelia.  We then sought to analyze the Ca2+ responses with corresponding chemical 
constituent data to predict flavoring chemicals that may be contributing to the response and then 
characterize the flavorings’ roles in Ca2+ signaling and inhalation toxicity. 
4.3. Methods 
Flavored e-liquids.  E-liquids were purchased from The Vapor Girl (www.thevaporgirl.com) and 
NJOY (www.njoy.com/e-juice), as designated in Table 4.1.  Nicotine concentrations for each flavored e-
liquid can also be found in Table 4.1.  A vehicle control of 55/45 propylene glycol (PG)/vegetable 
glycerin (VG) was prepared in our laboratory. 
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Chemicals and reagents.  PG, VG, DMSO, probenecid, thapsigargin, triacetin, isoamyl acetate, 
vanillin, ethyl vanillin, ethyl maltol, and menthol were purchased from Sigma-Aldrich.  Fluo-4 (AM), 
lipofectamine 2000, and the Vybrant MTT Cell Proliferation Assay Kit were purchased from 
ThermoFisher.  Paraformaldehyde (PFA) was purchased from Affymetrix.  Thapsigargin and fluo-4 (AM) 
were reconstituted using DMSO and applied to cells in experiments where the final DMSO concentration 
was ≤ 0.1%.  STIM1 tagged with mCherry on the C-terminus was kindly provided by Dr. Ricardo 
Dolmetsch (181). 
Cell culture and transfections.  CALU3 cells were cultured in Minimum Essential Media (MEM) 
alpha with 10% FBS and penicillin/streptomycin (Gibco) with 5% CO2 at 37°C.  CALU3 cells were 
seeded into 12 or 96 well plastic dishes (Corning) for fluo-4 experiments.  HEK293T cells were cultured 
in D-MEM (high glucose) with 10% FBS and penicillin/streptomycin (Gibco) with 5% CO2 at 37°C.  
HEK293T cells were plated onto glass coverslips for STIM1 puncta imaging experiments. 
Ca2+ signaling.  Changes in cytosolic [Ca2+] were measured using fluo-4 dye.  CALU3 cells were 
loaded with 8 μM fluo-4 in the presence of 1 mM probenecid for 40 min at 37°C prior to experiments.  
Cultures were then rinsed with PBS and replaced with a standard Ringer’s solution as described (211).  
Fluorescence intensities were measured every 15 or 30 sec using a Tecan Infinite Pro plate reader (ex: 
490 ± 10 nm, em: 516 ± 5 nm) at room temperature.  Changes in fluo-4 fluorescence were normalized to 
the baseline (F/F0) after subtracting background light levels.  Traces were plotted to show F/F0 over time 
and the peak change in F/F0 was measured for each dose.  Thapsigargin was added to cultures for a final 
concentration of 2 μM.  Individual chemical flavorings were prepared in either 100% ethanol or PG/VG, 
diluted in Ringer’s solution, and exposed to cells at the final concentration (mM).  Nonlinear regression 
curves were fit to each flavoring’s dose response in the fluo-4 assays using GraphPad Prism to calculate 
EC50 values, where appropriate. 
Heatmap of peak cytosolic Ca2+ screen.  Peak cytosolic Ca2+ responses of 100 flavored e-liquids 
were measured and compared to the 0% e-liquid control.  Statistically significant responses (P < 0.05) 
were log2-transformed and a heatmap was generated using Morpheus software (Broad Institute).  
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E-liquid chemical constituent analysis from cytosolic Ca2+ screen.  A random forest classification 
model using the statistical software R version 3.4.1 was used to predict whether significant cytosolic Ca2+ 
responses in cell cultures could be determined using qualitative gas chromatography-mass spectrometry 
(GC-MS) chemical constituent presence/absence data, as well as the sum of all chemicals within each e-
liquid as input features (138, 249).  The model (n = 100) used a randomly sampled training set (70%) in 
which the remaining data were used as a test set using 10001 decision trees.  The mtry parameter was 
determined by using the lowest out-of-bag error rate resulting from tuneRF with stepFactor = 0.85, 
ntreeTry = 10001, improve = 0.005.  The random forest models were repeated using 10 seeds (1, 2, 
3…10). 
STIM1 puncta quantification.  HEK293T cells were plated onto glass coverslips and transfected 
with STIM1-mCh using lipofectamine 2000 per manufacturer’s protocol as described (198).  Cells 
expressing STIM1-mCherry were treated with 0-30 mM ethyl vanillin or 2 µM thapsigargin for 5-10 min.  
Cells were fixed with 4% PFA for 10 min at room temperature following treatment, and rinsed with PBS 
before imaging.  All puncta imaging was conducted on a Leica SP8 confocal microscope with a 63 x 1.4 
NA oil immersion objective.  Multiple images were taken per coverslip from different parts of the 
coverslip and ≥ 12 transfected cells were visually analyzed for the percentage of puncta positive cells per 
coverslip.   
Cell proliferation.  The MTT assays were performed with CALU3 cells as instructed by the 
manufacturer following a 24 h exposure with 0-30 mM vanillin or ethyl vanillin.  Cells were allowed to 
proliferate for 4 h after removal of the treatments.  Data were calculated as percent absorbance of each 
treatment compared with the average of their respective 0 mM control treatments in each plate.  Nonlinear 
regression curves were fit to each flavoring’s dose response in the MTT assays using GraphPad Prism to 
calculate IC50 values, where appropriate.   
Quantitative GC-MS.  Flavor concentrations were determined by standard addition (216).  E-
liquids were diluted in methanol and quantitative standards.  Selected ion monitoring mass spectra were 
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acquired for each of the quantified flavors.  Peak areas of quantitative ions were integrated for 
quantification of each of the flavors. 
Statistical analyses.  All statistics were run using Prism Graphpad (San Diego) software.  Data 
were analyzed using the Kruskal-Wallis test with Dunn’s multiple comparisons test or the Mann-Whitney 
test where appropriate.  P-values ≤ 0.05 were found to be significant and reported (*P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001). 
4.4. Results 
Numerous commercially available e-liquids elicit cytosolic Ca2+ responses and analysis of 
chemical constituents reveals vanillin, ethyl vanillin, and ethyl maltol may contribute.  Since we 
discovered the novel action of a BP-flavored e-liquid on cytosolic Ca2+ signaling in lung epithelia from 
one brand of e-liquid, we decided to screen a number of flavored e-liquids from local and national 
vendors.  We found that 42 of 100 flavored e-liquids screened elicited a cytosolic Ca2+ signal compared to 
the 0% e-liquid control (P < 0.05) (Fig. 4.2A).  We previously analyzed over 200 e-liquids by GC-MS, 
which are accessible in an online database (www.eliquidinfo.org) (216).  To better understand why a 
number of e-liquids might be able to elicit a cytosolic Ca2+ response, these data were used to compare e-
liquids for chemical composition relative to their cytosolic Ca2+ response. 
The average accuracy of correctly classified e-liquids using random forest models was 75%, 
suggesting that qualitative constituent data may be able to predict cytosolic Ca2+ signaling (Fig. 4.2B).  
The total number of chemicals in each e-liquid was consistently found to be the most important variable 
in classification.  However, the presence of ethyl vanillin (CAS: 121-32-4), vanillin (CAS: 121-33-5), and 
ethyl maltol (CAS: 4940-11-8) were also considered to be major variables in classification (Fig. 4.2B).  It 
is worth noting that GC-MS analysis of BP revealed the presence of all three of these chemicals 
(www.eliquidinfo.org). 
Several common flavoring chemicals previously identified in Ca2+-eliciting e-liquids cause dose-
dependent cytosolic Ca2+ responses.  We chose to follow up with six chemicals identified as major 
variables associated with the Ca2+ response and common to commercial e-liquids (112).  We loaded 
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CALU3 cells with fluo-4 (cytosolic Ca2+ indicator) and then exposed cells to triacetin, isoamyl acetate 
(banana), vanillin, ethyl vanillin, ethyl maltol (caramel), or menthol and measured cytosolic Ca2+ 
responses.  We found that four of six chemicals were able to dose-dependently elicit a response in 
CALU3 cells above respective 0 mM and vehicle controls (Fig. 4.3A-C).  We calculated EC50s for those 
four chemicals, whose potency are summarized here: menthol > ethyl vanillin > vanillin > ethyl maltol 
(Table 4.2).  Menthol was not found in the BP-flavored e-liquid however, it was found in our top two 
screening hits (e.g., Arctic Tobacco, Menthol).  These common flavoring chemicals have the potential to 
dose-dependently alter important Ca2+ signaling responses in the lung with e-cig use.  
Ethyl vanillin recruits STIM1 puncta formation (SOCE).  Cytosolic Ca2+ influx is governed by 
plasma membrane receptors, pumps, and channels.  Generally, Ca2+ can either flow through membrane 
ion channels (e.g., TRP channels) or it can trigger a coordinated Ca2+ release from the ER, followed by an 
influx of Ca2+ through a membrane pore known as SOCE.  SOCE involves the aggregation of stromal 
interaction molecule 1 (STIM1), an ER transmembrane protein, into discrete puncta at the ER-plasma 
membrane junction. STIM1 aggregation activates Orai1, a plasma membrane Ca2+ channel which is 
required for the subsequent Ca2+ influx (141, 189).  We transfected HEK293T cells with STIM1-mCherry 
and looked for the puncta formation of these proteins following exposure.  Transfected cells were treated 
with 0-30 mM ethyl vanillin or 2 μM thapsigargin for 5-10 min and were imaged by confocal microscopy 
(Fig. 4.4A).  Cells treated with ≥ 10 mM ethyl vanillin increased STIM1 puncta formation to a similar 
degree as thapsigargin (Fig. 4.4B).  Ethyl vanillin dose-dependently caused downstream activation of 
STIM1, suggesting that the cytosolic Ca2+ response is likely ER/SOCE-dependent. 
Vanillin and ethyl vanillin reduce cell viability/proliferation following 24 h exposure.  Ca2+ 
signaling orchestrates many important cellular functions including cell viability/proliferation, and SOCE 
is important for these functions.  Since ethyl vanillin elicited an ER/SOCE-dependent Ca2+ response in 
lung epithelia, we used the MTT assay to indirectly assess cell viability and proliferative ability following 
chronic exposure to vanillin or ethyl vanillin.  24 h exposure to either vanillin or ethyl vanillin dose-
dependently decreased CALU3 cell viability/proliferation (Fig. 4.5A).  An IC50 of 11.37 mM was 
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calculated for ethyl vanillin, but an IC50 for vanillin could not be determined in this dosing range (Table 
4.2).  While vanillin and ethyl vanillin elicited ER/SOCE-dependent Ca2+ responses in CALU3 cells with 
acute exposures, longer exposures decreased cell viability/proliferation. 
Ca2+-eliciting e-liquids contain millimolar levels of vanillin and ethyl vanillin.  GC-MS was used 
previously to identify the presence/absence of chemical constituents in over 200 flavored e-liquids 
(www.eliquidinfo.org).  In this study, vanillin and ethyl vanillin were quantified using GC-MS and 
standard curves for each constituent.  Both vanillin and ethyl vanillin were quantified in two lots 
(designated #09 and #165) of BP-flavored e-liquids, which were both characterized to elicit an ER/SOCE-
dependent Ca2+ responses in CALU3 cells.  Vanillin was also quantified in Chocolate Banana, another 
Ca2+-eliciting flavor.  Vanillin was present at 22.58 ± 2.22 and 18.56 ± 4.47 mM, while ethyl vanillin was 
present at 15.19 ± 1.81 and 11.22 ± 3.74 mM in respective lots of BP (Fig. 4.6).  Vanillin was also present 
at 125.80 ± 1.80 mM in Chocolate Banana-flavored e-liquid.  These data show that some Ca2+-eliciting e-
liquids contain millimolar levels of vanillin and ethyl vanillin.  Moreover, vanillin concentrations ranged 
from 18.56 ± 4.47 to 125.80 ± 1.80 mM between two different Ca2+-eliciting e-liquids, suggesting that 
concentrations of each flavoring can vary greatly between e-liquids and toxicity information should cover 
a wide range of concentrations. 
Combining vanillin and ethyl vanillin produce increases in cytosolic Ca2+ responses, suggesting 
additive effects.  Since vanillin and ethyl vanillin were both present in millimolar concentrations and 
independently able to induce Ca2+ signaling, we tested the potential for additive effects of vanillin and 
ethyl vanillin in CALU3 cells.  We loaded cells with fluo-4 and acutely exposed them to increasing doses 
with equal parts of vanillin and ethyl vanillin as indicated (Fig. 4.7A-B).  We found that exposing cells to 
solutions containing 5 mM vanillin + 5 mM ethyl vanillin elicited a Ca2+ response.  Since 5 mM of either 
vanillin or ethyl vanillin alone was below the EC50 for Ca2+ signaling, these data suggest that additive 
effects of individual flavoring chemicals could play a role in lung epithelial Ca2+ responses. 
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4.5. Discussion 
 To understand the breadth of commercially available e-liquids and their ability to induce Ca2+ 
signaling, we screened 100 flavored e-liquids and found 42 of 100 increased cytosolic Ca2+ (Fig. 4.1A; 
Table 4.1).  Some e-cig studies have already identified chemical constituents in e-liquids and/or tested 
select flavoring chemicals on many different parameters in airway cell types (47, 85, 211, 216, 226, 252).  
However, our study is one of the first to try to systematically identify and predict flavoring chemicals 
affecting cytosolic Ca2+ responses from a large dataset.  Figure 4.2B highlights the top 27 chemicals that 
are correlated with cytosolic Ca2+ responses in lung epithelia.  It is worth noting that our model only 
correctly classified 75% of the dataset, which may not generally be considered robust.  However, there 
are other factors that may contribute to this value.  For instance, the GC-MS dataset incorporated into our 
model is strictly qualitative.  These data only provide presence or absence of a detected chemical in the 
model, not dose.  The model would likely be improved in the future with quantitative chemical datasets as 
well.  For example, Sassano et al. found that the concentrations of a single constituent present in seven 
different flavored-e-liquids varied greatly (216).   
 Interestingly, the model identified the number of chemicals detected in an e-liquid to be the top 
predictive variable correlated to Ca2+ responses (Fig. 4.2B), indicating that the more chemicals detected in 
a flavor, the more likely it was to elicit a cytosolic Ca2+ signal.  Reinikovaite et al., reported that e-cig 
cytotoxicity in their study was correlated with both the number and concentration of chemicals used in e-
liquids (200).  It is possible that more complex e-liquid mixtures (i.e., number of chemical constituents) 
can impact their effects on cells (e.g., Ca2+ responses), but would need to be tested.  The top three 
chemicals associated with a cytosolic Ca2+ responses from our analysis were ethyl vanillin, vanillin, and 
ethyl maltol (Fig. 4.2B).  All three chemicals have been commonly found in e-liquids and have the 
potential to affect cell function (15, 85, 112, 211, 216, 226, 252).  Therefore, we characterized the dose-
dependent Ca2+ responses of six chemicals from our list. 
 We found that four of six chemicals dose-dependently elicited a cytosolic Ca2+ signal above their 0 
mM and vehicle control (menthol > ethyl vanillin > vanillin > ethyl maltol) (Fig. 4.3).  Ethyl maltol has 
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not previously been shown to alter Ca2+ homeostasis and more work needs to be done to fully understand 
the impact of these findings.  However, many common flavoring chemicals have been reported to activate 
TRP channels.  For example, menthol is a known TRPM8 agonist with an EC50 of 80 µM (160).  Menthol 
also appeared in the top two flavored e-liquid hits (e.g., Arctic Tobacco, Menthol) from our Ca2+ screen.  
Vanillin and ethyl vanillin have been shown to activate TRPV1, TRPV3, and TRPA1 (143, 268, 269).  
Xu et al., reported that both vanillin and ethyl vanillin activated TRPV3-mediated Ca2+ signaling with 10 
mM (269), which was similar to our EC50 concentrations (Fig. 4.3C; Table 4.2).  However, we also 
showed that ethyl vanillin was capable of forming STIM1 puncta, suggesting that it activates SOCE, 
which is not associated with TRP channels (Fig. 4.4).  Ethyl vanillin was also found to cause IP3 
formation in odorant cilia, though a receptor or channel target was not reported (33).  We previously 
showed that acute exposure to BP e-liquid also generates IP3 formation and ER/SOCE-dependent 
responses in lung epithelia, suggesting that it is not acting through TRP channels despite containing both 
vanillin and ethyl vanillin.  More work is needed to characterize the Ca2+ signaling pathway that these 
vanillin species are working through to elucidate whether these chemicals may contribute to or be 
responsible for our BP e-liquid Ca2+ mechanism. 
 Ca2+ is a ubiquitous second messenger signaling system that cells use to regulate important 
processes (e.g., cell growth and proliferation, apoptosis) (26).  Indeed, vanillin, ethyl vanillin, and ethyl 
maltol are commonly detected in e-liquids and have been investigated for toxicity and other properties 
relevant to airway health (15, 85, 211, 216, 226).  We treated CALU3 cells with vanillin or ethyl vanillin 
for 24 h and measured cell viability/proliferation using the MTT assay and demonstrated dose-dependent 
decreases in cell viability/proliferation with both chemicals (Fig. 4.5).  This is in accordance with Sassano 
et al. where a positive correlation was demonstrated between vanillin, but not triacetin concentrations, and 
toxicity in commercial e-liquids (216).  They also reported a positive correlation between cinnamaldehyde 
concentrations and toxicity, though we did not include cinnamaldehyde in this study.   
 Interestingly, vanillin has been studied as an anti-cancer compound and demonstrated to reduce the 
proliferation and metastasis of some cancer cell lines (105, 142, 171).  Specifically, micromolar 
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concentrations of vanillin were shown to bind directly to calcium/calmodulin-dependent protein kinase IV 
(CAMKIV) in hepatic carcinoma and neuroblastoma cells, inducing apoptosis (171).  CAMKIV is 
involved in the regulation of apoptosis and cell cycle via Ca2+ signaling, and overexpression has been 
found in lung and hepatocellular carcinomas (113, 266).  Though we have not looked at the role of 
CAMKIV and vanillin, we have demonstrated that prolonged exposure to vanillin and the vanillin-
containing BP e-liquid reduce cell viability/proliferation in CALU3 cells (Fig. 4.5) (211).  Since vanillin 
is a reactive aldehyde, it has the potential to react with nucleophilic protein residues (e.g., cysteine) to 
form protein adducts similar to cinnamaldehdye or acrolein (120, 174).  In the case of CAMKIV, vanillin 
is covalently bound to lysine and aspartic acid residues (171).  It is unclear whether vanillin and ethyl 
vanillin are individually inhibiting cell proliferation in CALU3 cells through CAMKIV binding.  Both 
chemicals are also found in BP e-liquid, which altered Ca2+ homeostasis acutely (i.e., PLC-dependent IP3 
formation) and chronically (i.e., attenuated ER Ca2+/SOCE thapsigargin response, reduced cell 
viability/proliferation).  It is unclear if/how vanillin and ethyl vanillin may be involved in these outcomes, 
but future experiments should investigate the ability of these flavorings to interact with important proteins 
involved in PLC- and ER/SOCE-dependent Ca2+ signaling. 
 Current e-cig literature has also characterized roles for vanillin, maltol, and ethyl maltol in other 
airway cell functions.  For instance, Sherwood and Boitano tested vanillin (%vol/vol) and found that their 
dose range did not induce cytotoxicity on 16HBE14o- lung epithelia, while ethyl maltol did (226).  
Meanwhile, Gerloff et al. found that ortho-vanillin and maltol induced proinflammatory IL-8 secretion in 
Beas2B and HFL-1, but not H292 cells (85).  These data suggest that the individual flavorings may have 
the capacity to alter airway cells, dependent upon the cell type and dose.  Our results could be used to 
inform FDA regulations regarding the presence and concentrations of individual flavoring chemicals 
allowed in commercially available e-liquids.  Specifically, our data predicted flavorings from a large data 
set that may contribute to Ca2+ signaling and further characterized dose-dependent effects of six 
chemicals on Ca2+ homeostasis in lung epithelia.  Specifically, vanillin and ethyl vanillin were identified 
in a PLC-dependent Ca2+-eliciting BP e-liquid but also highly correlated with toxicity (216).  This study 
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also reported their dose-dependent outcomes in cytosolic Ca2+ signaling, SOCE activation, and cell 
viability/proliferation in lung epithelia.  We also demonstrated that there may be additive effects of 
flavoring concentration on cytosolic Ca2+ signaling (Fig. 4.6-7).  More studies are required to investigate 
the role of the presence of these chemicals, their concentrations, and possible additive effects in cell Ca2+ 
signaling and the effects of their aerosolized products on lung health.   
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Table 4.1.  List of flavored e-liquids used in 3% cytosolic Ca2+ screen in Fig. 4.2.  List of 100 e-
liquids used in the fluo-4 screen with their respective flavor, mean peak Ca2+ responses, SEM, P-value, 
vendor source, and advertised nicotine concentration. 
 
E-liquid Flavor Mean Peak 
Ca2+ 
Response 
SEM P-value Vendor Nicotine 
(mg/ml) 
0% E-liquid (control) 1.080 0.06 N/A N/A 0 
3% PG/VG (vehicle) 1.372 0.07 > 0.9999 Sigma 0 
Arctic Tobacco 10.832 0.52 < 0.0001 The Vapor Girl 12 
Menthol 8.703 0.46 < 0.0001 NJOY 10 
Hot Cinnamon 
Candies 
6.780 0.69 < 0.0001 The Vapor Girl 12 
Peach Tea 6.124 0.87 < 0.0001 NJOY 10 
Cool Mint 3.927 0.36 < 0.0001 The Vapor Girl 12 
Banana Pudding 3.216 0.37 < 0.0001 The Vapor Girl 12 
Banana Pudding 3.193 0.22 < 0.0001 The Vapor Girl 0 
Valkyrie 3.002 0.46 < 0.0001 The Vapor Girl 12 
Black Coffee 2.710 0.29 < 0.0001 The Vapor Girl 12 
Biscotti 2.605 0.25 < 0.0001 The Vapor Girl 12 
Caramel Corn Crunch 2.525 0.14 < 0.0001 The Vapor Girl 12 
Chocolate Tobacco 
Heaven 
2.350 0.18 < 0.0001 The Vapor Girl 12 
Candy Corn 2.282 0.12 < 0.0001 The Vapor Girl 12 
Key Lime Pie 2.182 0.11 < 0.0001 The Vapor Girl 12 
Caramel Apple 2.172 0.08 < 0.0001 The Vapor Girl 12 
Captain Suckle 1.994 0.08 0.0003 The Vapor Girl 12 
Cheesecake with 
Graham Cracker 
2.086 0.10 0.0004 The Vapor Girl 12 
Cinnamon Roll 2.098 0.15 0.0006 The Vapor Girl 12 
Strawberry Mango 
Smoothie 
2.180 0.20 0.0007 The Vapor Girl 12 
Missed Her Cookie 2.132 0.15 0.0007 The Vapor Girl 12 
Chocolate Pecan 
Fudge 
2.118 0.15 0.0007 The Vapor Girl 12 
Apple Pie 2.082 0.12 0.0007 The Vapor Girl 12 
Candy Cane 1.994 0.03 0.0007 The Vapor Girl 12 
Circus Guava 2.128 0.21 0.0008 The Vapor Girl 12 
Chocolate Banana 2.074 0.13 0.0009 The Vapor Girl 12 
Angel Lust 1.989 0.09 0.0009 The Vapor Girl 12 
Tiramisu 1.996 0.10 0.0015 The Vapor Girl 12 
Dulce de Leche 1.971 0.11 0.0019 The Vapor Girl 12 
Kola 3.226 0.82 0.0027 The Vapor Girl 12 
RY4 Doubler 1.960 0.16 0.0048 The Vapor Girl 12 
Pumpkin Pie 2.270 0.28 0.0056 The Vapor Girl 12 
Chocolate Dipt 
Raspberry 
1.891 0.11 0.0089 The Vapor Girl 12 
Double Espresso 1.891 0.17 0.0096 NJOY 10 
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E-liquid Flavor Mean Peak 
Ca2+ 
Response 
SEM P-value Vendor Nicotine 
(mg/ml) 
Honey Vanilla 
Tobacco 
1.854 0.10 0.0155 The Vapor Girl 12 
DB’s Dessert 1.818 0.08 0.0180 The Vapor Girl 12 
Chocolate Moo 1.949 0.19 0.0184 The Vapor Girl 12 
Bavarian Crème 
Donut 
1.801 0.11 0.0336 The Vapor Girl 12 
Sweet Potato Pie 1.784 0.08 0.0339 The Vapor Girl 12 
Lemon Meringue Pie 1.853 0.15 0.0350 The Vapor Girl 12 
Sugar Cookie 1.787 0.10 0.0398 The Vapor Girl 12 
Butterscotch 1.784 0.11 0.0461 The Vapor Girl 12 
Black Cherry 1.765 0.08 0.0461 The Vapor Girl 12 
Marshmallow 1.729 0.07 0.0781 The Vapor Girl 12 
Crispy Melon 1.742 0.09 0.0785 The Vapor Girl 12 
Strawberry Pop 
O’Tarts 
1.701 0.08 0.1204 The Vapor Girl 12 
Vanilla Custard 1.696 0.05 0.1251 The Vapor Girl 12 
Chocolate Fudge 1.675 0.07 0.1322 The Vapor Girl 12 
Buttery Nipple 1.718 0.12 0.1420 The Vapor Girl 12 
Menthol Tobacco 1.911 0.32 0.1727 The Vapor Girl 12 
Chai Latte 1.669 0.12 0.2911 The Vapor Girl 12 
Bubble Gum 1.691 0.15 0.3984 The Vapor Girl 12 
Arctic Raspberry 1.652 0.12 0.4539 The Vapor Girl 12 
Blueberry Cinnamon 
Streusel Muffin 
1.647 0.13 0.4544 The Vapor Girl 12 
Slug Juice 1.610 0.09 0.5847 The Vapor Girl 12 
Pillow Fight 1.596 0.07 0.6791 The Vapor Girl 12 
Peach Piano 1.597 0.04 0.6970 The Vapor Girl 12 
Root Beer 1.560 0.07 0.9216 The Vapor Girl 12 
Cuba Libre 1.564 0.09 > 0.9999 The Vapor Girl 12 
Black Dragon 1.563 0.09 > 0.9999 The Vapor Girl 12 
Black Thorn 1.562 0.09 > 0.9999 The Vapor Girl 12 
Orphan Tears 1.562 0.08 > 0.9999 The Vapor Girl 12 
Coconut Rum 1.552 0.08 > 0.9999 The Vapor Girl 12 
Banana 1.527 0.05 > 0.9999 The Vapor Girl 12 
Chai 1.525 0.10 > 0.9999 The Vapor Girl 12 
Coconut Water 1.501 0.08 > 0.9999 The Vapor Girl 12 
Desert Cow 1.500 0.18 > 0.9999 The Vapor Girl 12 
Cherry Kola 1.499 0.06 > 0.9999 The Vapor Girl 12 
RY4 Classic 1.498 0.07 > 0.9999 The Vapor Girl 12 
Cat Nip 1.477 0.09 > 0.9999 The Vapor Girl 12 
Clove Cigar 1.470 0.13 > 0.9999 The Vapor Girl 12 
Bubbly Berry 1.470 0.07 > 0.9999 The Vapor Girl 12 
Butter Crunch 1.455 0.10 > 0.9999 NJOY 10 
Alchemy 1.444 0.08 > 0.9999 The Vapor Girl 12 
Cotton Berry 1.429 0.06 > 0.9999 The Vapor Girl 12 
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E-liquid Flavor Mean Peak 
Ca2+ 
Response 
SEM P-value Vendor Nicotine 
(mg/ml) 
French Vanilla 
Hazelnut Espresso 
1.418 0.10 > 0.9999 The Vapor Girl 12 
Mt. DUDE 1.412 0.04 > 0.9999 The Vapor Girl 12 
Black and Blue 
Berries 
1.408 0.09 > 0.9999 NJOY 10 
Kiwi Blast 1.402 0.12 > 0.9999 The Vapor Girl 12 
Icy Blast 1.397 0.06 > 0.9999 The Vapor Girl 12 
Strawberries and 
Champagne 
1.389 0.08 > 0.9999 The Vapor Girl 12 
Single Malt Scotch 1.313 0.06 > 0.9999 NJOY 10 
Blue Pom 1.279 0.06 > 0.9999 The Vapor Girl 12 
Watermelon 1.268 0.06 > 0.9999 The Vapor Girl 12 
Pomegranate 1.266 0.11 > 0.9999 NJOY 10 
Pixie Dust 1.256 0.08 > 0.9999 The Vapor Girl 12 
Blue Moo 1.249 0.03 > 0.9999 The Vapor Girl 12 
Blood Orange 1.247 0.04 > 0.9999 NJOY 10 
Vanilla Bean 1.238 0.08 > 0.9999 NJOY 10 
Arctic Strawberry 1.237 0.04 > 0.9999 The Vapor Girl 12 
Bartlett Pear 1.207 0.03 > 0.9999 The Vapor Girl 12 
Grape Soda 1.201 0.09 > 0.9999 The Vapor Girl 12 
Raspberry 1.195 0.05 > 0.9999 The Vapor Girl 12 
Classic Tobacco 1.192 0.05 > 0.9999 NJOY 10 
Grape! 1.190 0.03 > 0.9999 The Vapor Girl 12 
Bahama Mama 1.174 0.04 > 0.9999 The Vapor Girl 12 
Sour Fruit Punch 1.149 0.05 > 0.9999 The Vapor Girl 12 
Black Peppercorn 1.134 0.05 > 0.9999 The Vapor Girl 12 
Captain Zach Cigar 1.098 0.06 > 0.9999 The Vapor Girl 0 
Cranberry Crunch 1.074 0.04 > 0.9999 The Vapor Girl 12 
Cranberry Delight 1.058 0.03 > 0.9999 The Vapor Girl 12 
 
  
  
104 
Table 4.2.  List of EC50 and IC50 values for flavoring chemicals dose response curves in Figures 4.3C 
and 4.5.  Nonlinear regression curves were fit to the mean peak cytosolic Ca2+ response (Fig. 4.3C) or 
mean percent absorbance results (Fig. 4.5).  ND represents ‘not determined’ where curves could not be fit 
in the range of doses tested.  The EC50 and IC50 values were reported where appropriate (mM). 
 
Treatment EC50 (mM) 
Triacetin ND 
Isoamyl Acetate ND 
Vanillin 15.88 
Ethyl Vanillin 9.52 
Ethyl Maltol 21.14 
Menthol 3.02 
  
Treatment IC50 (mM) 
Vanillin ND 
Ethyl Vanillin 11.37 
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Figure 4.1.  Similar signal transduction pathway of sweet and bitter taste receptors with different 
downstream effects in (1) airway epithelia, (2) airway smooth muscle, (3) airway solitary 
chemosensory, and gustatory cell types.  Sweet (T1R) and bitter (T2R) taste receptors are GPCRs that 
activate PLCβ2 to generate IP3 and induce ER Ca2+ release.  (1) In airway epithelial cells, increases in 
cytosolic Ca2+ stimulate downstream activation of cilia beat frequency.  (2) In airway smooth muscle 
cells, K+ channel activation is triggered downstream of cytosolic Ca2+ signaling that results in smooth 
muscle relaxation.  (3) In solitary chemosensory airway cells and gustatory cells of the tongue, direct 
activation of TRPM5 by Ca2+ is necessary to confer sweet and bitter taste reception. 
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Figure 4.2.  Multiple flavored e-liquids elevate cytosolic Ca2+ levels.  100 different flavored e-liquids 
were screened for their ability to elicit a cytosolic Ca2+ signal.  CALU3 cells were seeded into 96 well 
plates and loaded with fluo-4.  Cells were challenged with 3% flavored e-liquids and peak Ca2+ responses 
were compared.  Peak Ca2+ responses were reported in Table 4.1.  A: All significant responses (42) were 
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log2-transformed and plotted on a heat map.  B: Heatmap showing the top 28 factors/chemicals’ mean 
decrease in Gini index average across 10 random forest classifiers (n = 100).  Ordering of chemicals are 
hierarchically clustered.  A: n = 7-12 wells per treatment.  Doses were compared to the 0% e-liquid 
control. 
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Figure 4.3.  Common chemical constituents found in Ca2+-eliciting e-liquids dose-dependently 
elevate cytosolic Ca2+.  Cells were challenged acutely with triacetin, isoamyl acetate (banana), vanillin, 
ethyl vanillin, ethyl maltol (caramel), or menthol.  Vehicle controls for PG/VG and ethanol (EtOH) were 
also measured.  A-B: Representative traces of a non-Ca2+-eliciting and Ca2+-eliciting flavoring chemicals 
reported as the change in fluorescence (F/F0).  C: Peak changes in dose-dependent response from all 
flavoring chemicals and vehicles tested.  A-C: Symbols and bars represent mean ± SEM.  A-C: n = 7-15 
wells per treatment.  Statistical differences were shown between all treatments compared to their 
respective 0 mM control (**P < 0.01, ***P < 0.001).  NS represents not significant between dose and 
respective vehicle control.  
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Figure 4.4.  Ethyl vanillin stimulates STIM1 puncta formation, activating SOCE.  HEK293T cells 
were plated on glass coverslips and transfected with STIM1-mCherry.  Transfected cells were treated 
with 0-30 mM ethyl vanillin or thapsigargin for 5-10 min.  A: Cells were fixed and imaged.  Scale bar 
represents 25 μm.  B: The percentage of puncta-positive cells were measured.  Bars represent mean + 
SEM.  n = 4-9 coverslips per treatment.  Statistical differences were calculated between all groups 
compared to the 0 mM control (*P < 0.05, **P < 0.01).  
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Figure 4.5.  24 h exposure to vanillin and ethyl vanillin dose-dependently decreases cell 
viability/proliferation.  CALU3 cells were seeded into 96 well plates and then exposed to 0-30 mM 
vanillin or ethyl vanillin for 24 h.  Media was changed and cells were treated with MTT and allowed to 
proliferate for 4 h.  A: MTT absorbance was measured at the end of the 24 h treatment and plotted as 
percent absorbance compared to each treatment’s 0 mM control.  Bars represent mean + SEM.  n = 11-19 
wells per treatment.  Statistical differences were calculated between all doses and their respective 0 mM 
control (*P < 0.05, **P < 0.01, ***P < 0.001).    
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Figure 4.6.  Vanillin and ethyl vanillin quantified in Ca2+-eliciting banana-flavored e-liquids.  A: The 
presence of vanillin and ethyl vanillin were quantified in two different lots of Banana Pudding e-liquid 
purchased and used in previous Ca2+ signaling experiments.  Vanillin was also quantified in Chocolate 
Banana, another Ca2+-eliciting flavored e-liquid.  Quantifications were performed using GC-MS with 
vanillin or ethyl vanillin standard curves to measure respective amounts of each chemical per e-liquid.  
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Figure 4.7.  Additive effects of ethyl vanillin (EV) and vanillin (V) elicit cytosolic Ca2+ signal in 
CALU3 cells.  Cells were plated into 96 well plates and loaded with fluo-4 before acute exposure to 
combinations of EV and V.  A: Changes in fluorescence were measured over time with varying 
concentrations of EV and V.  B: Peak changes in fluorescence were reported.  Symbols and bars represent 
mean ± SEM.  n = 3 wells per treatment. 
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Chapter 5: Conclusions and Future Directions 
5.1. Overview 
 The overall goal of this dissertation was to better understand the biological effects of 
commercially available flavored e-cigarette (e-cig) products on pulmonary epithelial cells.  Since these 
products have only been available for the past 10 years as a ‘safer’ smoking alternative, there was very 
little known about their toxicological profiles or subsequent physiological effects when we began this 
research.  Instead of focusing our work on the rapidly changing design of e-cig devices, we specifically 
chose to tackle the issue of e-liquids and their chemical constituents (i.e., nicotine, PG/VG, flavors).  
Nicotine has been well studied and its presence in e-liquids presented the potential for nicotine addiction, 
which drives tobacco cravings, and physiological changes that nicotine can exert change on the body, 
especially in the brain during adolescent development (24, 59).  Both PG and VG are ‘generally 
recognized as safe’ (GRAS) for ingestion.  However, one study reported that short term controlled 
occupational exposures to aerosolized PG caused ocular and upper airway irritation in nonasthmatic 
adults (265).  Before the advent of e-cigs, most flavoring chemicals were used primarily in foods and 
were GRAS.  However, inhalation safety with regard to flavoring chemicals in e-cigs were questioned 
when diacetyl was detected in commercially available e-liquids (5).  Diacetyl (butter flavor) has caused 
the fibrotic lung disease bronchiolitis obliterans (‘Popcorn Lung’) in some manufacturing workers after 
inhalation exposure (124).  Therefore, we focused on characterizing the dose- and time-dependent 
toxicological and physiological effects of nicotine, PG/VG, flavored e-liquids, and individual flavoring 
chemicals on pulmonary epithelial cells to inform human health and e-cig regulations. 
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5.2. Flavor-Dependent E-liquid Toxicity 
 To establish whether a lung epithelial cell line showed variable toxicity responses to nicotine, 
PG/VG, or different flavored e-liquids, we first developed a set of screening assays to compare these 
responses.  We found that of the 13 different e-liquid flavors that we tested, 4 of the 13 had more toxic 
responses compared to the other flavors or the PG/VG control.  These exposures were performed with 
unheated e-liquids diluted in culture media and cells were treated for 24 h, which are not directly 
translatable to e-cig users’ vaping exposure.  However, this approach allowed us to precisely control dose 
and exposure time.  These data demonstrate that (1) PG/VG can potentially be toxic to lung epithelia and 
(2) there are flavor-dependent effects of commercially available e-liquids on lung epithelial toxicity.  At 
the time, there were few studies that investigated flavor-dependent toxicity categories for e-liquids in a 
variety of cell types (15, 21, 226).  Our group has since expanded e-liquid toxicity screening and found 
that from an additional 148 flavored e-liquids, cytotoxicity results ranged between flavors and could be 
classified as having ‘normal growth’, ‘reduced growth’, ‘no growth’ or ‘toxic’ effects on a variety of 
airway cells (216).   
In Chapter 2, we additionally found that trends in toxicity were recapitulated when we exposed 
cells to heated e-liquid aerosol.  These findings were also confirmed by Sassano et al. (216).  The work 
from Chapter 2 also explored nicotine-dependent effects and found that nicotine could exert physiological 
responses on a lung epithelial cell line, but appeared to be non-specific in the e-liquid dilution 
concentrations exposed to cells.  Lastly, our data showed that of the four most toxic flavors which we 
identified, two appeared to be cytotoxic (i.e., apoptotic, necrotic) while two others likely inhibited cell 
proliferation.  While the mechanisms of action are unclear, additional identification of their chemical 
constituents and comparison between these toxic flavors showed that they shared only nicotine and 
PG/VG, suggesting that the heterogeneous e-liquid mixtures likely possessed a number of flavoring 
chemicals that contributed to their measured toxicity, instead of just one or two. 
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5.3. Flavor-Dependent E-liquid Ca2+ Signaling 
 We followed up the observation that one of the more toxic flavored e-liquids (e.g., Banana 
Pudding or BP) inhibited cell proliferation by characterizing its acute and chronic effects on cell Ca2+ 
signaling, since Ca2+ can play a role in cell proliferation.  We found that BP acutely activated 
phospholipase C (PLC)-dependent generation of inositol 1,4,5-triphosphate (IP3) with downstream 
activation of ER/SOCE-dependent Ca2+ responses, which has not been previously reported.  This is the 
first study to characterize the role of flavored e-liquids in IP3 formation and cell Ca2+ dynamics.  
Activation of this signaling pathway is common in numerous cell functions and usually occurs 
downstream of G protein-coupled receptors (GPCRs) or receptor tyrosine kinases (RTKs) (64, 161, 173, 
233).  We demonstrated that these signaling events were independent of RTK activation, but have not yet 
isolated a specific upstream target (i.e., GPCR, PLC).  While we do not understand the long-term health 
outcomes of vaping Ca2+-eliciting flavors, we have demonstrated that longer exposures to BP caused the 
ER Ca2+ release and store-operated Ca2+ entry (SOCE) responses to diminish.  These data suggest that 
pulmonary epithelial functions requiring these signaling components could be altered with chronic 
exposure (i.e., regulation of exocytosis, enzyme activity, transcription, cell cycle, apoptosis).  It is 
therefore imperative Ca2+-eliciting e-liquids be further tested for effects of the vaped products on 
pulmonary morphology and function. 
5.4. Role of Individual Flavoring Chemicals in Ca2+ Signaling and Toxicity 
We performed a cytosolic Ca2+ screen on 100 commercially available flavored e-liquids and 
demonstrated that 42 elicited significant cytosolic Ca2+ responses in lung epithelia.  We followed this up 
with an analysis of chemicals present in each e-liquid that identified the mere presence of certain 
flavoring chemicals highly correlated with a cytosolic Ca2+ signal.  We chose six chemicals to further 
characterize and demonstrated that four were capable of eliciting dose-dependent cytosolic Ca2+ responses 
in lung epithelia.  We further investigated vanillin and ethyl vanillin because they were found in BP e-
liquid and were top hits from our Ca2+ screen analysis.  Sassano et al. also reported that 63 of 148 
screened e-liquids contained vanillin and there was a positive correlation between vanillin concentration 
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and toxicity (216).  Sherwood and Boitano previously published effects of vanillin on airway epithelial 
viability as well (226).  While vanillin and ethyl vanillin are known transient receptor potential vanilloid 
(TRPV) channel ligands (143, 269), we showed that ethyl vanillin activated SOCE, similar to BP e-liquid 
and not TRPV activation.  Longer exposures of vanillin and ethyl vanillin also dose-dependently reduced 
cell viability/proliferation similar to BP.  Vanillin previously has been reported as a natural cancer 
therapeutic that has some ability to inhibit cell proliferation (105, 142, 171).  In addition to the anti-
proliferative effects seen with vanillin, we found that ethyl maltol also induced cytosolic Ca2+ signaling 
but we did not find reports of this caramel flavor associated with Ca2+ signaling in the literature.  Since 
vanillin, ethyl vanillin, and ethyl maltol are such common flavorings and GRAS for ingestion, more 
research is necessary to understand the biological consequences of their dose-dependent exposures on 
airway cells as well as their potential additive roles in complex flavored e-liquid mixtures.  
5.5. Future Directions 
This dissertation sought to enhance our knowledge regarding flavor-dependent effects of 
commercially available e-liquids on pulmonary epithelia in an effort to inform the public of potential 
changes in lung physiology associated with chronic vaping.  Given that there were over 7,000 unique 
flavored e-liquids in the United States of America (276), we chose to broadly screen a number of flavored 
e-liquids for dose-dependent cytotoxicity.  We also characterized the flavor-dependent effects of e-liquids 
and their constituents to alter cell Ca2+ signaling following an observation from our toxicity screen.  We 
further coupled toxicity and Ca2+ screening outcomes with qualitative chemical constituent data to 
pinpoint common flavoring chemicals that could be contributing to our findings.  The overall goal of the 
studies were to use cell assays to identify the most biologically relevant components of e-liquids (i.e., 
nicotine, PG/VG, flavorings) to closely examine in follow up experiments with chronic e-cig exposure 
(i.e., primary lung cell models, mouse models).  In this way, we could better understand what cellular 
markers of exposure to measure and characterize dose- and time-dependent effects of these constituents 
on the lungs to target for regulation or validate for new biomarkers of e-cig exposure. 
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Upstream initiator of PLC-mediated IP3/Ca2+ response to BP e-liquid and the potential role of 
Ca2+-eliciting flavoring chemicals.  We detailed the effects of flavored e-liquids and their chemical 
constituents on Ca2+ homeostasis (Chapters 3-4).  While we characterized some of these effects in great 
detail, there are still many aspects that we have yet to understand.  For example, while we identified the 
novel ability of BP e-liquid to generate IP3 and ER-SOCE-dependent Ca2+ signaling, we have yet to 
identify (1) the upstream target of activation and (2) the roles of vanillin, ethyl vanillin, and ethyl maltol 
in this mechanism.  Understanding the upstream mechanism of action that allows flavored e-liquids and 
their constituents to alter a PLC-mediated signaling pathway is important to understanding how they will 
affect Ca2+ homeostasis and the oscillatory nature of Ca2+ regulation.  These are physiologically important 
processes that protect cells from toxic levels of cytosolic Ca2+ and deliver different cellular signals to 
various locations at optimal times (242).  In pulmonary epithelia, Ca2+ is also necessary to regulate innate 
defenses that are part of mucociliary clearance (e.g., mucin secretion, ciliary beat frequency, ion 
regulation of airway surface liquid height) (97, 129, 139, 153).  
We currently posit that upstream targets of IP3 formation might be ligand-binding to GPCRs or 
direct PLC activation via protein-adduct formation.  We had previously submitted BP and PG/VG stocks 
for primary screening of GPCR activation using competitive radioligand binding assays (28).  These 
results are summarized in Table 5.1 where > 50% indicates potential receptor binding.  Only 1 of 27 
screened receptors reported > 50% inhibition (i.e., histamine receptor 2 or H2).  H2 receptor is a Gs-
coupled receptor that stimulates cyclic adenosine monophosphate (cAMP) production and protein kinase 
A (PKA) activation, not IP3 formation (271).  Since the %inhibition was higher in PG/VG than BP, these 
data suggest that the potential binding of this GPCR is likely mediated by the vehicle (PG/VG) and is not 
specific to flavorings found in BP (Table 5.1).  In this dissertation, we did not investigate the ability of 
flavored e-liquids to regulate cAMP production, which is another important cell 2nd messenger.  Future 
studies should include characterizing cAMP production by e-liquids, and especially by PG/VG.  Of note, 
the experimental doses for the GPCR screen did not achieve the 3% threshold for experiment-specific 
reasons, suggesting that if the dosing were increased in a subsequent e-liquid screen, there could possibly 
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be more hits.  BP along with vanillin, ethyl vanillin, and ethyl maltol should tested for GPCR activation to 
rule in or out a single, shared GPCR target present in all of the cell types that we tested for IP3 formation 
and Ca2+ signaling.  
  Vanillin and ethyl vanillin are small reactive aldehydes with the potential for binding to proteins 
and forming adducts, altering protein activity.  For instance, vanillin has been shown to bind to 
calcium/calmodulin-dependent protein kinase type IV (CAMKIV) and inhibit cell proliferation in tumor 
cells (171), while cinnamaldehyde has been shown to inhibit immune cell function following thiolation of 
cysteine residues in certain kinases (120).  Since we demonstrated that vanillin and ethyl vanillin were 
present in BP e-liquid and were also able to activate Ca2+ signaling, we intend to explore whether BP, 
vanillin, and/or ethyl vanillin have the ability to form adducts with PLC, causing receptor-independent 
PLC activation.  
Inhibition of ER/SOCE-dependent Ca2+ responses following prolonged exposure to BP e-liquid 
and the potential role of flavoring chemicals.  While the upstream mechanism (i.e., GPCR and/or direct 
PLC activation) is important to understand e-liquid/flavor-induced changes in Ca2+ homeostasis, our 
finding that prolonged BP exposure caused inhibition of the thapsigargin-induced Ca2+ responses was also 
novel.  Inhibiting this response may be an indicator of potential harm since these Ca2+ responses play a 
role in many important cellular functions (e.g., cell proliferation, gene/protein expression, innate defense) 
(97, 139, 153).  Specifically, SOCE activation has been identified to alter growth factor and local 
inflammatory responses via transcription factors in airway epithelia (215).  We also found from our 
screen in Chapter 2 that a Kola-flavored e-liquid had a similar effect on thapsigargin-induced Ca2+ 
responses following prolonged exposure (Fig. 5.1A).  Thus, it is likely that these effects are not restricted 
to one or two unique e-liquids and we should conduct a larger, more comprehensive screen along with 
similar chemical constituent analyses to predict the potential contributions of flavoring chemicals. 
Interestingly, our GPCR screen included the sigma (σ) 1 receptor, which is an ER chaperone that 
has been shown to inhibit SOCE responses in cells by attenuating stromal interaction molecule 1 (STIM1) 
coupling to Orai1 (236).  The σ1 receptor results were not > 50% inhibition (BP ~31%; ~15% PG/VG) 
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however, it was one of the only receptors that showed any preference for BP over PG/VG at the dose 
tested (< 3%).  Generally, σ1 receptors are endogenously expressed throughout the body and when 
activated, can move within the ER membrane to interact with plasma membrane signaling proteins (e.g., 
ion channels) (239).  Therefore, it would be pertinent to look into a potential role for ER σ1 receptors in 
ER/SOCE-dependent regulation in Ca2+ signaling, especially with the attenuated Ca2+ response to 
thapsigargin.  Future experiments are necessary to ascertain whether 3% BP exposure can specifically 
bind to and activate the σ1 receptor.  
Role of altered kinase phosphorylation in response to Ca2+-eliciting e-liquids.  Lastly, we showed 
that BP-induced Ca2+ signaling can differentially regulate kinase phosphorylation in lung epithelia.  For 
example, we showed that BP caused transient increases in Ca2+-dependent protein kinase C (PKC) 
phosphorylation but did not increase total protein tyrosine phosphorylation.  Protein kinases are important 
cellular regulators of complex processes (e.g., cell cycle) and are grouped into distinct families (i.e. 
tyrosine kinases, AGC kinases, or calcium/calmodulin-dependent protein kinases) (12, 168, 207).  For 
example, tyrosine kinases phosphorylate protein tyrosine residues while other kinases may phosphorylate 
serine/threonine residues.  While total tyrosine phosphorylation in BP-treated cells did not statistically 
change over time, the responses trended toward decreased phosphorylation, with some individual bands in 
the western blot showing visual variability in protein expression over time.  Interestingly, we performed a 
kinase array (45 kinases/phosphorylation sites included) with lung epithelia following BP e-liquid 
exposure and found that protein phosphorylation was varied, but several kinases were dephosphorylated 
compared to the control group (Table 5.2; Fig. 5.2A).  Of course the array is only a snapshot of 
phosphorylation states at one time point post-exposure (10 min) and the transient changes of each kinase 
might change over time.  For example, our blots showed that changes in PKCα phosphorylation peaked at 
15-30 min post-exposure while total tyrosine phosphorylation did not change over 60 min.  We also 
exposed lung epithelia to heated BP aerosol (10x 70 ml puffs/culture) (Table 5.2; Fig. 5.2B).  Again we 
found that kinase phosphorylation was either unchanged or decreased compared with the control.  
However, few responses overlapped and included cAMP response element binding (CREB) protein and 
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β–catenin.  CREB is an important transcription factor whose downregulation is an indicator of 
neurological diseases, while β–catenin is responsible for regulating cell-cell adhesion, as well as 
transcription, and has been implicated in cancer (45, 104).  Though it is not clear exactly how BP e-liquid 
altered kinase phosphorylation, understanding this process will likely assist in assessing any disease risk 
associated with chronic vaping of a Ca2+-eliciting flavor.  
 Of note, we used a 2nd generation e-cig device and only 10 puffs, which may not have been 
enough to elicit a Ca2+ response following aerosol exposure similar to our data in Chapter 3 using a 3rd 
generation device at 100 W setting.  More detailed studies using parameters shown to elicit Ca2+ 
responses should be conducted using a 3rd generation device for comparison.  Interestingly, Schweitzer et 
al. found that exposing lung microvascular endothelia to condensed e-cig vapor containing nicotine 
increased p38 mitogen-activated protein kinase and myosin light chain phosphorylation (222).  In turn, 
these responses did not cause necrosis but did inhibit cell proliferation, suggesting nicotine was a 
contributing factor.  Therefore, it is likely that e-liquids are capable of altering a number of important 
cellular pathways through the regulation of kinase phosphorylation.  Future studies are needed to 
understand what kinases may be involved in exposure to common flavoring chemicals, how transient or 
permanent these changes to phosphorylation are, and the resulting effects on important airway cell 
functions (e.g., mucociliary clearance, innate defenses) in order to more accurately predict potential 
disease or identify new biomarkers of e-cig exposure. 
Overall, the long-term effects of chronic e-cig use in the airways are not known and there are 
many variables that could play a role in potential pathogenesis (i.e., nicotine, PG/VG, flavoring 
chemicals, user topography, device style, device settings).  In this dissertation, we focused on trying to 
determine whether or not e-liquids were safe for inhalation.  We did this by investigating how flavored e-
liquids and their constituent chemicals affect lung epithelial toxicity and function.  Specifically, our 
results demonstrated that there were flavor-dependent differences in e-liquid toxicity and cell Ca2+ 
signaling.  We currently know that e-cig use is associated with biological changes in pulmonary cells and 
chronic bronchitis respiratory symptoms in current vapers (88, 157, 199, 259), so it is important to 
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understand how flavor-dependent changes might be contributing to these changes to predict risk of 
potential disease with long-term use.  For instance, altering SOCE activity or the expression of its 
requisite components (i.e., STIM1/Orai1) has been demonstrated to play a role in cancer and immune 
diseases.  Since many of the individual flavoring chemicals that we focused on in our studies are GRAS 
for ingestion, it is vital that we elucidate how and why pulmonary cells are affected in a different fashion 
than those in the digestive tract.  For instance, some users reported inhaling over 200 puffs/day (6-30 ml 
of e-liquid/day) (88).  With e-cig aerosol deposition reported up to 45% in the lung (232), pulmonary cells 
may be exposed to a higher concentration of chemicals in the liquid lining fluid of the lung than their 
digestive tract counterparts.  It is also important to note that many of the e-liquid flavors and constituent 
chemicals we investigated are appealing to adolescent users (98).  Therefore, it is imperative that the 
dose-dependent effects of popular flavorings be further investigated to inform FDA regulations in an 
effort to fully communicate their potential health risks to e-cig users. 
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Table 5.1.  List of % inhibition values of Banana Pudding (BP) or PG/VG e-liquid per receptor 
subtype.  Primary screening results of dilutions of either BP-flavored e-liquid (0 mg/ml nicotine) or 
55PG/45VG vehicle from starting stocks of 10 or 30% e-liquid in DMSO.  Screening performed with 
competitive radioligand binding assays.  Significant inhibition is considered > 50% and negative 
inhibition representation binding stimulation, which can happen non-specifically with high concentrations 
of compounds.  n = 4 determinations per receptor subtype for each treatment.  NT = not tested.  Receptor 
families included in the screen were GABA (GABAA), serotonin (5-HT1-7), histamine (H1-4), 
adrenergic (α1A-2C, β1-3), dopamine (D1-4), and sigma (1-2) receptors. 
  
Receptor 10% BP Stock 30% BP Stock 30% PG/VG Stock 
5-HT1A 0.4 0.6 -2.4 
5-HT1D -10.3 -5.0 -0.1 
5-htle 5.4 NT NT 
5-HT2A 16.3 15.5 18.5 
5-HT2B 23.1 39.4 31.4 
5-HT2C 0.8 -0.2 11.9 
5-HT3 -14.3 -12.2 8.0 
5-ht5a -14.2 -14.9 7.4 
5-HT6 -22 -20.7 7.3 
5-HT7 -12.3 -19.5 5.9 
α1A 13.4 -10.0 -11.8 
α1B -7.7 3.6 3.9 
α2B -18.7 -13.9 -12.9 
α2C -17.6 -12.6 4.3 
β1 13.9 19.0 14.1 
β3 20.2 29.6 34.5 
D1 17.2 19.6 17.4 
D2 -1.4 10.9 3.6 
D3 -7.4 3.3 10.1 
D4 19.3 17.1 22.7 
GABAA 19.8 14.7 28.7 
H1 25.0 24.1 31.5 
H2 43.6 56.5 65.5 
H3 20.0 19.4 24.6 
H4 28.9 31.3 32.7 
Sigma 1 GP 31.2 32.4 14.7 
Sigma 2 -15.2 10.3 22.1 
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Table 5.2.  List of kinase phosphorylation responses in pulmonary epithelial cultures following BP 
e-liquid or aerosol exposures.  Kinase arrays were run on pooled samples of lysates from (1) CALU3 
cells exposed to 0 or 3% BP e-liquid for 10 min or (2) human bronchial epithelial cells (HBECs) exposed 
to 10x 70 ml puffs of air or BP aerosol.  Samples were pooled from at least three different cultures and 
run in duplicate per treatment.  Values represent average (AU) ± SD. 
 
 0% BP E-liquid 3% BP E-liquid Air Puffs (10x) BP Puffs (10x) 
Kinase AVG ± SD AVG ± SD AVG ± SD AVG ± SD 
Reference 1 213390 ± 2700 211753 ± 518 257040 ± 1 257030 ± 8 
P38a 13036 ± 2885 13639 ± 2923 132896 ± 13113 104816 ± 8994 
ERK1/2 74334 ± 590 46279 ± 1220 151765 ± 8657 165019 ± 6668 
JNK1/2/3 16811 ± 4 14673 ± 1297 120197 ± 9209 105711 ± 662 
GSK-3α/β 53277 ± 171 46606 ± 1338 121858 ± 909 109629 ± 178 
p53 161068 ± 489 154411 ± 1665 125854 ± 3837 119667 ± 5701 
Reference 2 183388 ± 1047 182074 ± 3205 257033 ± 11 257029 ± 16 
EGFR 79721 ± 4786 67863 ± 444 140317 ± 2876 99628 ± 35052 
MSK1/2 28546 ± 3267 26659 ± 75 182134 ± 445 161893 ± 4880 
AMPKα1 15697 ± 1749 11115 ± 2167 103279 ± 523 94329 ± 880 
Akt 1/2/3 154799 ± 4477 158877 ± 2197 119546 ± 3170 103671 ± 4605 
Akt 1/2/3 25134 ± 1354 19614 ± 2342 105313 ± 3299 106218 ± 679 
p53 142982 ± 382 127785 ± 459 181105 ± 2940 180480 ± 6766 
TOR 15297 ± 1259 13545 ± 1117 179462 ± 2452 152911 ± 2753 
CREB 136143 ± 2584 115320 ± 2688 191992 ± 1918 156111 ± 4909 
HSP27 22708 ± 1791 19210 ± 2713 135449 ± 802 116948 ± 8984 
AMPKα2 14243 ± 2739 11388 ± 186 178966 ± 4690 140790 ± 2810 
β-catenin 40878 ± 3297 27349 ± 1129 202297 ± 660 180160 ± 3859 
P70 S6 Kinase 10297 ± 1068 21616 ± 2084 96753 ± 2636 102824 ± 1197 
p53 86987 ± 5228 58810 ± 2886 81460 ± 878 84282 ± 2363 
c-Jun 56200 ± 3331 34186 ± 4335 96887 ± 2063 98966 ± 774 
Src 14702 ± 1037 9321 ± 257 117231 ± 7133 105595 ± 991 
Lyn 12752 ± 238 11374 ± 170 154924 ± 2679 130297 ± 200 
Lck 7456 ± 33 6042 ± 21 108142 ± 1488 86199 ± 57 
STAT2 17931 ± 72 17160 ± 139 207733 ± 2433 172146 ± 8896 
STAT5a 13816 ± 402 12088 ± 238 183657 ± 2127 166111 ± 218 
P70 S6 Kinase 21616 ± 2084 13403 ± 1911 113507 ± 4511 112995 ± 3998 
RSK1/2/3 7957 ± 800 4505 ± 1050 99936 ± 4163 103566 ± 69 
eNOS 369 ± 50 -1740 ± 318 78946 ± 4004 82737 ± 6432 
Fyn 13784 ± 432 9989 ± 674 136147 ± 2529 146555 ± 4378 
Yes 15818 ± 1148 7984 ± 30 144449 ± 888 119622 ± 1152 
Fgr 1059 ± 824 -899 ± 549 98695 ± 2668 96942 ± 787 
STAT6 13721 ± 518 11317 ± 290 179657 ± 2259 142167 ± 1536 
STAT5b 11269 ± 270 9534 ± 325 192960 ± 2676 175556 ± 4839 
STAT3 7502 ± 197 3288 ± 796 137152 ± 546 134359 ± 3544 
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Kinase 0% BP E-liquid 3% BP E-liquid Air Puffs (10x) BP Puffs (10x) 
p27  5407 ± 289 -908 ± 216 86790 ± 3764 89393 ± 485 
PLC-γ1 3149 ± 773 -792 ± 218 82741 ± 4964 88530 ± 4226 
Hck 36089 ± 134 26428 ± 2116 162538 ± 2240 150474 ± 4108 
Chk-2 37575 ± 2470 28168 ± 583 139497 ± 5027 119386 ± 5833 
FAK 21449 ± 1327 10234 ± 118 118687 ± 2031 103120 ± 4465 
PDGF Rβ 5292 ± 364 4066 ± 122 115853 ± 2473 98807 ±948 
STAT5a/b 7536 ± 542 6462 ± 216 150974 ± 943 131712 ± 5407 
STAT3 37689 ± 42 22016 ± 400 83194 ± 870 88903 ± 2015 
WNK1 136811 ± 1037 117692 ± 569 210277 ± 1088 209765 ± 3774 
PYK2 8332 ± 1941 1952 ± 602 88150 ± 3603 95472 ± 585 
Reference 3 211303 ± 2674 203782 ± 1807 257038 ± 4 257033 ± 9 
PRAS40 20718 ± 1078 20226 ± 945 162820 ± 9591 142599 ± 290 
HSP60 153054 ± 399 156458 ± 1025 252706 ±5976 248353 ± 11073 
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Figure 5.1.  Chronic exposure to Kola-flavored e-liquid found to inhibit thapsigargin-induced Ca2+ 
response, similar to BP.  CALU3 cells were exposed to Kola or BP-flavored e-liquids diluted in culture 
media for 24 h.  A: Cells were loaded with fluo-4 dye and peak Ca2+ responses to thapsigargin were 
measured.  B: Cells were fixed following Ca2+ assays and stained with DAPI for relative cell number per 
culture.  Bars represent mean + SEM.  n = 9-18 wells per treatment from 3 independent experiments.  
Statistical differences compared between all treatments and the 0% e-liquid control (***P < 0.001).    
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Figure 5.2.  Select kinases show decreased phosphorylation with exposure to either BP e-liquid or 
aerosol in airway cultures.  CALU3 cells were exposed to 0 or 3% BP (12 mg/ml nicotine) e-liquid for 
10 min and HBECs were exposed to 10x 70 ml puffs of air or heated BP e-liquid (aerosol).  Protein 
lysates were collected from the airway epithelial cultures and ran on kinase arrays.  A full list of the 
phosphorylation results are found in Table 5.2.  A-B: Select kinase results were plotted as the mean of 
pooled samples + SD for both e-liquid and aerosol exposures.  Samples were pooled from at least three 
cultures and run in duplicate per treatment. 
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